HighCostDrugsDemo/data/TA-recommendations.csv

1	Rec no.	TA ID	Year of Publication	STA/MTA process	Technology	Technology type	Indication	Categorisation (for specific recommendation)	Comment
2	1	TA001	1999/00	MTA	Prophylactic removal	Surgical procedure	Wisdom teeth	Recommended	Recommendation in line with clinical practice. Moved to static list (review in 2011).
3	2	TA002	2000/01	MTA	Hip prostheses	Medical device	Hip disease	Recommended	Recommendation in line with clinical practice. Moved to static list.
4	3	TA003	2000/01	MTA	Paclitaxel	Pharmaceutical	Ovarian cancer	Recommended	Guidance has been replaced by TA55. Recommendation in line with marketing authorisation.
5	4	TA004	2000/01	MTA	Coronary artery stents	Medical device	Ischaemic heart disease	Recommended	Guidance has been replaced by TA71. Recommendation in line with clinical practice.
6	5	TA005	2000/01	MTA	Liquid Based Cytology (LBC)	Other therapeutic therapies	Cervical cancer	Only in Research	Guidance has been replaced by TA69. At the time of appraisal the Committee advised that there was insufficient evidence to justify the nationwide introduction of LBC technology. However they recommended that large-scale pilot implementation studies should be carried out to evaluate the effectiveness, costs and practical implications of the introduction of LBC technology into the cervical screening programme.
7	6	TA006	2000/01	MTA	Docetaxel	Pharmaceutical	Advanced breast cancer	Recommended	Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
8	7	TA006	2000/01	MTA	Paclitaxel	Pharmaceutical	Advanced breast cancer	Recommended	Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
9	8	TA007	2000/01	MTA	Lansoprazole	Pharmaceutical	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
10	9	TA007	2000/01	MTA	Omeprazole	Pharmaceutical	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
11	10	TA007	2000/01	MTA	Pantoprazole	Pharmaceutical	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
12	11	TA007	2000/01	MTA	Rabeprazole	Pharmaceutical	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
13	12	TA008	2000/01	MTA	Analogue hearing aids	Medical device	Deafness	Recommended	The Department of Health made digital hearing aid technology available across the NHS after TA008 was published which made guidance obsolete. Guidance withdrawn from May 2003.
14	13	TA008	2000/01	MTA	Digital hearing aids	Medical device	Deafness	Not Recommended	The Department of Health made digital hearing aid technology available across the NHS after TA008 was published which made guidance obsolete. Guidance withdrawn from May 2003.
15	14	TA009	2000/01	MTA	Rosiglitazone	Pharmaceutical	Type 2 diabetes	Recommended	Guidance has been replaced by TA63 and incorporated in CG66. Recommendation in line with marketing authorisation.
16	15	TA010	2000/01	MTA	Dry powder inhalers (DPI)	Medical device	Asthma (children under 5 years)	Recommended	Recommendation in line with marketing authorisation.
17	16	TA010	2000/01	MTA	Nebulised therapy	Other therapeutic therapies	Asthma (children under 5 years)	Recommended	Recommendation in line with marketing authorisation.
18	17	TA010	2000/01	MTA	Pressurised metered dose inhalers (pMDI) and spacer system	Medical device	Asthma (children under 5 years)	Recommended	Recommendation in line with marketing authorisation.
19	18	TA011	2000/01	MTA	Implantable cardioverter defibrillators (ICDs)	Medical device	Arrhythmias	Recommended	Guidance has been replaced by TA95. Recommendation in line with clinical practice.
20	19	TA012	2000/01	MTA	Abciximab (intravenous)	Pharmaceutical	Acute coronary syndromes	Recommended	Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
21	20	TA012	2000/01	MTA	Eptifibatide (intravenous)	Pharmaceutical	Acute coronary syndromes	Recommended	Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
22	21	TA012	2000/01	MTA	Tirofiban (intravenous)	Pharmaceutical	Acute coronary syndromes	Recommended	Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
23	22	TA013	2000/01	MTA	Methylphenidate	Pharmaceutical	Attention-Deficit Hyperactivity Disorder	Recommended	Guidance has been replaced by TA98. Recommendation in line with marketing authorisation
24	23	TA014	2000/01	MTA	Interferon alpha	Pharmaceutical	Hepatitis C	Recommended	Guidance has been replaced by TA75 & TA106. Recommendation in line with marketing authorisation.
25	24	TA014	2000/01	MTA	Ribavirin and interferon alpha combination therapy	Pharmaceutical	Hepatitis C	Recommended	Guidance has been replaced by TA75 & TA106. Recommendation in line with marketing authorisation.
26	25	TA015	2000/01	MTA	Zanamivir	Pharmaceutical	Influenza	Recommended	Guidance has been replaced by TA58 and then TA168. Recommendation in line with national influenza guidelines.
27	26	TA016	2000/01	MTA	Autologous Cartilage Transplantation (ACT)	Surgical procedure	Knee joints (defective)	Only in Research	Guidance has been replaced by TA89. At the time of appraisal it was recommended that ACT should only be performed as part of a properly structured clinical trial, which, wherever possible, is randomised and adequately powered.
28	27	TA017	2000/01	MTA	Laparoscopic surgery	Surgical procedure	Colorectal cancer	Only in Research	Guidance replaced by TA105. At the time of appraisal it was recommended that laparoscopic surgery for colorectal cancer should be limited to use in a randomised controlled trial setting.
29	28	TA018	2000/01	MTA	Laparoscopic surgery	Surgical procedure	Hernia	Recommended	Recommendation in line with clinical practice.
30	29	TA019	2000/01	MTA	Donepezil	Pharmaceutical	Alzheimer's disease	Optimised	Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer’s disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
31	30	TA019	2000/01	MTA	Galantamine	Pharmaceutical	Alzheimer's disease	Optimised	Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer’s disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
32	31	TA019	2000/01	MTA	Rivastigmine	Pharmaceutical	Alzheimer's disease	Optimised	Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer’s disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
33	32	TA020	2000/01	MTA	Riluzole	Pharmaceutical	Motor neurone disease	Recommended	Recommendation in line with marketing authorisation.
34	33	TA021	2000/01	MTA	Pioglitazone	Pharmaceutical	Type 2 Diabetes	Recommended	Guidance has been replaced by TA63. Recommendation in line with marketing authorisation.
35	34	TA022	2000/01	MTA	Orlistat	Pharmaceutical	Obesity	Recommended	Guidance has been incorporated in CG43. Recommendation in line with marketing authorisation.
36	35	TA023	2001/02	MTA	Temozolomide	Pharmaceutical	Brain cancer (recurrent)	Recommended	Recommendation in line with marketing authorisation.
37	36	TA024	2001/02	MTA	Alginate dressings	Other therapeutic therapies	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
38	37	TA024	2001/02	MTA	Debriding agents - bio-surgical techniques (sterile maggots)	Other therapeutic therapies	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
39	38	TA024	2001/02	MTA	Foam dressings	Other therapeutic therapies	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
40	39	TA024	2001/02	MTA	Hydrocolloids	Medical device	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
41	40	TA024	2001/02	MTA	Hydrogels	Medical device	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
42	41	TA024	2001/02	MTA	Polysaccharide beads/paste	Medical device	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
43	42	TA025	2001/02	MTA	Gemcitabine (1st line)	Pharmaceutical	Pancreatic cancer	Recommended	Recommended in line with clinical practice.
44	43	TA025	2001/02	MTA	Gemcitabine (2nd line)	Pharmaceutical	Pancreatic cancer	Not Recommended	At the time of appraisal there was insufficient evidence to support the use of gemcitabine as a second-line treatment in patients with pancreatic adenocarcinoma.
45	44	TA026	2001/02	MTA	Docetaxel (2nd line)	Pharmaceutical	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
46	45	TA026	2001/02	MTA	Gemcitabine (1st line)	Pharmaceutical	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
47	46	TA026	2001/02	MTA	Paclitaxel (1st line)	Pharmaceutical	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
48	47	TA026	2001/02	MTA	Vinorelbine (1st line)	Pharmaceutical	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
49	48	TA027	2001/02	MTA	Celecoxib	Pharmaceutical	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
50	49	TA027	2001/02	MTA	Etodolac	Pharmaceutical	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
51	50	TA027	2001/02	MTA	Meloxicam	Pharmaceutical	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
52	51	TA027	2001/02	MTA	Rofecoxib	Pharmaceutical	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients. Marketing authorisation for this technology was withdrawn by EMA after TA027 was published.
53	52	TA028	2001/02	MTA	Topotecan (2nd and subsequent lines of treatment)	Pharmaceutical	Advanced ovarian cancer	Recommended	Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
54	53	TA029	2001/02	MTA	Fludarabine - Intravenous formulation (2nd line)	Pharmaceutical	Leukaemia (B-cell chronic lymphocytic)	Recommended	Recommendation in line with marketing authorisation.
55	54	TA029	2001/02	MTA	Fludarabine - Oral formulation (2nd line)	Pharmaceutical	Leukaemia (B-cell chronic lymphocytic)	Recommended	Recommendation in line with marketing authorisation.
56	55	TA030	2001/02	MTA	Docetaxel (2nd line)	Pharmaceutical	Advanced breast cancer	Recommended	Update of guidance TA6. Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
57	56	TA030	2001/02	MTA	Docetaxel in combination with an anthracycline (1st line)	Pharmaceutical	Advanced breast cancer	Not Recommended	Update of guidance TA6. Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
58	57	TA030	2001/02	MTA	Paclitaxel (2nd line)	Pharmaceutical	Advanced breast cancer	Recommended	Update of guidance TA6. Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
59	58	TA031	2001/02	MTA	Sibutramine	Pharmaceutical	Obesity	Recommended	Guidance has been incorporated in CG43. Recommendation in line with marketing authorisation.
60	59	TA032	2001/02	MTA	Beta interferon	Pharmaceutical	Multiple sclerosis	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Moved to static list.
61	60	TA032	2001/02	MTA	Glatiramer acetate	Pharmaceutical	Multiple sclerosis	Not Recommended	At the time of appraisal, the technology was not considered to be a good use of NHS resources based on the data available. Moved to static list.
62	61	TA033	2001/02	MTA	Irinotecan in combination with 5-fluorouracil and folinic acid (5FU/FA) (1st-line)	Pharmaceutical	Colorectal cancer (advanced)	Not Recommended	Guidance replaced by TA93. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
63	62	TA033	2001/02	MTA	Irinotecan monotherapy (2nd line)	Pharmaceutical	Colorectal cancer (advanced)	Recommended	Guidance replaced by TA93. Recommendation in line with marketing authorisation.
64	63	TA033	2001/02	MTA	Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (1st-line)	Pharmaceutical	Colorectal cancer (advanced)	Optimised	Guidance has been replaced by TA93. Optimised recommendation for use in specific circumstances in patients with advanced colorectal cancer in patients with metastases that are confined solely to the liver and may become resectable (‘down staged’) following treatment.
65	64	TA033	2001/02	MTA	Raltitrexed	Pharmaceutical	Colorectal cancer (advanced)	Only in Research	Guidance replaced by TA93. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the technology was only recommended for use in the context of appropriately designed clinical trials.
66	65	TA034	2001/02	MTA	Trastuzumab in combination with paclitaxel	Pharmaceutical	Breast cancer	Recommended	Recommendation in line with marketing authorisation.
67	66	TA034	2001/02	MTA	Trastuzumab monotherapy	Pharmaceutical	Breast cancer	Recommended	Recommendation in line with marketing authorisation.
68	67	TA035	2001/02	MTA	Etanercept	Pharmaceutical	Arthritis (juvenile idiopathic)	Recommended	Recommendation in line with marketing authorisation.
69	68	TA036	2001/02	MTA	Etanercept	Pharmaceutical	Rheumatoid arthritis	Optimised	Guidance has been partially replaced by TA130 and TA195. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated).
70	69	TA036	2001/02	MTA	Infliximab in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis	Optimised	Guidance has been replaced by TA130. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated).
71	70	TA037	2001/02	MTA	Rituximab (3rd and subsequent lines of treatment)	Pharmaceutical	Lymphoma (follicular non-Hodgkin's)	Not recommended	Guidance replaced by TA137. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
72	71	TA037	2001/02	MTA	Rituximab (last line)	Pharmaceutical	Lymphoma (follicular non-Hodgkin's)	Only in Research	Guidance replaced by TA137. At the time of appraisal, the technology was only recommended for last-line therapy in the context of the construction of a case series of past and new patients, to determine with more certainty its effectiveness in this indication.
73	72	TA038	2001/02	MTA	Breath actuated pressurised metered dose aerosol inhalers	Medical device	Asthma (older children)	Recommended	Recommendation in line with marketing authorisations.
74	73	TA038	2001/02	MTA	Dry powder inhalers (DPI)	Medical device	Asthma (older children)	Recommended	Recommendation in line with marketing authorisations.
75	74	TA038	2001/02	MTA	Pressurised metered dose inhalers (pMDIs)	Medical device	Asthma (older children)	Recommended	Recommendation in line with marketing authorisations.
76	75	TA039	2001/02	MTA	Nicotine replacement therapy (NRT) and bupropion in combination	Pharmaceutical	Smoking cessation	Recommended	Guidance has been incorporated in PH10. Recommendation in line with marketing authorisation.
77	76	TA039	2001/02	MTA	Bupropion	Pharmaceutical	Smoking cessation	Recommended	Guidance has been incorporated in PH10. Recommendation in line with marketing authorisations.
78	77	TA039	2001/02	MTA	Nicotine replacement therapy (NRT)	Pharmaceutical	Smoking cessation	Recommended	Guidance has been incorporated in PH10. Recommendation in line with marketing authorisations.
79	78	TA040	2002/03	MTA	Infliximab	Pharmaceutical	Crohn's disease (active severe)	Recommended	Recommendation in line with marketing authorisation.
80	79	TA040	2002/03	MTA	Infliximab	Pharmaceutical	Crohn's disease (fistulising)	Recommended	Recommendation in line with marketing authorisation.
81	80	TA041	2002/03	MTA	Routine antenatal anti-D prophylaxis (RAADP)	Pharmaceutical	Pregnancy	Recommended	Guidance has been replaced by TA156. Recommendation in line with marketing authorisation and clinical practice.
82	81	TA042	2002/03	MTA	Somatropin	Pharmaceutical	Growth hormone deficiency (children)	Recommended	Guidance has been replaced by TA188. Recommendation in line with marketing authorisation.
83	82	TA043	2002/03	MTA	Amisulpride	Pharmaceutical	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
84	83	TA043	2002/03	MTA	Olanzapine	Pharmaceutical	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
85	84	TA043	2002/03	MTA	Quetiapine	Pharmaceutical	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
86	85	TA043	2002/03	MTA	Risperidone	Pharmaceutical	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
87	86	TA043	2002/03	MTA	Sertindole	Pharmaceutical	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
88	87	TA043	2002/03	MTA	Zotepine	Pharmaceutical	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
89	88	TA044	2002/03	MTA	Metal on metal (MoM) hip resurfacing arthroplasty	Surgical procedure	Hip disease	Only in Research	At the time of appraisal, it was recommended that where hip resurfacing arthroplasty is considered appropriate, the procedure should only be performed in the context of the ongoing collection of data on both the clinical effectiveness and cost-effectiveness of this technology. Ideally this data collection should form part of a UK national joint registry.
90	89	TA045	2002/03	MTA	Pegylated liposomal doxorubicin hydrochloride (PLDH)	Pharmaceutical	Ovarian cancer (advanced)	Recommended	Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
91	90	TA046	2002/03	MTA	Malabsorptive Surgery	Surgical procedure	Obesity (morbid)	Recommended	Guidance has been incorporated in CG43. Recommendation in line with clinical practice.
92	91	TA046	2002/03	MTA	Restrictive Surgery	Surgical procedure	Obesity (morbid)	Recommended	Guidance has been incorporated in CG43. Recommendation in line with clinical practice.
93	92	TA047	2002/03	MTA	Abciximab	Pharmaceutical	Acute coronary syndromes	Recommended	Update of guidance TA12. Recommendation in line with marketing authorisation.
94	93	TA047	2002/03	MTA	Eptifibitide	Pharmaceutical	Acute coronary syndromes	Recommended	Update of guidance TA12. Recommendation in line with marketing authorisation.
95	94	TA047	2002/03	MTA	Tirofiban	Pharmaceutical	Acute coronary syndromes	Recommended	Update of guidance TA12. Recommendation in line with marketing authorisation.
96	95	TA048	2002/03	MTA	Home haemodialysis	Other therapeutic therapies	Renal failure	Recommended	Recommendation in line with clinical practice.
97	96	TA049	2002/03	MTA	Audio-guided Doppler ultrasound guidance	Other therapeutic therapies	Central venous catheters	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
98	97	TA049	2002/03	MTA	Two-dimensional (2-D) imaging ultrasound guidance	Other therapeutic therapies	Central venous catheters	Optimised	Optimised recommendation for use in specific circumstances for adults and children in elective or emergency situations.
99	98	TA050	2002/03	MTA	Imatinib	Pharmaceutical	Leukaemia (CML)	Recommended	Guidance has been replaced by TA70. Recommendation in line with marketing authorisation.
100	99	TA051	2002/03	MTA	Beating the Blues - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. The evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
101	100	TA051	2002/03	MTA	Calipso Overcoming Depression Self-Help Materials - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient basis to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
102	101	TA051	2002/03	MTA	COPE - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
103	102	TA051	2002/03	MTA	FearFighter - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
104	103	TA051	2002/03	MTA	Restoring the Balance - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
105	104	TA051	2002/03	MTA	StressPac - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
106	105	TA052	2002/03	MTA	Alteplase	Pharmaceutical	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
107	106	TA052	2002/03	MTA	Reteplase	Pharmaceutical	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
108	107	TA052	2002/03	MTA	Streptokinase	Pharmaceutical	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
109	108	TA052	2002/03	MTA	Tenecteplase	Pharmaceutical	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
110	109	TA053	2002/03	MTA	Insulin glargine	Pharmaceutical	Type 1 diabetes	Recommended	Recommendation in line with clinical practice.
111	110	TA053	2002/03	MTA	Insulin glargine	Pharmaceutical	Type 2 diabetes	Optimised	Optimised recommendation for use in specific circumstances for people who require assistance with their treatment administration, or whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemic episodes, or for those who would otherwise need twice daily basal insulin injections in combination with oral anti-diabetic drugs.
112	111	TA054	2002/03	MTA	Vinorelbine combination therapies	Pharmaceutical	Breast cancer	Not Recommended	Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
113	112	TA054	2002/03	MTA	Vinorelbine monotherapy	Pharmaceutical	Breast cancer	Recommended	Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
114	113	TA055	2002/03	MTA	Paclitaxel (1st line)	Pharmaceutical	Ovarian cancer	Recommended	Update of guidance TA3. Recommendation in line with marketing authorisation.
115	114	TA055	2002/03	MTA	Paclitaxel (2nd line)	Pharmaceutical	Ovarian cancer	Recommended	Update of guidance TA3. Recommendation in line with clinical practice. In view of the limited evidence available on the clinical effectiveness of paclitaxel as a second-line treatment, the Committee concluded that paclitaxel should be considered as an option for second-line treatment only for women who do not receive it as part of their first-line therapy. For such women, it should be offered alongside other drugs that are licensed for second-lien treatment of ovarian cancer.
116	115	TA056	2002/03	MTA	Tension-free vaginal tape (Gynecare TVT)	Medical device	Stress incontinence	Recommended	Guidance has been incorporated in CG40. Recommendation in line with clinical practice.
117	116	TA057	2002/03	MTA	Continuous subcutaneous insulin infusion (CSII or ‘insulin pump therapy')	Pharmaceutical	Type 1 diabetes	Optimised	Guidance has been replaced by TA151. Optimised recommended for use in specific circumstances, for people whose HbA1c levels have remained high (at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care.
118	117	TA057	2002/03	MTA	Continuous subcutaneous insulin infusion (CSII or ‘insulin pump therapy')	Pharmaceutical	Type 2 diabetes	Not Recommended	Guidance has been replaced by TA151. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
119	118	TA058	2002/03	MTA	Amantadine	Pharmaceutical	Influenza (treatment)	Not Recommended	Guidance has been replaced by TA168. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
120	119	TA058	2002/03	MTA	Oseltamivir	Pharmaceutical	Influenza (treatment)	Recommended	Update of guidance TA15. Guidance has been replaced by TA168. Recommendation in line with national influenza guidelines.
121	120	TA058	2002/03	MTA	Zanamivir	Pharmaceutical	Influenza (treatment)	Recommended	Update of guidance TA15. Guidance has been replaced by TA168. Recommendation in line with national influenza guidelines.
122	121	TA059	2003/04	MTA	Electroconvulsive therapy (ECT)	Other therapeutic therapies	Electroconvulsive therapy (ECT)	Optimised	Optimised recommendation for use in specific circumstances as a last-line treatment option for those with severe depressive illness, catatonia and prolonged or severe manic episode.
123	122	TA060	2003/04	MTA	Structured patient education	Health promotion activities	Diabetes (types 1 and 2)	Recommended	Recommendation in line with clinical practice.
124	123	TA061	2003/04	MTA	Capecitabine	Pharmaceutical	Colorectal cancer	Recommended	Recommendation in line with marketing authorisation.
125	124	TA061	2003/04	MTA	Tegafur with uracil	Pharmaceutical	Colorectal cancer	Recommended	Recommendation in line with marketing authorisation.
126	125	TA062	2003/04	MTA	Capecitabine	Pharmaceutical	Breast cancer (locally advanced or metastatic)	Recommended	Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
127	126	TA062	2003/04	MTA	Capecitabine, plus docetaxel	Pharmaceutical	Breast cancer (locally advanced or metastatic)	Recommended	Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
128	127	TA063	2003/04	MTA	Pioglitazone in combination with a sulphonylurea	Pharmaceutical	Type 2 diabetes	Optimised	Update of guidance TA21. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances, for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.
129	128	TA063	2003/04	MTA	Pioglitazone in combination with metformin	Pharmaceutical	Type 2 diabetes	Optimised	Update of guidance TA21. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.
130	129	TA063	2003/04	MTA	Rosiglitazone in combination with a sulphonylurea	Pharmaceutical	Type 2 diabetes	Optimised	Update of guidance TA9. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.
131	130	TA063	2003/04	MTA	Rosiglitazone in combination with metformin	Pharmaceutical	Type 2 diabetes	Optimised	Update of guidance TA9. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.
132	131	TA064	2003/04	MTA	Somatropin	Pharmaceutical	Growth hormone deficiency (adults)	Optimised	Optimised recommendation for use in specific circumstances for people who have severe GH deficiency and they have a perceived impairment of quality of life (QoL), as demonstrated by a reported score of at least 11 in the disease-specific ‘Quality of life assessment of growth hormone deficiency in adults’ (QoL-AGHDA) questionnaire; and they are already receiving treatment for any other pituitary hormone deficiencies as required.
133	132	TA065	2003/04	MTA	Rituximab	Pharmaceutical	Non-Hodgkin's lymphoma - stage II - IV	Recommended	Recommendation in line with marketing authorisation.
134	133	TA065	2003/04	MTA	Rituximab	Pharmaceutical	Non-Hodgkin's lymphoma - stage I	Only in Research	At the time of appraisal, the clinical and cost-effectiveness of rituximab in patients with localised (stage 1) disease had not been established. Therefore use in these circumstances was only recommended as part of ongoing or new clinical studies.
135	134	TA066	2003/04	MTA	Olanzapine	Pharmaceutical	Bipolar disorder	Recommended	Guidance has been incorporated in CG38. Recommendation in line with marketing authorisation.
136	135	TA066	2003/04	MTA	Valproate semisodium	Pharmaceutical	Bipolar disorder	Recommended	Guidance has been incorporated in CG38. Recommendation in line with marketing authorisation.
137	136	TA067	2003/04	MTA	Amantadine	Pharmaceutical	Influenza (prevention)	Not recommended	Guidance has been replaced by TA158. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups.
138	137	TA067	2003/04	MTA	Oseltamivir	Pharmaceutical	Influenza (prevention)	Recommended	Guidance has been replaced by TA158. Recommendation in line with national influenza guidelines.
139	138	TA068	2003/04	MTA	Photodynamic therapy (PDT)	Other therapeutic therapies	Macular degeneration	Optimised	Optimised recommendation for use in specific circumstances for people with wet age-related macular degeneration who have a confirmed diagnosis of classic with no occult subfoveal CNV and best-corrected visual acuity 6/60 or better.
140	139	TA069	2003/04	MTA	Liquid Based Cytology (LBC)	Other therapeutic therapies	Cervical cancer	Recommended	Update of guidance TA5. Moved to static list in 2007. Recommendation in line with clinical practice.
141	140	TA070	2003/04	MTA	Imatinib	Pharmaceutical	Leukaemia (CML)	Recommended	Update of guidance TA50. Guidance has been partially updated by TA241 and TA251. Recommendation in line with marketing authorisation.
142	141	TA071	2003/04	MTA	Bare-metal stent (BMS)	Medical device	Ischaemic heart disease	Recommended	Update of guidance TA4. Recommendation in line with clinical practice.
143	142	TA071	2003/04	MTA	Drug-eluting stent (DES) - paclitaxel-eluting	Medical device	Ischaemic heart disease	Optimised	Update of guidance TA4. Optimised recommendation for use under specific circumstances depending on vessel anatomy.
144	143	TA071	2003/04	MTA	Drug-eluting stent (DES) - sirolimus-eluting	Medical device	Ischaemic heart disease	Optimised	Update of guidance TA4. Optimised recommendation for use under specific circumstances depending on vessel anatomy.
145	144	TA072	2003/04	MTA	Anakinra	Pharmaceutical	Rheumatoid arthritis	Only in Research	Guidance has been incorporated in CG79. At the time of appraisal, there was insufficient evidence to recommend anakinra for the treatment of rheumatoid arthritis, except in the context of a controlled, long-term clinical study.
146	145	TA073	2003/04	MTA	Myocardial perfusion scintigraphy (MPS) using single photon emission computed tomography (SPECT)	Other therapeutic therapies	Angina and myocardial infarction	Recommended	Guidance has been partially incorporated in CG95. Recommendation in line with clinical practice.
147	146	TA074	2003/04	MTA	Pre-hospital fluid replacement therapy - crystalloid solutions	Other therapeutic therapies	Trauma	Recommended	Recommendation in line with clinical practice.
148	147	TA075	2003/04	MTA	Peginterferon alfa and ribavirin – combination therapy	Pharmaceutical	Hepatitis C	Recommended	Update of guidance TA14. Recommendation in line with marketing authorisation.
149	148	TA075	2003/04	MTA	Peginterferon alfa monotherapy	Pharmaceutical	Hepatitis C	Recommended	Update of guidance TA14. Recommendation in line with marketing authorisation.
150	149	TA076	2003/04	MTA	Gabapentin	Pharmaceutical	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
151	150	TA076	2003/04	MTA	Lamotrigine	Pharmaceutical	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
152	151	TA076	2003/04	MTA	Levetiracetam	Pharmaceutical	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
153	152	TA076	2003/04	MTA	Oxcarbazepine	Pharmaceutical	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
154	153	TA076	2003/04	MTA	Tiagabine	Pharmaceutical	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
155	154	TA076	2003/04	MTA	Topiramate	Pharmaceutical	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
156	155	TA076	2003/04	MTA	Vigabatrin	Pharmaceutical	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
157	156	TA077	2004/05	MTA	Zaleplon	Pharmaceutical	Insomnia	Recommended	Recommendation in line with marketing authorisation.
158	157	TA077	2004/05	MTA	Zolpidem	Pharmaceutical	Insomnia	Recommended	Recommendation in line with marketing authorisation.
159	158	TA077	2004/05	MTA	Zopiclone	Pharmaceutical	Insomnia	Recommended	Recommendation in line with marketing authorisation.
160	159	TA078	2003/04	MTA	Fluid-filled thermal balloon endometrial ablation	Surgical procedure	Menstrual bleeding	Recommended	Recommendation in line with clinical practice.
161	160	TA078	2003/04	MTA	Microwave endometrial ablation	Surgical procedure	Menstrual bleeding	Recommended	Recommendation in line with clinical practice.
162	161	TA079	2004/05	MTA	Gabapentin	Pharmaceutical	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
163	162	TA079	2004/05	MTA	Lamotrigine	Pharmaceutical	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
164	163	TA079	2004/05	MTA	Oxcarbazepine	Pharmaceutical	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
165	164	TA079	2004/05	MTA	Tiagabine	Pharmaceutical	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
166	165	TA079	2004/05	MTA	Topiramate	Pharmaceutical	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
167	166	TA079	2004/05	MTA	Vigabatrin	Pharmaceutical	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
168	167	TA080	2004/05	MTA	Clopidogrel	Pharmaceutical	Acute coronary syndromes	Optimised	Guidance has been incorporated in CG94. Optimised recommendation for use in specific circumstances for people who are at moderate to high risk of myocardial infarction or death.
169	168	TA081	2004/05	MTA	Alclometasone dipropionate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
170	169	TA081	2004/05	MTA	Beclometasone dipropionate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
171	170	TA081	2004/05	MTA	Betamethasone Esters (in guidance: Betamethasone valerate)	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
172	171	TA081	2004/05	MTA	Clobetasol propionate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
173	172	TA081	2004/05	MTA	Clobetasone butyrate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
174	173	TA081	2004/05	MTA	Desoximetasone (old name: desoxymethasone)	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
175	174	TA081	2004/05	MTA	Diflucortolone valerate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
176	175	TA081	2004/05	MTA	Fludroxycortide	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
177	176	TA081	2004/05	MTA	Fluocinolone acetonide	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
178	177	TA081	2004/05	MTA	Fluocinonide	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
179	178	TA081	2004/05	MTA	Fluocortolone	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
180	179	TA081	2004/05	MTA	Fluticasone propionate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
181	180	TA081	2004/05	MTA	Halcinonide	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
182	181	TA081	2004/05	MTA	Hydrocortisone	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
183	182	TA081	2004/05	MTA	Hydrocortisone butyrate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
184	183	TA081	2004/05	MTA	Mometasone furoate	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
185	184	TA082	2004/05	MTA	Pimecrolimus	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
186	185	TA082	2004/05	MTA	Tacrolimus	Pharmaceutical	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
187	186	TA083	2004/05	MTA	Laparoscopic surgery - totally extraperitonea procedurel [TEP]	Surgical procedure	Hernia	Recommended	Recommendation in line with clinical practice.
188	187	TA083	2004/05	MTA	Laparoscopic surgery - transabdominal preperitoneal procedure [TAPP]	Surgical procedure	Hernia	Recommended	Recommendation in line with clinical practice.
189	188	TA084	2004/05	MTA	Drotrecogin	Pharmaceutical	Sepsis (severe)	Recommended	Recommendation in line with marketing authorisation.
190	189	TA085	2004/05	MTA	Induction therapy (basiliximab)	Pharmaceutical	Renal transplantation (adults)	Recommended	Recommendation in line with marketing authorisation.
191	190	TA085	2004/05	MTA	Induction therapy (daclizumab)	Pharmaceutical	Renal transplantation (adults)	Recommended	Recommendation in line with marketing authorisation.
192	191	TA085	2004/05	MTA	Mycophenolate mofetil (MMF)	Pharmaceutical	Renal transplantation (adults)	Optimised	Optimised recommendation for use in specific circumstances for people with proven intolerance to calcineurin inhibitors, particularly nephrotoxicity leading to risk of chronic allograft dysfunction, or; in situations where there is a very high risk of nephrotoxicity necessitating minimisation or avoidance of a calcineurin inhibitor.
193	192	TA085	2004/05	MTA	Sirolimus	Pharmaceutical	Renal transplantation (adults)	Optimised	Optimised recommendation for use in specific circumstances for people with proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitating complete withdrawal of these treatments.
194	193	TA085	2004/05	MTA	Tacrolimus	Pharmaceutical	Renal transplantation (adults)	Recommended	Recommendation in line with marketing authorisation.
195	194	TA086	2004/05	MTA	Imatinib	Pharmaceutical	Gastrointestinal stromal tumours (unresectable, metastatic)	Recommended	Guidance has been partially updated by TA209. Recommendation in line with marketing authorisation.
196	195	TA087	2004/05	MTA	Alendronate	Pharmaceutical	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor.
197	196	TA087	2004/05	MTA	Etidronate	Pharmaceutical	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor.
198	197	TA087	2004/05	MTA	Raloxifene	Pharmaceutical	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use under specific circumstances for women in whom bisphosphonates are contraindicated or who are physically unable to comply with the special recommendations for use of bisphosphonates, or who have had an unsatisfactory response to bisphosphonates, or who are intolerant of bisphosphonates.
199	198	TA087	2004/05	MTA	Risedronate	Pharmaceutical	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor.
200	199	TA087	2004/05	MTA	Teriparatide	Pharmaceutical	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use under specific circumstances for women aged 65 years and older who have had an unsatisfactory response to bisphosphonates or intolerance to bisphosphonates, and who have an extremely low BMD (with a T-score of approximately –4 SD or below), or who have a very low BMD (with a T-score of approximately –3 SD or below) plus multiple fractures (that is, more than two) plus one, or more, additional age-independent risk factor: low body mass index (< 19 kg/m2); family history of maternal hip fracture before the age of 75 years; untreated premature menopause; conditions associated with prolonged immobility.
201	200	TA088	2004/05	MTA	Dual chamber pacemakers	Medical device	Bradycardia	Recommended	Recommendation in line with clinical practice.
202	201	TA089	2005/06	MTA	Autologous chondrocyte implantation (ACI)	Surgical procedure	Cartilage injury	Only in Research	Update of guidance TA16. At the time of appraisal, there was insufficient evidence on the effectiveness of ACI for it to be recommended, except in the context of new or ongoing clinical studies designed to generate robust and relevant outcome data including the measurement of health related quality of life and long term follow up.
203	202	TA090	2005/06	MTA	Modified-release (MR) dipyridamole	Pharmaceutical	Vascular disease	Optimised	Guidance has been replaced by TA210. Optimised recommendation for use in specific circumstances for people who are intolerant of low-dose aspirin and either have experienced an occlusive vascular event or have symptomatic peripheral arterial disease.
204	203	TA090	2005/06	MTA	Clopidogrel	Pharmaceutical	Vascular disease	Optimised	Guidance has been replaced by TA210. Optimised recommendation for use in specific circumstances in combination with aspirin for people who have had an ischaemic stroke or a transient ischaemic attack for a period of 2 years from the most recent event.
205	204	TA091	2005/06	MTA	Pegylated liposomal doxorubicin hydrochloride (PLDH)	Pharmaceutical	Ovarian cancer (advanced)	Recommended	Recommendation in line with marketing authorisation.
206	205	TA091	2005/06	MTA	Topotecan	Pharmaceutical	Ovarian cancer (advanced)	Recommended	Recommendation in line with marketing authorisation.
207	206	TA091	2005/06	MTA	Paclitaxel	Pharmaceutical	Ovarian cancer (advanced)	Recommended	Update of guidance TA45. Recommendation in line with marketing authorisation.
208	207	TA091	2005/06	MTA	Paclitaxel in combination with a platinum-based compound	Pharmaceutical	Ovarian cancer (advanced)	Recommended	Update of guidance TA28. Recommendation in line with clinical practice for women in whom PLDH and single-agent paclitaxel are considered inappropriate because they have previously been exposed to PLDH and single-agent paclitaxel, or if the impact of the adverse effects of treatment with these drugs is considered unacceptable.
209	208	TA092	2005/06	MTA	HealOzone	Medical device	Tooth decay	Only in Research	At the time of appraisal, the Committee concluded that there was insufficient evidence on the effectiveness of HealOzone treatment for this technology to be recommended, except as part of well designed randomised controlled trials.
210	209	TA093	2005/06	MTA	Irinotecan	Pharmaceutical	Colorectal cancer (advanced)	Recommended	Update of guidance TA33. Recommendation in line with marketing authorisation.
211	210	TA093	2005/06	MTA	Irinotecan in combination with 5-fluorouracil and folinic acid	Pharmaceutical	Colorectal cancer (advanced)	Recommended	Update of guidance TA33. Recommendation in line with marketing authorisation.
212	211	TA093	2005/06	MTA	Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA)	Pharmaceutical	Colorectal cancer (advanced)	Recommended	Update of guidance TA33. Recommendation in line with marketing authorisation.
213	212	TA093	2005/06	MTA	Raltitrexed	Pharmaceutical	Colorectal cancer (advanced)	Only in Research	Update of guidance TA33. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the technology was only recommended for use in the context of appropriately designed clinical trials.
214	213	TA094	2005/06	MTA	Atorvastatin	Pharmaceutical	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
215	214	TA094	2005/06	MTA	Fluvastatin	Pharmaceutical	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
216	215	TA094	2005/06	MTA	Pravastatin	Pharmaceutical	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
217	216	TA094	2005/06	MTA	Rosuvastatin	Pharmaceutical	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
218	217	TA094	2005/06	MTA	Simvastatin	Pharmaceutical	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
219	218	TA095	2005/06	MTA	Implantable cardioverter defibrillators (ICDs)	Medical device	Arrhythmia (secondary prevention)	Recommended	Update of guidance TA11. Recommendation in line with clinical practice.
220	219	TA095	2005/06	MTA	Implantable cardioverter defibrillators (ICDs)	Medical device	Arrhythmia (primary prevention)	Recommended	Update of guidance TA11. Recommendation in line with clinical practice.
221	220	TA096	2005/06	MTA	Adefovir dipivoxil	Pharmaceutical	Hepatitis B (chronic)	Optimised	Optimised recommendation for use under specific circumstances if treatment with interferon alfa or peginterferon alfa-2a has been unsuccessful, or a relapse occurs after successful initial treatment, or treatment with interferon alfa or peginterferon alfa-2a is poorly tolerated or contraindicated.
222	221	TA096	2005/06	MTA	Adefovir dipivoxil in combination with lamivudine	Pharmaceutical	Hepatitis B (chronic)	Optimised	Optimised recommendation for use under specific circumstances either alone or in combination with lamivudine when: treatment with lamivudine has resulted in viral resistance, or lamivudine resistance is likely to occur rapidly (for example, in the presence of highly replicative hepatitis B disease), and development of lamivudine resistance is likely to have an adverse outcome (for example, if a flare of the infection is likely to precipitate decompensated liver disease.
223	222	TA096	2005/06	MTA	Peginterferon alfa-2a	Pharmaceutical	Hepatitis B (chronic)	Recommended	Recommendation in line with marketing authorisation.
224	223	TA097	2005/06	MTA	OCFighter (previously known as BTSteps) - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Not Recommended	Update of guidance TA51. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
225	224	TA097	2005/06	MTA	Beating the Blues - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Recommended	Update of guidance TA51. Recommendation in line with clinical practice.
226	225	TA097	2005/06	MTA	FearFighter - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Recommended	Update of guidance TA51. Recommendation in line with clinical practice.
227	226	TA097	2005/06	MTA	COPE - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Update of guidance TA51. At the time of appraisal there was insufficient evidence to recommend the technology as an option for the management of depression except as part of new or ongoing clinical trials designed to generate robust and relevant clinical effectiveness data.
228	227	TA097	2005/06	MTA	Overcoming Depression - computerised cognitive behavioural therapy (CCBT) package	Other therapeutic therapies	Depression and anxiety	Only in Research	Update of guidance TA51. At the time of appraisal there was insufficient evidence to recommend the technology as an option for the management of depression except as part of new or ongoing clinical trials designed to generate robust and relevant clinical effectiveness data.
229	228	TA098	2005/06	MTA	Atomoxetine	Pharmaceutical	Attention deficit hyperactivity disorder (ADHD)	Recommended	Update of guidance TA13. Recommendation in line with marketing authorisation.
230	229	TA098	2005/06	MTA	Dexamfetamine	Pharmaceutical	Attention deficit hyperactivity disorder (ADHD)	Recommended	Update of guidance TA13. Recommendation in line with marketing authorisation.
231	230	TA098	2005/06	MTA	Methylphenidate	Pharmaceutical	Attention deficit hyperactivity disorder (ADHD)	Recommended	Update of guidance TA13. Recommendation in line with marketing authorisation.
232	231	TA099	2006/07	MTA	Basiliximab	Pharmaceutical	Renal transplantation - children and adolescents	Recommended	Recommendation in line with marketing authorisation.
233	232	TA099	2006/07	MTA	Daclizumab	Pharmaceutical	Renal transplantation - children and adolescents	Recommended	Recommendation in line with marketing authorisation.
234	233	TA099	2006/07	MTA	Mycophenolate mofetil (MMF)	Pharmaceutical	Renal transplantation (children)	Optimised	Optimised recommendation for use in specific circumstances when there is proven intolerance to calcineurin inhibitors, particularly nephrotoxicity which could lead to risk of chronic allograft dysfunction, or there is a very high risk of nephrotoxicity necessitating the minimisation or avoidance of a calcineurin inhibitor until the period of high risk has passed.
235	234	TA099	2006/07	MTA	Mycophenolate sodium (MPS)	Pharmaceutical	Renal transplantation (children)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
236	235	TA099	2006/07	MTA	Sirolimus	Pharmaceutical	Renal transplantation (children)	Optimised	Optimised recommendation for use in specific circumstances for children or adolescents undergoing renal transplantation except proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitates the complete withdrawal of these treatments.
237	236	TA099	2006/07	MTA	Tacrolimus	Pharmaceutical	Renal transplantation (children)	Recommended	Recommendation in line with marketing authorisation.
238	237	TA100	2006/07	MTA	Capecitabine (adjuvant)	Pharmaceutical	Colon cancer	Recommended	Recommendation in line with marketing authorisation. Moved to static list.
239	238	TA100	2006/07	MTA	Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (adjuvant)	Pharmaceutical	Colon cancer	Recommended	Recommendation in line with marketing authorisation. Moved to static list.
240	239	TA101	2006/07	MTA	Docetaxel	Pharmaceutical	Prostate cancer (hormone-refractory)	Recommended	Recommendation in line with marketing authorisation.
241	240	TA102	2006/07	MTA	Group-based parent-training/education programmes	Health promotion activities	Conduct disorder in children	Recommended	Recommendation in line with clinical practice.
242	241	TA102	2006/07	MTA	Individual-based parent-training/education programmes	Health promotion activities	Conduct disorder in children	Recommended	Recommendation in line with clinical practice.
243	242	TA103	2006/07	MTA	Efaluzimab	Pharmaceutical	Psoriasis	Optimised	Optimised recommendation for use in specific circumstances in people with severe disease defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 after failure or intolerance to etanercept. Marketing authorisation was withdrawn by EMA after publication of TA103.
244	243	TA103	2006/07	MTA	Etanercept	Pharmaceutical	Psoriasis	Recommended	Recommendation in line with clinical practice.
245	244	TA104	2006/07	MTA	Etanercept	Pharmaceutical	Psoriatic arthritis	Recommended	Guidance has been replaced by TA199. Recommendation in line with clinical practice.
246	245	TA104	2006/07	MTA	Infliximab	Pharmaceutical	Psoriatic arthritis	Optimised	Guidance has been replaced by TA199. Optimised recommendation for use in specific circumstances when a person has peripheral arthritis with three or more tender joints and three or more swollen joints; the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying anti-rheumatic drugs (DMARDs), administered either individually or in combination; the person has been shown to be intolerant of, or have contraindications to, treatment with etanercept or has major difficulties with self administered injections.
247	246	TA105	2006/07	MTA	Laparoscopic resection	Surgical procedure	Colorectal cancer	Recommended	Update of guidance TA17. Recommendation in line with clinical practice.
248	247	TA106	2006/07	MTA	Peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin Combination therapy	Pharmaceutical	Hepatitis C	Recommended	Recommendation in line with marketing authorisation.
249	248	TA106	2006/07	MTA	Peginterferon alfa-2a or peginterferon alfa-2b	Pharmaceutical	Hepatitis C	Recommended	Recommendation in line with marketing authorisation.
250	249	TA107	2006/07	STA	Trastuzumab	Pharmaceutical	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
251	250	TA108	2006/07	STA	Paclitaxel	Pharmaceutical	Breast cancer (early)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
252	251	TA109	2006/07	STA	Docetaxel with doxorubicin and cyclophosphamide (the TAC regimen)	Pharmaceutical	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
253	252	TA110	2006/07	STA	Rituximab	Pharmaceutical	Follicular lymphoma	Recommended	Guidance has been replaced by TA243. Recommendation in line with marketing authorisation.
254	253	TA111	2006/07	MTA	Donepezil	Pharmaceutical	Alzheimer's disease	Optimised	Guidance has been replaced by TA217. Previously was update of guidance TA19. Optimised recommendation for use in specific circumstances for people with Alzheimer’s disease with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10.
255	254	TA111	2006/07	MTA	Galantamine	Pharmaceutical	Alzheimer's disease	Optimised	Guidance has been replaced by TA217. Previously was update of guidance TA19. Optimised recommendation for use in specific circumstances for people with Alzheimer’s disease with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10.
256	255	TA111	2006/07	MTA	Memantine	Pharmaceutical	Alzheimer's disease	Only in research	Guidance has been replaced by TA217. Previously was update of guidance TA19. Only recommended in the context of well designed clinical trials.
257	256	TA111	2006/07	MTA	Rivastigmine	Pharmaceutical	Alzheimer's disease	Optimised	Guidance has been replaced by TA217. Previously was update of guidance TA19. Optimised recommendation for use in specific circumstances, for people with Alzheimer’s disease only with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10.
258	257	TA112	2006/07	MTA	Anastrozole	Pharmaceutical	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
259	258	TA112	2006/07	MTA	Exemestane	Pharmaceutical	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
260	259	TA112	2006/07	MTA	Letrozole	Pharmaceutical	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
261	260	TA113	2006/07	MTA	Inhaled insulin (Exubera)	Pharmaceutical	Diabetes (types 1 and 2)	Optimised	Optimised recommendation for use in specific circumstances for people with type 1 or type 2 diabetes mellitus who show evidence of poor glycaemic control despite other therapeutic interventions (including, where appropriate, diet, oral hypoglycaemic agents [OHAs] and subcutaneous insulin) and adequate educational support, and who are unable to initiate or intensify pre-prandial subcutaneous insulin therapy because of either: a marked and persistent fear of injections that meet DSM-IV criteria for specific phobia ‘blood injection injury type’ diagnosed by a diabetes specialist or mental health professional; severe and persistent problems with injection sites (for example, as a consequence of lipohypertrophy) despite support with injection site rotation. Guidance now obsolete because manufacturer has ceased production of this technology.
262	261	TA114	2006/07	MTA	Buprenorphine (oral formulations)	Pharmaceutical	Drug misuse	Recommended	Recommendation in line with clinical practice.
263	262	TA114	2006/07	MTA	Methadone (oral formulations)	Pharmaceutical	Drug misuse	Recommended	Recommendation in line with clinical practice.
264	263	TA115	2006/07	MTA	Naltrexone	Pharmaceutical	Drug misuse	Recommended	Recommendation in line with clinical practice.
265	264	TA116	2006/07	STA	Gemcitabine	Pharmaceutical	Breast cancer	Recommended	Recommendation in line with marketing authorisation.
266	265	TA117	2006/07	MTA	Cinacalcet	Pharmaceutical	Hyperparathyroidism (refractory)	Optimised	Optimised recommendation for use in specific circumstances for people with end-stage renal disease (including those with calciphylaxis) who have ‘very uncontrolled’ plasma levels of intact parathyroid hormone (defined as greater than 85 pmol/litre [800 pg/ml]) that are refractory to standard therapy; and a normal or high adjusted serum calcium level, and in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery are considered to outweigh the benefits.
267	266	TA118	2006/07	MTA	Bevacizumab in combination with 5-fluorouracil plus folinic acid (with or without irinotecan)	Pharmaceutical	Colorectal cancer (metastatic)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
268	267	TA118	2006/07	MTA	Cetuximab in combination with irinotecan	Pharmaceutical	Colorectal cancer (metastatic)	Not Recommended	Guidance has been partially replaced by TA242. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
269	268	TA119	2006/07	STA	Fludarabine (monotherapy)	Pharmaceutical	Leukaemia (lymphocytic)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
270	269	TA120	2007/08	MTA	Cardiac resynchronisation therapy with a defibrillator device (CRT-D)	Medical device	Heart failure	Recommended	Recommendation in line with clinical practice.
271	270	TA120	2007/08	MTA	Cardiac resynchronisation therapy with a pacing device (CRT-P)	Medical device	Heart failure	Recommended	Recommendation in line with clinical practice.
272	271	TA121	2007/08	MTA	Carmustine implants	Pharmaceutical	Glioma (newly diagnosed)	Recommended	Recommendation in line with clinical practice.
273	272	TA121	2007/08	MTA	Temozolomide	Pharmaceutical	Glioma (newly diagnosed)	Recommended	Recommendation in line with clinical practice.
274	273	TA122	2007/08	STA	Alteplase	Pharmaceutical	Ischaemic stroke (acute)	Recommended	Guidance has been replaced by TA264. Recommendation in line with marketing authorisation.
275	274	TA123	2007/08	STA	Varenicline	Pharmaceutical	Smoking cessation	Recommended	Recommendation in line with marketing authorisation.
276	275	TA124	2007/08	STA	Pemetrexed (2nd line)	Pharmaceutical	Non-small cell lung cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
277	276	TA125	2007/08	STA	Adalimumab	Pharmaceutical	Psoriatic arthritis	Recommended	Guidance has been replaced by TA199. Recommendation in line with clinical practice.
278	277	TA126	2007/08	STA	Rituximab	Pharmaceutical	Rheumatoid arthritis (refractory)	Recommended	Guidance has been replaced by TA195. Recommendation in line with clinical practice.
279	278	TA127	2007/08	STA	Natalizumab	Pharmaceutical	Multiple sclerosis	Optimised	Optimised recommendation for use in specific circumstances for people with rapidly evolving severe relapsing–remitting multiple sclerosis (RES) only.
280	279	TA128	2007/08	MTA	Stapled haemorroidopexy	Surgical procedure	Haemorrhoid	Recommended	Recommendation in line with clinical practice.
281	280	TA129	2007/08	STA	Bortezomib	Pharmaceutical	Multiple myeloma	Recommended	Recommended after agreement of Patient Access Scheme.
282	281	TA130	2007/08	MTA	Adalimumab (1st line)	Pharmaceutical	Rheumatoid arthritis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced by TA375.
283	282	TA130	2007/08	MTA	Etanercept (1st line)	Pharmaceutical	Rheumatoid arthritis	Not recommended	Update of guidance TA36. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced by TA375.
284	283	TA130	2007/08	MTA	Infliximab (1st line)	Pharmaceutical	Rheumatoid arthritis	Not recommended	Update of guidance TA36. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced by TA375.
285	284	TA130	2007/08	MTA	Adalimumab (after DMARD failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Optimised recommendation for use in specific circumstances for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Replaced by TA375.
286	285	TA130	2007/08	MTA	Etanercept (after DMARD failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36. Optimised recommendation for use in specific circumstances, for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Replaced by TA375.
287	286	TA130	2007/08	MTA	Infliximab (after DMARD failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36. Optimised recommendation for use in specific circumstances for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Replaced by TA375.
288	287	TA131	2007/08	MTA	Inhaled corticosteroids (ICS) including beclometasone, budesonide, fluticasone, budesonide/formoterol combination, fluticasone/salmeterol combination	Pharmaceutical	Asthma (in children)	Recommended	Recommendation in line with marketing authorisation.
289	288	TA132	2007/08	MTA	Ezetimibe monotherapy	Pharmaceutical	Primary (heterozygous-familial and non-familial) hypercholesterolaemia	Recommended	Recommendation in line with marketing authorisation.
290	289	TA132	2007/08	MTA	Ezetimibe (in combination with a statin)	Pharmaceutical	Primary (heterozygous-familial and non-familial) hypercholesterolaemia	Recommended	Recommendation in line with marketing authorisation.
291	290	TA133	2007/08	STA	Omalizumab	Pharmaceutical	Severe persistent allergic (IgE mediated) asthma	Recommended	Recommendation in line with marketing authorisation.
292	291	TA134	2007/08	STA	Infliximab (2nd line)	Pharmaceutical	Plaque psoriasis	Optimised	Optimised recommendation for use in specific circumstances when the psoriasis is very severe and has failed to respond to standard systemic therapies or the person is intolerant to or has a contraindication to these treatments. Treatment with infliximab should only be continued beyond 10 weeks if an adequate response to treatment is achieved.
293	292	TA135	2007/08	MTA	Pemetrexed disodium	Pharmaceutical	Malignant pleural mesothelioma	Recommended	Recommendation in line with clinical practice.
294	293	TA136	2007/08	MTA	Structural neuroimaging techniques (either magnetic resonance imaging [MRI] or computed axial tomography [CT] scanning)	Surgical procedure	Psychosis (first episode)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
295	294	TA137	2007/08	STA	Rituximab (3rd line)	Pharmaceutical	Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma	Recommended	Update of guidance TA37. Recommendation in line with marketing authorisation.
296	295	TA138	2007/08	MTA	Inhaled corticosteroids (ICS) including beclometasone, budesonide, fluticasone, budesonide/formoterol combination, fluticasone/salmeterol combination	Pharmaceutical	Asthma (in adults)	Recommended	Recommendation in line with clinical practice.
297	296	TA139	2007/08	MTA	Fixed or autotitrating continuous positive airway pressure (CPAP) device	Medical device	Obstructive sleep apnoea/hypopnoea syndrome (mild)	Recommended	Recommendation in line with clinical practice.
298	297	TA139	2007/08	MTA	Fixed or autotitrating continuous positive airway pressure (CPAP) device	Medical device	Obstructive sleep apnoea/hypopnoea syndrome (moderate - severe)	Recommended	Recommendation in line with clinical practice.
299	298	TA140	2008/09	STA	Infliximab	Pharmaceutical	Subacute, moderately to severely active ulcerative colitis	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
300	299	TA141	2008/09	STA	Abatacept	Pharmaceutical	Rheumatoid arthritis	Not Recommended	Guidance has been replaced by TA195. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
301	300	TA142	2008/09	MTA	Erythropoietin analogues (epoetin alpha, epoetin beta, darbepoetin)	Pharmaceutical	Cancer treatment-induced anaemia	Optimised	Optimised recommendation for use in specific circumstances for cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer who have symptomatic anaemia with a haemoglobin level of 8 g/100 ml or lower.
302	301	TA143	2008/09	MTA	Adalimumab	Pharmaceutical	Severe ankylosing spondylitis (adults)	Recommended	Recommendation in line with clinical practice.
303	302	TA143	2008/09	MTA	Etanercept	Pharmaceutical	Severe ankylosing spondylitis (adults)	Recommended	Recommendation in line with clinical practice.
304	303	TA143	2008/09	MTA	Infliximab	Pharmaceutical	Severe ankylosing spondylitis (adults)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
305	304	TA144	2008/09	STA	Rimonabant	Pharmaceutical	Overweight and obese adults	Optimised	Optimised recommendation for use in specific circumstances for adults who are obese or overweight and who have had an inadequate response to, are intolerant of, or are contraindicated to orlistat and sibutramine. EMA withdrew the marketing authorisation for this product after TA144 was published.
306	305	TA145	2008/09	STA	Cetuximab	Pharmaceutical	Locally advanced squamous cell cancer of the head and neck	Optimised	Optimised recommendation for use in specific circumstances for people with locally advanced squamous cell cancer of the head and neck whose Karnofsky performance-status score is 90% or greater and for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated.
307	306	TA146	2008/09	STA	Adalimumab	Pharmaceutical	Plaque psoriasis	Recommended	Recommendation in line with clinical practice.
308	307	TA147	2008/09	STA	Bevacizumab (1st line)	Pharmaceutical	Metastatic breast cancer	Terminated Appraisal - non submission	Guidance has been replaced by TA214. The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
309	308	TA148	2008/09	STA	Bevacizumab (1st line)	Pharmaceutical	Unresectable advanced, metastatic or recurrent non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
310	309	TA149	2008/09	STA	Carmustine implants	Pharmaceutical	Recurrent glioblastoma multiforme	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
311	310	TA150	2008/09	STA	Cetuximab (2nd-3rd line)	Pharmaceutical	Metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy	Terminated Appraisal - non submission	Guidance has been replaced by TA242. The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
312	311	TA151	2008/09	MTA	Continuous subcutaneous insulin infusion (CSII or ‘insulin pump’) therapy	Pharmaceutical	Type 1 diabetes	Optimised	Update of guidance TA57. Optimised recommendation for use in specific circumstances for people with type 1 diabetes whose HbA1c levels have remained high (at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care.
313	312	TA152	2008/09	MTA	Drug-eluting stents	Medical device	Coronary artery disease	Optimised	Update of recommendations 1.2 – 1.4 in guidance TA71. Optimised recommendation for use in specific circumstances if a patient’s target artery to be treated has less than a 3-mm calibre or the lesion is longer than 15 mm.
314	313	TA153	2008/09	STA	Entecavir	Pharmaceutical	Chronic Hepatitis B	Recommended	Recommendation in line with marketing authorisation.
315	314	TA154	2008/09	STA	Telbivudine	Pharmaceutical	Chronic Hepatitis B	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
316	315	TA155	2008/09	MTA	Ranibizumab	Pharmaceutical	Wet age-related macular degeneration	Recommended	Recommended after agreement of Patient Access Scheme.
317	316	TA155	2008/09	MTA	Pegaptanib	Pharmaceutical	Wet age-related macular degeneration	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
318	317	TA156	2008/09	MTA	Routine antenatal anti-D prophylaxis	Pharmaceutical	Pregnancy (rhesus negative women)	Recommended	Update of guidance TA41. Recommendation in line with marketing authorisation.
319	318	TA157	2008/09	STA	Dabigatran etexilate	Pharmaceutical	Venous thromboembolism after hip or knee replacement surgery	Recommended	Recommendation in line with marketing authorisation.
320	319	TA158	2008/09	MTA	Amantadine	Pharmaceutical	Influenza (post-exposure prophylaxis)	Not Recommended	Update of guidance TA67. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups.
321	320	TA158	2008/09	MTA	Oseltamivir	Pharmaceutical	Influenza (post-exposure prophylaxis)	Recommended	Update of guidance TA67. Recommendation in line with national influenza guidelines.
322	321	TA158	2008/09	MTA	Zanamivir	Pharmaceutical	Influenza (post-exposure prophylaxis)	Recommended	Recommendation in line with national influenza guidelines.
323	322	TA159	2008/09	MTA	Spinal cord stimulation	Other therapeutic therapies	Chronic pain of neuropathic origin	Optimised	Optimised recommendation for use in specific circumstances for adults who continue to experience chronic pain for at least 6 months despite appropriate conventional medical management.
324	323	TA159	2008/09	MTA	Spinal cord stimulation	Other therapeutic therapies	Chronic pain of ischaemic origin	Only in Research	Only recommended in the context of research designed to generate robust evidence about the benefits of spinal cord stimulation (including pain relief, functional outcomes and quality of life) compared with standard of care.
325	324	TA160	2008/09	MTA	Alendronate	Pharmaceutical	Primary prevention of fragility fractures in postmenopausal women with osteoporosis	Optimised	Optimised recommendation for use under specific circumstances, for postmenopausal women aged 70 years or older who have an independent clinical risk factor for fracture or an indicator of low BMD and who are confirmed to have osteoporosis; In women aged 75 years or older who have two or more independent clinical risk factors for fracture or indicators of low BMD, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible; Women aged 65–69 years who have an independent clinical risk factor for fracture and who are confirmed to have osteoporosis; postmenopausal women younger than 65 years who have an independent clinical risk factor for fracture and at least one additional indicator of low BMD and who are confirmed to have osteoporosis (that is, a T-score of −2.5 SD or below. Replaced with TA464.
326	325	TA160	2008/09	MTA	Etidronate	Pharmaceutical	Primary prevention of fragility fractures in postmenopausal women with osteoporosis	Optimised	Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Withdrawn guidance - no longer marketed in the UK.
327	326	TA160	2008/09	MTA	Risedronate	Pharmaceutical	Primary prevention of fragility fractures in postmenopausal women with osteoporosis	Optimised	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced with TA464.
328	327	TA160	2008/09	MTA	Strontium ranelate	Pharmaceutical	Primary prevention of fragility fractures in postmenopausal women with osteoporosis	Optimised	Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Withdrawn guidance - no longer marketed in the UK.
329	328	TA160	2008/09	MTA	Raloxifene	Pharmaceutical	Primary prevention of fragility fractures in postmenopausal women with osteoporosis	Not recommended	Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture.
330	329	TA161	2008/09	MTA	Alendronate	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Recommended	Update of guidance TA87. Recommendation in line with marketing authorisation. Replaced with TA464.
331	330	TA161	2008/09	MTA	Etidronate	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Update of guidance TA87. Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Withdrawn guidance - no longer marketed in the UK.
332	331	TA161	2008/09	MTA	Raloxifene	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture.
333	332	TA161	2008/09	MTA	Risedronate	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Update of guidance TA87. Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Replaced with TA464.
334	333	TA161	2008/09	MTA	Strontium ranelate	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. Withdrawn guidance - no longer marketed in the UK.
335	334	TA161	2008/09	MTA	Teriparatide	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Update of guidance TA87. Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to take alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate, or who have a contraindication to, or are intolerant of strontium ranelate, or who have had an unsatisfactory response to treatment with alendronate, risedronate or etidronate and who are 65 years or older and have a T-score of –4.0 SD or below, or a T-score of –3.5 SD or below plus more than two fractures, or who are aged 55–64 years and have a T-score of –4 SD or below plus more than two fractures.
336	335	TA162	2008/09	STA	Erlotinib (2nd-line treatment in patients for whom docetaxel is suitable)	Pharmaceutical	Non-small-cell lung cancer	Recommended	Recommendation in line with marketing authorisation and following agreement of a Patient Access Scheme.
337	336	TA162	2008/09	STA	Erlotinib (2nd-line treatment in patients for whom docetaxel is unsuitable; or as a 3rd-line treatment after docetaxel therapy)	Pharmaceutical	Non-small-cell lung cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
338	337	TA163	2008/09	STA	Infliximab	Pharmaceutical	Acute, severely active ulcerative colitis	Recommended	Recommendation in line with marketing authorisation.
339	338	TA164	2008/09	STA	Febuxostat	Pharmaceutical	Chronic hyperuricaemia (in people with gout)	Recommended	Recommendation in line with clinical practice.
340	339	TA165	2008/09	MTA	Cold Static Storage (Belzer UW storage solution or Marshall's hypertonic citrate solution)	Medical device	Organ preservation (renal)	Recommended	Recommendation in line with clinical practice.
341	340	TA165	2008/09	MTA	Machine perfusion systems (LifePort kidney transporter)	Medical device	Organ preservation (renal)	Recommended	Recommendation in line with clinical practice.
342	341	TA166	2008/09	MTA	Sequential bilateral cochlear implantation	Medical device	Severe to profound deafness in children and adults	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
343	342	TA166	2008/09	MTA	Simultaneous bilateral cochlear implantation	Medical device	Severe to profound deafness in children and adults	Optimised	Optimised recommendation for use in specific circumstances for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids; or children; or adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness.
344	343	TA166	2008/09	MTA	Unilateral cochlear implantation	Medical device	Severe to profound deafness in children and adults	Recommended	Recommendation in line with clinical practice.
345	344	TA167	2008/09	MTA	Endovascular stent-grafts	Medical device	Infra-renal abdominal aortic aneurysms (unruptured)	Recommended	Recommendation in line with clinical practice.
346	345	TA167	2008/09	MTA	Endovascular stent-grafts	Medical device	Infra-renal abdominal aortic aneurysms (ruptured)	Only in Research	Only recommended for use in the context of research.
347	346	TA168	2008/09	MTA	Zanamivir	Pharmaceutical	Influenza (treatment)	Recommended	Update of guidance TA58. Recommendation In line with national influenza guidelines.
348	347	TA168	2008/09	MTA	Amantadine	Pharmaceutical	Influenza (treatment)	Not Recommended	Update of guidance TA58. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups.
349	348	TA168	2008/09	MTA	Oseltamivir	Pharmaceutical	Influenza (treatment)	Recommended	Update of guidance TA58. Recommendation In line with national influenza guidelines.
350	349	TA169	2008/09	MTA	Sunitinib (1st line)	Pharmaceutical	Advanced and/or metastatic renal cell carcinoma	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
351	350	TA170	2009/10	STA	Rivaroxaban	Pharmaceutical	Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention)	Recommended	Recommendation in line with marketing authorisation.
352	351	TA171	2009/10	STA	Lenalidomide	Pharmaceutical	Multiple myeloma	Recommended	Recommended following agreement on Patient Access Scheme.
353	352	TA172	2009/10	STA	Cetuximab	Pharmaceutical	Recurrent and/or metastatic squamous cell cancer of the head and neck	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
354	353	TA173	2009/10	STA	Tenofovir disoproxil fumarate	Pharmaceutical	Chronic hepatitis B	Recommended	Recommendation in line with marketing authorisation.
355	354	TA174	2009/10	STA	Rituximab in combination with fludarabine and cyclophosphamide (1st line)	Pharmaceutical	Chronic lymphocytic leukaemia	Optimised	Optimised recommendation for use in specific circumstances in combination with fludarabine and cyclophosphamide.
356	355	TA175	2009/10	STA	Gefitinib (2nd line)	Pharmaceutical	Locally advanced or metastatic non-small-cell-lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
357	356	TA176	2009/10	STA	Cetuximab in combination with 5-fluorouracil (5-FU), folinic acid and oxaliplatin (FOLFOX) (1st line)	Pharmaceutical	Metastatic colorectal cancer	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
358	357	TA176	2009/10	STA	Cetuximab in combination with 5-FU, folinic acid and irinotecan (FOLFIRI) (1st line)	Pharmaceutical	Metastatic colorectal cancer	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
359	358	TA177	2009/10	STA	Alitretinoin	Pharmaceutical	Severe chronic hand eczema	Recommended	Recommendation in line with clinical practice.
360	359	TA178	2009/10	MTA	Bevacizumab (1st line)	Pharmaceutical	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
361	360	TA178	2009/10	MTA	Sorafenib (1st line)	Pharmaceutical	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
362	361	TA178	2009/10	MTA	Temsirolimus (1st line)	Pharmaceutical	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
363	362	TA178	2009/10	MTA	Sunitinib (2nd line)	Pharmaceutical	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
364	363	TA178	2009/10	MTA	Sorafenib (2nd line)	Pharmaceutical	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
365	364	TA179	2009/10	STA	Sunitinib	Pharmaceutical	Unresectable and/or metastatic malignant gastrointestinal stromal tumours	Recommended	Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
366	365	TA180	2009/10	STA	Ustekinumab	Pharmaceutical	Plaque psoriasis	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
367	366	TA181	2009/10	STA	Pemetrexed in combination with cisplatin (1st line)	Pharmaceutical	Locally advanced or metastatic non-small-cell lung cancer	Recommended	Recommendation in line with clinical practice.
368	367	TA182	2009/10	STA	Prasugrel in combination with aspirin	Pharmaceutical	Atherothrombotic events in people with acute coronary syndromes (prevention)	Recommended	Recommendation in line with clinical practice.
369	368	TA183	2009/10	STA	Topotecan in combination with cisplatin	Pharmaceutical	Recurrent or stage IV cervical cancer	Recommended	Recommended in line with marketing authorisation.
370	369	TA184	2009/10	MTA	Oral topotecan	Pharmaceutical	Relapsed small-cell lung cancer	Recommended	Recommendation in line with clinical practice.
371	370	TA184	2009/10	MTA	Intravenous topotecan	Pharmaceutical	Relapsed small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
372	371	TA185	2009/10	STA	Intravenous trabectedin	Pharmaceutical	Advanced soft tissue sarcoma	Recommended	Recommended following agreement of Patient Access Scheme.
373	372	TA186	2009/10	STA	Certolizumab (subcutaneous injection)	Pharmaceutical	Rheumatoid arthritis	Optimised	Optimised recommendation for use in specific circumstances in people who have not had an adequate response following the use of at least 2 DMARDs, and following agreement of Patient Access Scheme.
374	373	TA187	2010/11	MTA	Infliximab	Pharmaceutical	Severe active Crohn's disease (adults)	Recommended	Update of guidance TA40. Recommendation in line with clinical practice.
375	374	TA187	2010/11	MTA	Adalimumab	Pharmaceutical	Severe active Crohn's disease (adults)	Recommended	Recommendation in line with clinical practice.
376	375	TA187	2010/11	MTA	Infliximab	Pharmaceutical	Active fistulising Crohn's disease (adults)	Recommended	Update of guidance TA40. Recommendation in line with clinical practice.
377	376	TA187	2010/11	MTA	Infliximab	Pharmaceutical	Severe active Crohn's disease (children aged 6 - 17 years)	Recommended	Update of guidance TA40. Recommendation in line with clinical practice.
378	377	TA188	2010/11	MTA	Somatropin	Pharmaceutical	Growth failure (children)	Recommended	Update of guidance TA42. Recommendation in line with clinical practice.
379	378	TA189	2010/11	STA	Sorafenib (1st line)	Pharmaceutical	Advanced and metastatic hepatocellular carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
380	379	TA190	2010/11	STA	Pemetrexed (maintenance treatment)	Pharmaceutical	Non-small-cell lung cancer	Recommended	Recommendation in line with marketing authorisation.
381	380	TA191	2010/11	STA	Capecitabine (1st line)	Pharmaceutical	Inoperable advanced gastric cancer	Recommended	Recommendation in line with marketing authorisation
382	381	TA192	2010/11	STA	Gefitinib (1st line)	Pharmaceutical	Locally advanced or metastatic non-small-cell lung cancer	Recommended	Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
383	382	TA193	2010/11	STA	Rituximab in combination with chemotherapy (other than fludarabine and cyclophosphamide)	Pharmaceutical	Relapsed or refractory chronic lymphocytic leukaemia	Only in Research	Due to a lack of clinical and cost effectiveness evidence, the Committee concluded that rituximab plus chemotherapy (other than fludarabine and cyclophosphamide) should only be used for the treatment of relapsed or refractory chronic lymphocytic leukaemia in the context of research.
384	383	TA193	2010/11	STA	Rituximab in combination with fludarabine and cyclophosphamide	Pharmaceutical	Relapsed or refractory chronic lymphocytic leukaemia	Optimised	Optimised recommendation for use in specific circumstances for the treatment of people who have not previously received rituximab (or who have only received rituximab in the context of a clinical trial at a dose lower than the licensed dose for chronic lymphocytic leukaemia, or in combination with chemotherapy other than fludarabine and cyclophosphamide) and whose disease is not refractory to fludarabine.
385	384	TA193	2010/11	STA	Rituximab in combination with fludarabine and cyclophosphamide	Pharmaceutical	Relapsed or refractory chronic lymphocytic leukaemia	Only in Research	For patients who have already received rituximab (in circumstances other than in the context of a clinical trial), rituximab in combination with fludarabine and cyclophosphamide should only be used in the context of research.
386	385	TA194	2010/11	STA	Denosumab	Pharmaceutical	Therapy-induced bone loss in non-metastatic prostate cancer	Terminated Appraisal - non submission	Guidance has been replaced by CG175The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
387	386	TA195	2010/11	MTA	Abatacept in combination with methotrexate (after TNF failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event.
388	387	TA195	2010/11	MTA	Adalimumab in combination with methotrexate (after TNF failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.
389	388	TA195	2010/11	MTA	Adalimumab monotherapy (after TNF failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.
390	389	TA195	2010/11	MTA	Etanercept in combination with methotrexate (after TNF failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Recommendation in line with clinical practice.
391	390	TA195	2010/11	MTA	Etanercept monotherapy (after TNF failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event.
392	391	TA195	2010/11	MTA	Infliximab in combination with methotrexate (after TNF failure)	Pharmaceutical	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.
393	392	TA195	2010/11	MTA	Rituximab in combination with methotrexate (after TNF failure)	Pharmaceutical	Rheumatoid arthritis	Recommended	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.
394	393	TA196	2010/11	STA	Imatinib adjuvant	Pharmaceutical	Gastrointestinal stromal tumours (resectable)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
395	394	TA197	2010/11	STA	Dronedarone (2nd line)	Pharmaceutical	Non-permanent atrial fibrillation	Optimised	Optimised recommendation for use under specific circumstances in people with atrial fibrillation not controlled by first line treatment who also have at least one cardiovascular risk factor.
396	395	TA198	2010/11	STA	Tocilizumab in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis	Optimised	Guidance has been replaced by TA247. Optimised recommendation for use under specific circumstances in people whose rheumatoid arthritis has responded inadequately to one or more tumour necrosis factor alpha (TNF-) inhibitors and whose rheumatoid arthritis has responded inadequately to rituximab or in whom rituximab is contraindicated or when rituximab is withdrawn because of an adverse effect.
397	396	TA199	2010/11	MTA	Adalimumab	Pharmaceutical	Psoriatic arthritis	Recommended	Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
398	397	TA199	2010/11	MTA	Etanercept	Pharmaceutical	Psoriatic arthritis	Recommended	Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
399	398	TA199	2010/11	MTA	Infliximab	Pharmaceutical	Psoriatic arthritis	Recommended	Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
400	399	TA200	2010/11	MTA	Pegylated interferon (2a and 2b) in combination with ribavirin	Pharmaceutical	Chronic hepatitis C	Recommended	Partial update of guidance TA75 and TA106. Recommendation in line with marketing authorisation for people who have been treated previously and whose condition either did not respond to treatment or responded initially to treatment but subsequently relapsed or who are co-infected with HIV.
401	400	TA200	2010/11	MTA	Pegylated interferon (2a and 2b) in combination with ribavirin – shortened treatment course	Pharmaceutical	Chronic hepatitis C	Recommended	Partial update of guidance TA75 and TA106. Recommendation in line with marketing authorisation.
402	401	TA201	2010/11	STA	Omalizumab	Pharmaceutical	Treatment of severe persistent allergic asthma in children aged 6 to 11 years	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
403	402	TA202	2010/11	STA	Ofatumumab	Pharmaceutical	Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available and the proposed Patient Access Scheme.
404	403	TA203	2010/11	STA	Liraglutide 1.2 mg in triple therapy regimens (that is, in combination with metformin and a sulphonylurea, or in combination with metformin and a thiazolidinedione)	Pharmaceutical	Type 2 diabetes	Recommended	Recommendation in line with clinical practice.
405	404	TA203	2010/11	STA	Liraglutide 1.2 mg in dual therapy regimens (that is, in combination with metformin or a sulphonylurea)	Pharmaceutical	Type 2 diabetes	Optimised	Optimised recommendation for use under specific circumstances for people are intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and they are intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated
406	405	TA203	2010/11	STA	Liraglutide 1.8 mg	Pharmaceutical	Type 2 diabetes	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
407	406	TA204	2010/11	STA	Denosumab	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (primary prevention)	Optimised	Optimised recommendation for use under specific circumstances for postmenopausal women who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture.
408	407	TA204	2010/11	STA	Denosumab	Pharmaceutical	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Optimised recommendation for use under specific circumstances for postmenopausal women who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture.
409	408	TA205	2010/11	STA	Eltrombopag	Pharmaceutical	Chronic immune (idiopathic) thrombocytopenic purpura	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
410	409	TA206	2010/11	STA	Bendamustine	Pharmaceutical	Indolent non-Hodgkin's lymphoma that is refractory to rituximab	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
411	410	TA207	2010/11	STA	Temsirolimus	Pharmaceutical	Mantle cell lymphoma (relapsed)	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
412	411	TA208	2010/11	STA	Trastuzumab in combination with cisplatin and capecitabine or 5-fluorouracil	Pharmaceutical	Gastric cancer (HER2-positive, metastatic)	Optimised	Optimised recommendation for use under specific circumstances for people with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior treatment for their metastatic disease and have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3 (IHC3 positive).
413	412	TA209	2010/11	MTA	Imatinib (dose escalation to 600mg/day or 800mg/day following disease progression on 400 mg/day imatinib)	Pharmaceutical	Gastrointestinal stromal tumours (unresectable, metastatic)	Not Recommended	Partial update of guidance TA86 (recommendation 1.4). At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
414	413	TA210	2010/11	MTA	Clopidogrel	Pharmaceutical	Vascular disease	Optimised	Update of guidance TA90. Optimised recommendation for use in specific circumstances for clinical practice for people who have had a myocardial infarction only if aspirin is contraindicated or not tolerated.
415	414	TA210	2010/11	MTA	Clopidogrel	Pharmaceutical	Vascular disease	Recommended	Update of guidance TA90. Recommended in line with clinical practice for people who have had an ischaemic stroke or who have peripheral arterial disease or multivascular disease.
416	415	TA210	2010/11	MTA	Modified-release dipyridamole	Pharmaceutical	Vascular disease	Optimised	Update of guidance TA90. Optimised recommendation for use in specific circumstances for people who have had an ischaemic stroke only if aspirin and clopidogrel are contraindicated or not tolerated.
417	416	TA210	2010/11	MTA	Modified-release dipyridamole	Pharmaceutical	Vascular disease	Recommended	Update of guidance TA90. Recommended in line with clinical practice for people who have had an ischaemic stroke and aspirin is contraindicated or not tolerated.
418	417	TA210	2010/11	MTA	Modified-release dipyridamole in combination with aspirin	Pharmaceutical	Vascular disease	Recommended	Update of guidance TA90. Recommended in line with clinical practice for people who have had a transient ischaemic attack.
419	418	TA210	2010/11	MTA	Modified-release dipyridamole in combination with aspirin	Pharmaceutical	Vascular disease	Optimised	Update of guidance TA90. Optimised recommendation for use in specific circumstances for people who have had an ischaemic stroke only if clopidogrel is contraindicated or not tolerated.
420	419	TA211	2010/11	STA	Prucalopride	Pharmaceutical	Chronic constipation (in women)	Recommended	Recommendation in line with clinical practice
421	420	TA212	2010/11	STA	Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine	Pharmaceutical	Metastatic colorectal cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
422	421	TA213	2010/11	STA	Aripiprazole	Pharmaceutical	Schizophrenia in people aged 15-17 years	Recommended	Recommended in line with clinical practice.
423	422	TA214	2010/11	STA	Bevacizumab in combination with a taxane (1st line)	Pharmaceutical	Metastatic breast cancer	Not Recommended	Update of guidance TA147. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
424	423	TA215	2010/11	STA	Pazopanib (1st line)	Pharmaceutical	Metastatic renal cell carcinoma	Recommended	Recommended in line with clinical practice and after agreement of Patient Access Scheme.
425	424	TA216	2010/11	STA	Bendamustine (1st line)	Pharmaceutical	Chronic lymphocytic leukaemia (Binet stage B or C)	Recommended	Recommendation in line with marketing authorisation.
426	425	TA217	2010/11	MTA	Donepezil	Pharmaceutical	Alzheimer's disease (mild to moderate)	Recommended	Recommendation in line with marketing authorisation.
427	426	TA217	2010/11	MTA	Galantamine	Pharmaceutical	Alzheimer's disease (mild to moderate)	Recommended	Recommendation in line with marketing authorisation.
428	427	TA217	2010/11	MTA	Memantine	Pharmaceutical	Alzheimer's disease (moderate)	Optimised	Optimised recommendation for use under specific circumstances for people with moderate Alzheimer’s disease who are intolerant of or have a contraindication to AChE inhibitors.
429	428	TA217	2010/11	MTA	Memantine	Pharmaceutical	Alzheimer's disease (severe)	Recommended	Recommendation in line with marketing authorisation.
430	429	TA217	2010/11	MTA	Rivastigmine	Pharmaceutical	Alzheimer's disease (mild to moderate)	Recommended	Recommendation in line with marketing authorisation.
431	430	TA218	2010/11	STA	Azacitidine	Pharmaceutical	Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia	Recommended	Recommendation in line with marketing authorisation and after agreement of Patient Access Scheme.
432	431	TA219	2011/12	STA	Everolimus	Pharmaceutical	Advanced renal cell carcinoma (2nd line)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
433	432	TA220	2011/12	STA	Golimumab	Pharmaceutical	Psoriatic arthritis (active and progressive disease)	Recommended	Recommended in line with clinical practice and after agreement of Patient Access Scheme.
434	433	TA221	2011/12	STA	Romiplostim	Pharmaceutical	Chronic immune (idiopathic) thrombocytopenic purpura	Recommended	Recommended in line with clinical practice and after agreement of Patient Access Scheme.
435	434	TA222	2011/12	STA	Trabectedin in combination with pegylated liposomal doxorubicin hydrochloride	Pharmaceutical	Relapsed platinum-sensitive ovarian cancer in women	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
436	435	TA223	2011/12	MTA	Naftidrofyryl oxalate	Pharmaceutical	Intermittent claudication in people with peripheral arterial disease	Recommended	Recommended in line with clinical practice.
437	436	TA223	2011/12	MTA	Cilostazol	Pharmaceutical	Intermittent claudication in people with peripheral arterial disease	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
438	437	TA223	2011/12	MTA	Pentoxifylline	Pharmaceutical	Intermittent claudication in people with peripheral arterial disease	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
439	438	TA223	2011/12	MTA	Inositol nicotinate	Pharmaceutical	Intermittent claudication in people with peripheral arterial disease	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
440	439	TA224	2011/12	STA	Golimumab	Pharmaceutical	Methotrexate-naïve rheumatoid arthritis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
441	440	TA225	2011/12	STA	Golimumab in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate	Optimised	Optimised recommendation for use in specific circumstances in line with TA130, for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Recommendation made after agreement of patient access scheme.
442	441	TA225	2011/12	STA	Golimumab in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor	Optimised	Optimised recommendation for use in specific circumstances in line with TA195, for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event. Recommendation made after agreement of patient access scheme.
443	442	TA226	2011/12	STA	Rituximab (1st line maintenance treatment)	Pharmaceutical	Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.	Recommended	Recommended in line with marketing authorisation.
444	443	TA227	2011/12	STA	Erlotinib (1st line maintenance treatment)	Pharmaceutical	Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available, despite agreement of a patient access scheme.
445	444	TA228	2011/12	MTA	Thalidomide in combination with an alkylating agent and a corticosteroid	Pharmaceutical	Multiple myeloma	Recommended	Recommended in line with marketing authorisation.
446	445	TA228	2011/12	MTA	Bortezomib in combination with an alkylating agent and a corticosteroid	Pharmaceutical	Multiple myeloma	Optimised	Optimised recommendation for use in specific circumstances for people with multiple myeloma if high-dose chemotherapy with stem cell transplantation is considered inappropriate and they are unable to tolerate or have contraindications to thalidomide.
447	446	TA229	2011/12	STA	Dexamethasone intravitreal implant	Pharmaceutical	Macular oedema caused following central retinal vein occlusion	Recommended	Recommended in line with marketing authorisation.
448	447	TA229	2011/12	STA	Dexamethasone intravitreal implant	Pharmaceutical	Macular oedema following branch retinal vein occlusion	Optimised	Optimised recommendation for use in specific circumstances for people with macular oedema following branch retinal vein occlusion when treatment with laser photocoagulation has not been beneficial or is not considered suitable because of the extent of macular haemorrhage.
449	448	TA230	2011/12	STA	Bivalirudin in combination with aspirin and clopidogrel	Pharmaceutical	ST-segment-elevation myocardial infarction	Recommended	Recommended in line with marketing authorisation.
450	449	TA231	2011/12	STA	Agomelatine	Pharmaceutical	Major depressive episodes	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
451	450	TA232	2011/12	STA	Retigabine (adjuvant)	Pharmaceutical	Partial onset seizures in epilepsy	Recommended	Recommended in line with clinical practice.
452	451	TA233	2011/12	STA	Golimumab	Pharmaceutical	Severe ankylosing spondylitis (adults)	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
453	452	TA234	2011/12	STA	Abatacept in combination with methotrexate (2nd line)	Pharmaceutical	Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate	Not Recommended	Guidance has been replaced by TA280. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
454	453	TA235	2011/12	STA	Mifamurtide	Pharmaceutical	Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
455	454	TA236	2011/12	STA	Ticagrelor in combination with low-dose aspirin	Pharmaceutical	Treatment of acute coronary syndromes	Recommended	Recommended in line with clinical practice.
456	455	TA237	2011/12	STA	Ranibizumab	Pharmaceutical	Treatment of visual impairment due to diabetic macular oedema	Not Recommended	Guidance has been replaced by TA274. Optimised recommendation for use in specific circumstances for people with retinal thickness of 400 micrometres or more at the start of treatment and following agreement of patient access scheme.
457	456	TA238	2011/12	STA	Tocilizumab	Pharmaceutical	Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
458	457	TA238	2011/12	STA	Tocilizumab	Pharmaceutical	Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease continues to respond to methotrexate or who have not been previously treated with methotrexate	Not Recommended	At the time of appraisal, no clinical evidence was provided to assess the effect of tocilizumab in children whose disease continues to respond to methotrexate, or in whom methotrexate has not been previously administered.
459	458	TA239	2011/12	STA	Fulvestrant	Pharmaceutical	Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
460	459	TA240	2011/12	STA	Panitumumab in combination with chemotherapy	Pharmaceutical	Treatment of metastatic colorectal cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
461	460	TA241	2011/12	MTA	Nilotinib	Pharmaceutical	Treatment of chronic or accelerated phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults whose CML is resistant to treatment with standard-dose imatinib or who have imatinib intolerance	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
462	461	TA241	2011/12	MTA	Dasatinib	Pharmaceutical	Treatment of chronic, accelerated or blast-crisis phase CML in adults with imatinib intolerance or whose CML is resistant to treatment with standard-dose imatinib	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
463	462	TA241	2011/12	MTA	High dose imatinib	Pharmaceutical	Treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
464	463	TA242	2011/12	MTA	Cetuximab monotherapy or combination chemotherapy	Pharmaceutical	Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy	Not Recommended	The guidance updates and replaces recommendations in TA150. This guidance also partially updates recommendations TA118.
465	464	TA242	2011/12	MTA	Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy	Pharmaceutical	Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
466	465	TA242	2011/12	MTA	Panitumumab monotherapy	Pharmaceutical	Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
467	466	TA243	2011/12	MTA	Rituximab in combination with chemotherapy	Pharmaceutical	First-line treatment of stage III-IV follicular lymphoma	Recommended	This guidance updates and replaces TA110. Recommendation in line with marketing authorisation.
468	467	TA244	2011/12	STA	Roflumilast	Pharmaceutical	Management of severe chronic obstructive pulmonary disease	Only in Research	Only recommended for use in the context of research.
469	468	TA245	2011/12	STA	Apixaban	Pharmaceutical	Prevention of venous thromboembolism after total hip or knee replacement	Recommended	Recommendation in line with marketing authorisation.
470	469	TA246	2011/12	MTA	Pharmalgen	Pharmaceutical	Treatment of bee and wasp venom allergy	Recommended	Recommendation in line with clinical practice.
471	470	TA247	2011/12	STA	Tocilizumab in combination with methotrexate	Pharmaceutical	Treatment of rheumatoid arthritis	Recommended	Update of guidance TA198. Recommendation in line with clinical practice and following agreement of patient access scheme for adults with rheumatoid arthritis if the disease has responded inadequately to DMARDs or the disease has responded inadequately to DMARDs and a TNF inhibitor and the person cannot receive rituximab because of a contraindication to rituximab, or because rituximab is withdrawn because of an adverse event; or the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab.
472	471	TA248	2011/12	STA	Exenatide prolonged-release suspension for injection in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione (triple therapy regimen)	Pharmaceutical	Treatment of type 2 diabetes	Recommended	Recommendation in line with clinical practice.
473	472	TA248	2011/12	STA	Exenatide prolonged-release suspension for injection in combination with metformin or a sulphonylurea (dual therapy regimen)	Pharmaceutical	Treatment of type 2 diabetes	Recommended	Recommendation in line with clinical practice.
474	473	TA249	2011/12	STA	Dabigatran etexilate	Pharmaceutical	Prevention of stroke and systemic embolism in atrial fibrillation	Recommended	Recommendation in line with marketing authorisation.
475	474	TA250	2012/13	STA	Eribulin	Pharmaceutical	Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available despite agreement of a patient access scheme.
476	475	TA251	2012/13	MTA	Standard-dose imatinib (400mg/day)	Pharmaceutical	Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia	Recommended	Partially updates TA70. Recommended in line with marketing authorisation.
477	476	TA251	2012/13	MTA	Nilotinib	Pharmaceutical	Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of PAS.
478	477	TA251	2012/13	MTA	Dasatinib	Pharmaceutical	Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available
479	478	TA252	2012/13	STA	Telaprevir in combination with peginterferon alfa and ribavirin	Pharmaceutical	Treatment of genotype 1 chronic hepatitis C	Recommended	Withdrawn guidance, telaprevir is no longer marketed in the UK. Recommended in line with marketing authorisation
480	479	TA253	2012/13	STA	Boceprevir in combination with peginterferon alfa and ribavirin	Pharmaceutical	Treatment of genotype 1 chronic hepatitis C	Recommended	Recommendation in line with marketing authorisation.
481	480	TA254	2012/13	STA	Fingolimod	Pharmaceutical	Treatment of highly active relapsing-remitting multiple sclerosis	Recommended	Recommendation in line with marketing authorisation and following agreement of patient access scheme.
482	481	TA255	2012/13	STA	Cabazitaxel in combination with prednisone or prednisolone	Pharmaceutical	Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
483	482	TA256	2012/13	STA	Rivaroxaban	Pharmaceutical	Prevention of stroke and systemic embolism in atrial fibrillation	Recommended	Recommendation in line with marketing authorisation.
484	483	TA257	2012/13	MTA	Lapatinib in combination with an aromatase inhibitor (1st line)	Pharmaceutical	Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
485	484	TA257	2012/13	MTA	Trastuzumab in combination with an aromatase inhibitor (1st line)	Pharmaceutical	Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
486	485	TA258	2012/13	STA	Erlotinib (1st line)	Pharmaceutical	Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
487	486	TA259	2012/13	STA	Abiraterone in combination with prednisolone or prednisone (2nd line)	Pharmaceutical	Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
488	487	TA260	2012/13	STA	Botulinum toxin type A	Pharmaceutical	Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.	Recommended	Recommended in line with clinical practice.
489	488	TA261	2012/13	STA	Rivaroxaban	Pharmaceutical	Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism	Recommended	Recommended in line with marketing authorisation.
490	489	TA262	2012/13	STA	Adalimumab	Pharmaceutical	Treatment of moderate to severe ulcerative colitis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
491	490	TA263	2012/13	STA	Bevacizumab in combination with capecitabine (1st line)	Pharmaceutical	First-line treatment of metastatic breast cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
492	491	TA264	2012/13	STA	Alteplase	Pharmaceutical	Ischaemic stroke (acute)	Recommended	Update of guidance TA122. Recommended in line with marketing authorisation.
493	492	TA265	2012/13	MTA	Denosumab	Pharmaceutical	Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate	Recommended	Recommended in line with clinical practice following agreement of patient access scheme.
494	493	TA265	2012/13	MTA	Denosumab	Pharmaceutical	Prevention of skeletal-related events in adults with bone metastases from prostate cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available despite agreement of a patient access scheme.
495	494	TA266	2012/13	STA	Mannitol dry powder for inhalation	Pharmaceutical	Cystic fibrosis	Optimised	Optimised recommendation for use in specific circumstances in people who cannot use rhDNase because of ineligibility, intolerance or inadequate response to rhDNase and whose lung function is rapidly declining (forced expiratory volume in 1 second [FEV1] decline greater than 2% annually) and for whom other osmotic agents are not considered appropriate.
496	495	TA267	2012/13	STA	Ivabradine	Pharmaceutical	Chronic heart failure	Recommended	Recommended in line with clinical practice.
497	496	TA268	2012/13	STA	Ipilimumab	Pharmaceutical	Previously treated advanced (unresectable or metastatic) melanoma	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
498	497	TA269	2012/13	STA	Vemurafenib	Pharmaceutical	Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
499	498	TA270	2012/13	STA	Decitabine	Pharmaceutical	Acute myeloid leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
500	499	TA271	2012/13	STA	Fluocinolone acetonide intravitreal implant	Medical device	Chronic diabetic macular oedema after an inadequate response to prior therapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
501	500	TA272	2012/13	STA	Vinflunine	Pharmaceutical	Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
502	501	TA273	2012/13	STA	Tadalafil	Pharmaceutical	Hyperplasia (benign prostatic)	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
503	502	TA274	2012/13	STA	Ranibizumab	Pharmaceutical	Treatment of visual impairment due to diabetic macular oedema	Optimised	Update of guidance TA237. Optimised recommendation for use in specific circumstances for people with retinal thickness of 400 micrometres or more at the start of treatment and following agreement of patient access scheme.
504	503	TA275	2012/13	STA	Apixaban	Pharmaceutical	Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation	Recommended	Recommended in line with marketing authorisation.
505	504	TA276	2012/13	MTA	Colistimethate sodium	Pharmaceutical	Pseudomonas lung infection in cystic fibrosis	Optimised	Optimised recommendation for use in people with cystic fibrosis only if they would clinically benefit from continued colistimethate sodium but do not tolerate it in its nebulised form and thus tobramycin therapy would otherwise be considered, and following agreement of a patient access scheme.
506	505	TA276	2012/13	MTA	Tobramycin	Pharmaceutical	Pseudomonas lung infection in cystic fibrosis	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
507	506	TA277	2012/13	STA	Methylnaltrexone	Pharmaceutical	Treatment of opioid-induced bowel dysfunction in people with advanced illness receiving palliative care	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
508	507	TA278	2013/14	MTA	Omalizumab	Pharmaceutical	Add-on treatment for severe persistent allergic asthma	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
509	508	TA279	2013/14	MTA	Percutaneous vertebroplasty	Medical device	Vertebral compression fractures	Recommended	Recommended in line with clinical practice.
510	509	TA279	2013/14	MTA	Percutaneous balloon kyphoplasty (without stenting)	Medical device	Vertebral compression fractures	Recommended	Recommended in line with clinical practice.
511	510	TA280	2013/14	STA	Abatacept in combination with methotrexate (2nd line)	Pharmaceutical	Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate	Optimised	Update of guidance TA234. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated) and following agreement of patient access scheme.
512	511	TA281	2013/14	STA	Canakinumab	Pharmaceutical	Gouty arthritis attacks	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
513	512	TA282	2013/14	STA	Pirfenidone	Pharmaceutical	Idiopathic pulmonary fibrosis	Optimised	Optimised recommendation for use under specific circumstances in people who have a forced vital capacity (FVC) between 50% and 80% predicted, and following agreement of a patient access scheme.
514	513	TA283	2013/14	STA	Ranibizumab	Pharmaceutical	Visual impairment caused by macular oedema secondary to central retinal vein occlusion	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
515	514	TA283	2013/14	STA	Ranibizumab	Pharmaceutical	Visual impairment caused by macular oedema secondary to branch retinal vein occlusion	Optimised	Optimised recommendation for treating visual impairment caused by macular oedema following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage, and following agreement of a patient access scheme.
516	515	TA284	2013/14	STA	Bevacizumab in combination with paclitaxel and carboplatin	Pharmaceutical	Advanced ovarian cancer (1st line)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
517	516	TA285	2013/14	STA	Bevacizumab in combination with gemcitabine and carboplatin	Pharmaceutical	First recurrence of platinum-sensitive advanced ovarian cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
518	517	TA286	2013/14	STA	Loxapine inhalation	Pharmaceutical	Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
519	518	TA287	2013/14	STA	Rivaroxaban	Pharmaceutical	Treating pulmonary embolism and preventing recurrent venous thromboembolism	Recommended	Recommended in line with marketing authorisation.
520	519	TA288	2013/14	STA	Dapagliflozin in a dual therapy regimen in combination with metformin	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
521	520	TA288	2013/14	STA	Dapagliflozin in combination with insulin with or without other antidiabetic drugs	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with marketing authorisation.
522	521	TA288	2013/14	STA	Dapagliflozin in a triple therapy regimen in combination with metformin and a sulfonylurea	Pharmaceutical	Type 2 diabetes	Only in Research	Only recommended as part of a clinical trial.
523	522	TA289	2013/14	STA	Ruxolitinib	Pharmaceutical	Disease-related splenomegaly or symptoms in adults with myelofibrosis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
524	523	TA290	2013/14	STA	Mirabegron	Pharmaceutical	Symptoms of overactive bladder	Optimised	Optimised recommendation for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.
525	524	TA291	2013/14	STA	Pegloticase	Pharmaceutical	Severe debilitating chronic tophaceous gout	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
526	525	TA292	2013/14	STA	Aripiprazole	Pharmaceutical	Moderate to severe manic episodes in adolescents with bipolar I disorder	Recommended	Recommended in line with marketing authorisation.
527	526	TA293	2013/14	STA	Eltrombopag	Pharmaceutical	Chronic immune (idiopathic) thrombocytopenic purpura	Optimised	Optimised recommendation for treating adults with chronic immune (idiopathic) thrombocytopenic purpura, within its marketing authorisation, only if: their condition is refractory to standard active treatments and rescue therapies, or they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies and the manufacturer provides eltrombopag with the discount agreed in the patient access scheme.
528	527	TA294	2013/14	STA	Aflibercept solution for injection	Pharmaceutical	Wet age‑related macular degeneration	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
529	528	TA295	2013/14	STA	Everolimus in combination with exemestane	Pharmaceutical	Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
530	529	TA296	2013/14	STA	Crizotinib	Pharmaceutical	Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
531	530	TA297	2013/14	STA	Ocriplasmin	Pharmaceutical	Vitreomacular traction	Optimised	Optimised recommendation for treating vitreomacular traction in adults, only if: an epiretinal membrane is not present and they have a stage II full-thickness macular hole with a diameter of 400 micrometres or less and/or they have severe symptoms.
532	531	TA298	2013/14	STA	Ranibizumab	Pharmaceutical	Choroidal neovascularisation associated with pathological myopia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
533	532	TA299	2013/14	STA	Bosutinib	Pharmaceutical	Previously treated chronic myeloid leukaemia	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Guidance has been replaced.
534	533	TA300	2013/14	MTA	Peginterferon alfa in combination with ribavirin	Pharmaceutical	Chronic hepatitis C in children and young people	Recommended	Recommended in line with marketing authorisation.
535	534	TA301	2013/14	STA	Fluocinolone acetonide intravitreal implant	Medical device	Chronic diabetic macular oedema after an inadequate response to prior therapy	Optimised	Optimised recommendation for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if the implant is to be used in an eye with an intraocular (pseudophakic) lens and the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.
536	535	TA302	2013/14	STA	Canakinumab	Pharmaceutical	Systemic juvenile idiopathic arthritis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
537	536	TA303	2013/14	STA	Teriflunomide	Pharmaceutical	Relapsing-remitting multiple sclerosis	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme
538	537	TA304	2013/14	MTA	Total hip replacement	Medical device	End-stage arthritis of the hip	Recommended	Recommended in line with clinical practice
539	538	TA304	2013/14	MTA	Resurfacing anthroplasty	Medical device	End-stage arthritis of the hip	Recommended	Recommended in line with clinical practice
540	539	TA305	2013/14	STA	Aflibercept solution for injection	Pharmaceutical	Visual impairment caused by macular oedema secondary to central retinal vein occlusion	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
541	540	TA306	2013/14	STA	Pixantrone monotherapy	Pharmaceutical	Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma	Optimised	Optimised recommendation for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma only if: the person has previously been treated with rituximab and the person is receiving third- or fourth-line treatment and the manufacturer provides pixantrone with the discount agreed in the patient access scheme.
542	541	TA307	2013/14	STA	Aflibercept in combination with irinotecan and fluorouracil-based therapy	Pharmaceutical	Metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
543	542	TA308	2013/14	STA	Rituximab in combination with glucocorticoids	Pharmaceutical	Anti-neutrophil cytoplasmic antibody-associated vasculitis	Optimised	Optimised recommendation for inducing remission in adults with ANCA-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if: further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose or cyclophosphamide is contraindicated or not tolerated or the person has not completed their family and treatment with cyclophosphamide may materially affect their fertility or the disease has remained active or progressed despite a course of cyclophosphamide lasting 3–6 months or the person has had uroepithelial malignancy.
544	543	TA309	2014/15	STA	Pemetrexed	Pharmaceutical	Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
545	544	TA310	2014/15	STA	Afatinib	Pharmaceutical	Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
546	545	TA311	2014/15	STA	Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide	Pharmaceutical	For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation	Recommended	Recommended in line with marketing authorisation.
547	546	TA312	2014/15	STA	Alemtuzumab	Pharmaceutical	Relapsing-remitting multiple sclerosis	Recommended	Recommended in line with marketing authorisation.
548	547	TA313	2014/15	STA	Ustekinumab alone or in combination with methotrexate	Pharmaceutical	Active psoriatic arthritis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
549	548	TA314	2014/15	MTA	Implantable cardioverter defibrillators	Medical device	Arrhythmias and heart failure	Optimised	Optimised recommendation. The Committee looked at 20 subgroups of patients for all combinations of New York Heart Association (NYHA) class, QRS duration and presence of left bundle branch block (LBBB). Please see table 1 in TA314 for the recommendations for each subgroup. The Committee also concluded that the recommendation in NICE technology appraisal guidance 95 regarding previous serious ventricular arrhythmia, certain familial cardiac conditions and after surgical repair of congenital heart disease did not need to be changed.
550	549	TA314	2014/15	MTA	Cardiac resynchronisation therapy (CRT-D and CRT-P)	Medical device	Arrhythmias and heart failure	Optimised	Optimised recommendation. The Committee looked at 20 subgroups of patients for all combinations of New York Heart Association (NYHA) class, QRS duration and presence of left bundle branch block (LBBB). Please see table 1 in TA314 for the recommendations for each subgroup.
551	550	TA315	2014/15	STA	Canagliflozin in combination with metformin (dual therapy)	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with marketing authorisation.
552	551	TA315	2014/15	STA	Canagliflozin in combination with metformin and a sulfonylurea/thiazolidinedione (triple therapy)	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
553	552	TA315	2014/15	STA	Canagliflozin in combination with insulin with or without other antidiabetic drugs	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
554	553	TA316	2014/15	STA	Enzalutamide	Pharmaceutical	Metastatic hormone-relapsed prostate cancer	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
555	554	TA317	2014/15	MTA	Prasugrel in combination with aspirin	Pharmaceutical	Acute coronary syndromes	Recommended	Recommended in line with marketing authorisation
556	555	TA318	2014/15	STA	Lubiprostone	Pharmaceutical	Chronic idiopathic constipation	Recommended	Recommended in line with clinical practice
557	556	TA319	2014/15	STA	Ipilimumab	Pharmaceutical	Previously untreated advanced (unresectable or metastatic) melanoma	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
558	557	TA320	2014/15	STA	Dimethyl fumarate	Pharmaceutical	Relapsing-remitting multiple sclerosis	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme
559	558	TA321	2014/15	STA	Dabrafenib	Pharmaceutical	Unresectable or metastatic BRAF V600 mutation‑positive melanoma	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
560	559	TA322	2014/15	STA	Lenalidomide	Pharmaceutical	Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
561	560	TA323	2014/15	MTA	Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa)	Pharmaceutical	Treating anaemia in people with cancer having chemotherapy	Recommended	Recommended in line with marketing authorisation
562	561	TA324	2014/15	MTA	Dual chamber pacemakers	Medical device	Symptomatic bradycardia due to sick sinus syndrome without atrioventricular block	Recommended	Recommended in line with clinical practice
563	562	TA325	2014/15	STA	Nalmefene	Pharmaceutical	Reducing alcohol consumption in people with alcohol dependence	Recommended	Recommended in line with marketing authorisation
564	563	TA326	2014/15	STA	Imatinib	Pharmaceutical	Adjuvant treatment of gastrointestinal stromal tumours	Recommended	Recommended in line with clinical practice
565	564	TA327	2014/15	STA	Dabigatran etexilate	Pharmaceutical	treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Recommended	Recommended in line with marketing authorisation
566	565	TA328	2014/15	STA	Idelalisib	Pharmaceutical	follicular lymphoma that is refractory to 2 prior treatments	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
567	566	TA329	2014/15	MTA	Infliximab	Pharmaceutical	moderately to severely active ulcerative colitis after the failure of conventional therapy	Recommended	Recommended in line with marketing authorisation
568	567	TA329	2014/15	MTA	Adalimumab	Pharmaceutical	moderately to severely active ulcerative colitis after the failure of conventional therapy	Recommended	Recommended in line with marketing authorisation
569	568	TA329	2014/15	MTA	Golimumab	Pharmaceutical	moderately to severely active ulcerative colitis after the failure of conventional therapy	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
570	569	TA330	2014/15	STA	Sofosbuvir	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation. Sofosbuvir was recommended only for some groups depending on genotype combined with treatment history.
571	570	TA331	2014/15	STA	Simeprevir in combination with peginterferon alfa and ribavirin	Pharmaceutical	Treating genotypes 1 and 4 chronic hepatitis C	Recommended	Recommended in line with marketing authorisation. Simeprevir also has a marketing authorisation for use in combination with sofosbuvir. Recommendations for simeprevir in combination with sofosbuvir will be developed in separate guidance.
572	571	TA332	2014/15	STA	Sipuleucel-T	Pharmaceutical	Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. This guidance has been withdrawn after publication, because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
573	572	TA333	2014/15	STA	Axitinib	Pharmaceutical	treating advanced renal cell carcinoma after failure of prior systemic treatment	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
574	573	TA334	2014/15	STA	Regorafenib	Pharmaceutical	Metastatic colorectal cancer after treatment for metastatic disease	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
575	574	TA335	2014/15	STA	Rivaroxaban in combination with aspirin plus clopidogrel or aspirin alone	Pharmaceutical	Preventing adverse outcomes after acute management of acute coronary syndrome	Recommended	Recommended in line with marketing authorisation.
576	575	TA336	2014/15	STA	Empagliflozin in a dual therapy regimen in combination with metformin	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
577	576	TA336	2014/15	STA	Empagliflozin in a triple therapy regimen in combination with metformin and either a sulfonylurea or a thiazolidinedione	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
578	577	TA336	2014/15	STA	Empagliflozin in combination with insulin with or without other antidiabetic drugs	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
579	578	TA337	2014/15	STA	Rifaximin	Pharmaceutical	Preventing episodes of overt hepatic encephalopathy	Recommended	Recommended in line with marketing authorisation.
580	579	TA338	2014/15	STA	Pomalidomide in combination with dexamethasone	Pharmaceutical	Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
581	580	TA339	2015/16	STA	Omalizumab	Pharmaceutical	Previously treated chronic spontaneous urticaria	Optimised	Optimised recommendation for omalizumab as an option as add‑on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over only if: • the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or morethe person's condition has not responded to standard treatment with H1‑antihistamines and leukotriene receptor antagonists; • omalizumab is stopped at or before the fourth dose if the condition has not responded; • omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded, to establish whether the condition has gone into spontaneous remission, and is restarted only if the condition relapses; • omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy; and the company provides omalizumab with the discount agreed in the patient access scheme.
582	581	TA340	2015/16	STA	Ustekinumab, alone or in combination with methotrexate	Pharmaceutical	Active psoriatic arthritis	Optimised	Optimised recommendation for ustekinumab, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when: • treatment with tumour necrosis factor (TNF) alpha inhibitors is contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and golimumab for the treatment of psoriatic arthritis) or • the person has had treatment with 1 or more TNF‑alpha inhibitors. and if the company provides the 90 mg dose of ustekinumab for people who weigh more than 100 kg at the same cost as the 45 mg dose, as agreed in the patient access scheme.
583	582	TA341	2015/16	STA	Apixaban	Pharmaceutical	Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Recommended	Recommended in line with marketing authorisation
584	583	TA342	2015/16	STA	Vedolizumab	Pharmaceutical	Moderately to severely active ulcerative colitis	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
585	584	TA343	2015/16	STA	Obinutuzumab in combination with chlorambucil	Pharmaceutical	Untreated chronic lymphocytic leukaemia	Optimised	Optimised recommendation for obinutuzumab in combination with chlorambucil as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full‑dose fludarabine‑based therapy unsuitable for them, only if: bendamustine‑based therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme.
586	585	TA344	2015/16	STA	Ofatumumab in combination with chlorambucil	Pharmaceutical	Untreated chronic lymphocytic leukaemia	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
587	586	TA345	2015/16	STA	Naloxegol	Pharmaceutical	Opioid‑induced constipation	Recommended	Recommended in line with marketing authorisation.
588	587	TA346	2015/16	STA	Aflibercept	Pharmaceutical	Diabetic macular oedema	Optimised	Optimised recommendation for aflibercept solution for injection as an option for treating visual impairment caused by diabetic macular oedema only if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and the company provides aflibercept with the discount agreed in the patient access scheme.
589	588	TA347	2015/16	STA	Nintedanib in combination with docetaxel	Pharmaceutical	Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
590	589	TA348	2015/16	STA	Everolimus	Pharmaceutical	Preventing organ rejection in liver transplantation	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
591	590	TA349	2015/16	STA	Dexamethasone intravitreal implant	Pharmaceutical	Diabetic macular oedema	Optimised	Optimised recommendation for dexamethasone intravitreal implant as an option for treating diabetic macular oedema only if: the implant is to be used in an eye with an intraocular (pseudophakic) lens and the diabetic macular oedema does not respond to non‑corticosteroid treatment, or such treatment is unsuitable.
592	591	TA350	2015/16	STA	Secukinumab	Pharmaceutical	Moderate to severe plaque psoriasis	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
593	592	TA351	2015/16	STA	Cangrelor	Pharmaceutical	Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
594	593	TA352	2015/16	STA	Vedolizumab	Pharmaceutical	Treating moderately to severely active Crohn's disease after prior therapy	Optimised	Optimised recommendation for vedolizumab for treating moderately to severely active Crohn's disease only if: a tumour necrosis factor‑alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is contraindicated. Vedolizumab is recommended only if the company provides it with the discount agreed in the patient access scheme.
595	594	TA353	2015/16	STA	Bevacizumab	Pharmaceutical	Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
596	595	TA354	2015/16	STA	Edoxaban	Pharmaceutical	Treating and preventing deep vein thrombosis and pulmonary embolism	Recommended	Recommended in line with marketing authorisation.
597	596	TA355	2015/16	STA	Edoxaban	Pharmaceutical	Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation	Recommended	Recommended in line with marketing authorisation.
598	597	TA356	2015/16	STA	Ruxolitinib	Pharmaceutical	Treating polycythaemia vera	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
599	598	TA357	2015/16	STA	Pembrolizumab	Pharmaceutical	Treating advanced melanoma after disease progression with ipilimumab	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
600	599	TA358	2015/16	STA	Tolvaptan	Pharmaceutical	Treating autosomal dominant polycystic kidney disease	Optimised	Optimised recommendation for tolvaptan as an option for treating autosomal dominant polycystic kidney disease (ADPKD) in adults to slow the progression of cyst development and renal insufficiency only if: • they have chronic kidney disease stage 2 or 3 at the start of treatment • there is evidence of rapidly progressing disease and • the company provides it with the discount agreed in the patient access scheme.
601	600	TA359	2015/16	STA	Idelalisib in combination with rituximab	Pharmaceutical	Treating chronic lymphocytic leukaemia	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme. Note: no evidence presented for population not recommended.
602	601	TA360	2015/16	STA	Paclitaxel as albumin‑bound nanoparticles in combination with gemcitabine	Pharmaceutical	Previously untreated metastatic pancreatic cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
603	602	TA361	2015/16	STA	Simeprevir in combination with sofosbuvir	Pharmaceutical	Treating genotype 1 or 4 chronic hepatitis C	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
604	603	TA362	2015/16	STA	Paclitaxel as albumin-bound nanoparticles with carboplatin	Pharmaceutical	Untreated non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
605	604	TA363	2015/16	STA	Ledipasvir–sofosbuvir	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation for ledipasvir–sofosbuvir for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history. Please see the final guidance section 1 for the detailed recommendations.
606	605	TA363	2015/16	STA	Ledipasvir–sofosbuvir plus ribavirin	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation for ledipasvir–sofosbuvir plus ribavirin for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history. Please see the final guidance section 1 for the detailed recommendations.
607	606	TA364	2015/16	STA	Daclatasvir plus sofosbuvir	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation for daclatasvir plus sofosbuvir for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history and only if the company provides daclatasvir at the same price or lower than that agreed with the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations.
608	607	TA364	2015/16	STA	Daclatasvir plus sofosbuvir and ribavirin	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation for daclatasvir plus sofosbuvir and ribavirin for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history and only if the company provides daclatasvir at the same price or lower than that agreed with the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations.
609	608	TA364	2015/16	STA	Daclatasvir plus peginterferon alfa and ribavirin	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation for daclatasvir plus peginterferon alfa and ribavirin for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history and only if the company provides daclatasvir at the same price or lower than that agreed with the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations.
610	609	TA365	2015/16	STA	Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin	Pharmaceutical	Chronic hepatitis C	Recommended	Recommended in line with marketing authorisation and only if only if the company provides ombitasvir–paritaprevir–ritonavir and dasabuvir at the same price or lower than that agreed with the Commercial Medicines Unit
611	610	TA365	2015/16	STA	Ombitasvir–paritaprevir–ritonavir with ribavirin	Pharmaceutical	Chronic hepatitis C	Recommended	Recommended in line with marketing authorisation and only if only if the company provides ombitasvir–paritaprevir–ritonavir and ribavirin at the same price or lower than that agreed with the Commercial Medicines Unit
612	611	TA366	2015/16	STA	Pembrolizumab	Pharmaceutical	Advanced melanoma not previously treated with ipilimumab	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme. Note: The MA was appraised across 2 separate appraisals, both recommended (see TA357).
613	612	TA367	2015/16	STA	Vortioxetine	Pharmaceutical	Major depressive episodes	Recommended	Recommended in line with clinical practice.
614	613	TA368	2015/16	STA	Apremilast	Pharmaceutical	Moderate to severe plaque psoriasis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
615	614	TA369	2015/16	STA	Ciclosporin	Pharmaceutical	Treating dry eye disease that has not improved despite treatment with artificial tears	Recommended	Recommended in line with marketing authorisation
616	615	TA370	2015/16	STA	Bortezomib	Pharmaceutical	Previously untreated mantle cell lymphoma	Recommended	Recommended in line with marketing authorisation
617	616	TA371	2015/16	STA	Trastuzumab emtansine	Pharmaceutical	Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
618	617	TA372	2015/16	STA	Apremilast alone or in combination with disease‑modifying antirheumatic drug (DMARD) therapy	Pharmaceutical	Treating active psoriatic arthritis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
619	618	TA373	2015/16	MTA	Abatecept	Pharmaceutical	Treating juvenile idiopathic arthritis	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
620	619	TA373	2015/16	MTA	Adalimumab	Pharmaceutical	Treating juvenile idiopathic arthritis	Recommended	Recommended in line with marketing authorisation.
621	620	TA373	2015/16	MTA	Etanercept	Pharmaceutical	Treating juvenile idiopathic arthritis	Recommended	Recommended in line with marketing authorisation.
622	621	TA373	2015/16	MTA	Tocilizumab	Pharmaceutical	Treating juvenile idiopathic arthritis	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
623	622	TA374	2015/16	MTA	Erlotinib	Pharmaceutical	Treating non-small-cell lung cancer that has progressed after prior chemotherapy	Optimised	Optimised recommendation for erlotinib, only if the company provides erlotinib with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 258: Erlotinib is recommended as an option for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed in people who have had non‑targeted chemotherapy because of delayed confirmation that their tumour is epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation‑positive. Erlotinib is recommended as an option for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed after non‑targeted chemotherapy in people with tumours of unknown EGFR‑TK mutation status, only if: the result of an EGFR‑TK mutation diagnostic test is unobtainable because of an inadequate tissue sample or poor‑quality DNA and the treating clinician considers that the tumour is very likely to be EGFR‑TK mutation‑positive and the person's disease responds to the first 2 cycles of treatment with erlotinib. Erlotinib is not recommended for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed after non‑targeted chemotherapy in people with tumours that are EGFR‑TK mutation‑negative.
624	623	TA374	2015/16	MTA	Gefitinib	Pharmaceutical	Treating non-small-cell lung cancer that has progressed after prior chemotherapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
625	624	TA375	2015/16	MTA	Adalimumab	Pharmaceutical	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Optimised	Optimised recommendation for adalimumab in combination with methotrexate only if: disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional DMARDs Adalimumab as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met.
626	625	TA375	2015/16	MTA	Etanercept	Pharmaceutical	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Optimised	Optimised recommendation for etanercept in combination with methotrexate only if: disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional DMARDs Etanercept as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met.
627	626	TA375	2015/16	MTA	Infliximab in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Optimised	Optimised recommendation for infliximab in combination with methotrexate only if: disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional DMARDs
628	627	TA375	2015/16	MTA	Certolizumab Pegol	Pharmaceutical	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Optimised	Optimised recommendation for Certolizumab pegol in combination with methotrexate only if: disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional DMARDs the company provides certolizumab pegol as agreed in the patient access scheme Certolizumab pegol as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met.
629	628	TA375	2015/16	MTA	Golimumab in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Optimised	Optimised recommendation for golimumab in combination with methotrexate only if: disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional DMARDs the company provides golimumab as agreed in the patient access scheme
630	629	TA375	2015/16	MTA	Tocilizumab	Pharmaceutical	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Optimised	Optimised recommendation for tocilizumab in combination with methotrexate only if: disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional DMARDs the company provides tocilizumab as agreed in the patient access scheme Tocilizumab as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met.
631	630	TA375	2015/16	MTA	Abatacept in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Optimised	Optimised recommendation for abatacept in combination with methotrexate only if: disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional DMARDs the company provides abatacept as agreed in the patient access scheme
632	631	TA376	2015/16	STA	Radium-223 dichloride	Pharmaceutical	Treating hormone-relapsed prostate cancer with bone metastases	Optimised	Optimised recommendation for Radium‑223 dichloride as an option for treating adults with hormone‑relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, only if: • they have had treatment with docetaxel, and • the company provides radium‑223 dichloride with the discount agreed in the patient access scheme.
633	632	TA377	2015/16	STA	Enzalutamide	Pharmaceutical	Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
634	633	TA378	2015/16	STA	Ramucirumab alone or with paclitaxel	Pharmaceutical	Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
635	634	TA379	2015/16	STA	Nintedanib	Pharmaceutical	Treating idiopathic pulmonary fibrosis	Optimised	Optimised recommendation for nintedanib as an option for treating idiopathic pulmonary fibrosis, only if: the person has a forced vital capacity (FVC) between 50% and 80% of predicted the company provides nintedanib with the discount agreed in the patient access scheme treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12‑month period.
636	635	TA380	2015/16	STA	Panobinostat in combination with bortezomib and dexamethasone	Pharmaceutical	Treating multiple myeloma after at least 2 previous treatments	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
637	636	TA381	2015/16	STA	Olaparib	Pharmaceutical	Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy	Optimised	Optimised recommendation for olaparib as an option for treating adults with relapsed, platinum‑sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum‑based chemotherapy only if: they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months will be met by the company.
638	637	TA382	2015/16	STA	Eltrombopag	Pharmaceutical	Treating severe aplastic anaemia refractory to immunosuppressive therapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
639	638	TA383	2015/16	MTA	Adalimumab	Pharmaceutical	Ankylosing spondylitis and non-radiographic axial spondyloarthritis	Recommended	Recommended in line with marketing authorisation.
640	639	TA383	2015/16	MTA	Certolizumab pegol	Pharmaceutical	Ankylosing spondylitis and non-radiographic axial spondyloarthritis	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
641	640	TA383	2015/16	MTA	Etanercept	Pharmaceutical	Ankylosing spondylitis	Recommended	Recommended in line with marketing authorisation.
642	641	TA383	2015/16	MTA	Golimumab	Pharmaceutical	Ankylosing spondylitis	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme. Golimumab has a marketing authorisation for non‑radiographic axial spondyloarthritis. However, regulatory approval was received at a late stage in the appraisal process so golimumab was not included for this indication.
643	642	TA383	2015/16	MTA	Infliximab	Pharmaceutical	Ankylosing spondylitis	Recommended	Recommended in line with marketing authorisation.
644	643	TA384	2015/16	STA	Nivolumab	Pharmaceutical	Advanced (unresectable or metastatic) melanoma	Recommended	Recommended in line with marketing authorisation.
645	644	TA385	2015/16	STA	Ezetimibe monotherapy	Pharmaceutical	Treating primary heterozygous-familial and non-familial hypercholesterolaemia	Recommended	Recommended in line with marketing authorisation.
646	645	TA385	2015/16	STA	Ezetimibe co‑administered with initial statin therapy	Pharmaceutical	Treating primary heterozygous-familial and non-familial hypercholesterolaemia	Recommended	Recommended in line with marketing authorisation.
647	646	TA386	2015/16	STA	Ruxolitinib	Pharmaceutical	Treating disease-related splenomegaly or symptoms in adults with myelofibrosis	Optimised	Optimised recommendation for ruxolitinib for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only: •in people with intermediate‑2 or high-risk disease, and •if the company provides ruxolitinib with the discount agreed in the patient access scheme.
648	647	TA387	2016/17	STA	Abiraterone in combination with prednisone or prednisolone	Pharmaceutical	Treating metastatic hormone-relapsed prostate cancer before chemotherapy	Recommended	Recommended in line with the marketing authorisation, only if the company rebates the drug cost of abiraterone from the 11th month until the end of treatment for people who remain on treatment for more than 10 months.
649	648	TA388	2016/17	STA	Sacubitril valsartan	Pharmaceutical	Treating symptomatic chronic heart failure with reduced ejection fraction	Optimised	Optimised recommendation for treating symptomatic chronic heart failure with reduced ejection fraction, only in people: •with New York Heart Association (NYHA) class II to IV symptoms and •with a left ventricular ejection fraction of 35% or less and •who are already taking a stable dose of angiotensin‑converting enzyme (ACE) inhibitors or angiotensin II receptor‑blockers (ARBs).
650	649	TA389	2016/17	MTA	Paclitaxel in combination with platinum or as monotherapy	Pharmaceutical	Treating recurrent ovarian cancer	Recommended	Recommended in line with marketing authorisation.
651	650	TA389	2016/17	MTA	Pegylated liposomal doxorubicin hydrochloride (PLDH) monotherapy	Pharmaceutical	Treating recurrent ovarian cancer	Recommended	Recommended in line with marketing authorisation.
652	651	TA389	2016/17	MTA	PLDH in combination with platinum	Pharmaceutical	Treating recurrent ovarian cancer	Recommended	Recommended in line with clinical practice. The use of PLDH (Caelyx) in combination with platinum is outside the terms of the marketing authorisation. Consequently the statutory funding requirement does not apply to this recommendation.
653	652	TA389	2016/17	MTA	Gemcitabine in combination with carboplatin	Pharmaceutical	Treating recurrent ovarian cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
654	653	TA389	2016/17	MTA	Trabectedin in combination with PLDH	Pharmaceutical	Treating recurrent ovarian cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
655	654	TA389	2016/17	MTA	Topotecan	Pharmaceutical	Treating recurrent ovarian cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
656	655	TA390	2016/17	MTA	Canagliflozin monotherapy	Pharmaceutical	Treating type 2 diabetes	Optimised	Optimised recommendation for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if: • a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and • a sulfonylurea or pioglitazone is not appropriate.
657	656	TA390	2016/17	MTA	Dapagliflozin monotherapy	Pharmaceutical	Treating type 2 diabetes	Optimised	Optimised recommendation for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if: • a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and • a sulfonylurea or pioglitazone is not appropriate.
658	657	TA390	2016/17	MTA	Empagliflozin monotherapy	Pharmaceutical	Treating type 2 diabetes	Optimised	Optimised recommendation for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if: • a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and • a sulfonylurea or pioglitazone is not appropriate.
659	658	TA391	2016/17	STA	Cabazitaxel in combination with prednisone or prednisolone	Pharmaceutical	Treating hormone-relapsed metastatic prostate cancer treated with docetaxel	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
660	659	TA392	2016/17	STA	Adalimumab	Pharmaceutical	Treating moderate to severe hidradenitis suppurativa	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
661	660	TA393	2016/17	STA	Alirocumab	Pharmaceutical	Treating primary hypercholesterolaemia and mixed dyslipidaemia	Optimised	Optimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if: Low‑density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid‑lowering therapy. That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in NICE's guideline on familial hypercholesterolaemia: identification and management), and the company provides alirocumab with the discount agreed in the patient access scheme.
662	661	TA394	2016/17	STA	Evolocumab	Pharmaceutical	Treating primary hypercholesterolaemia and mixed dyslipidaemia	Optimised	Optimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if: The dosage is 140 mg every 2 weeks. Low-density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached, or further titration is limited by intolerance (as defined in NICE's guideline on familial hypercholesterolaemia). The company provides evolocumab with the discount agreed in the patient access scheme
663	662	TA395	2016/17	STA	Ceritinib	Pharmaceutical	Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation
664	663	TA396	2016/17	STA	Trametinib in combination with dabrafenib	Pharmaceutical	Treating unresectable or metastatic melanoma	Recommended	Recommended in line with marketing authorisation
665	664	TA397	2016/17	STA	Belimumab	Pharmaceutical	Treating active autoantibody-positive systemic lupus erythematosus	Optimised	Optimised recommendation for belimumab as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in adults only if all of the following apply: ·         There is evidence for serological disease activity (defined as positive anti-double-stranded DNA and low complement) and a Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of greater than or equal to 10 despite standard treatment. ·         Treatment with belimumab is continued beyond 24 weeks only if the SELENA-SLEDAI score has improved by 4 points or more. ·         The company provides belimumab with the discount agreed in the patient access scheme. ·         Under the conditions for data collection, monitoring, patient eligibility and consent, ongoing treatment, cost to the NHS, and review by NICE as laid out in sections 5 and 6 of this document.
666	665	TA398	2016/17	STA	Lumacaftor–ivacaftor	Pharmaceutical	Treating cystic fibrosis homozygous for the F508del mutation	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
667	666	TA399	2016/17	STA	Azacitidine	Pharmaceutical	Treating acute myeloid leukaemia with more than 30% bone marrow blasts	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
668	667	TA400	2016/17	STA	Nivolumab in combination with ipilimumab	Pharmaceutical	Treating advanced melanoma	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
669	668	TA401	2016/17	STA	Bosutinib	Pharmaceutical	Previously treated chronic myeloid leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
670	669	TA402	2016/17	STA	Pemetrexed	Pharmaceutical	Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
671	670	TA403	2016/17	STA	Ramucirumab in combination with docetaxel	Pharmaceutical	Previously treated locally advanced or metastatic non-small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
672	671	TA404	2016/17	STA	Degarelix	Pharmaceutical	Advanced hormone-dependent prostate cancer	Optimised	Optimised recommendation for degarelix as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016.
673	672	TA405	2016/17	STA	Trifluridine–tipiracil	Pharmaceutical	Previously treated metastatic colorectal cancer	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
674	673	TA406	2016/17	STA	Crizotinib	Pharmaceutical	Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
675	674	TA407	2016/17	STA	Secukinumab	Pharmaceutical	Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
676	675	TA408	2016/17	STA	Pegaspargase, as part of antineoplastic combination therapy	Pharmaceutical	Treating acute lymphoblastic leukaemia	Optimised	Optimised recommendation for pegaspargase, as part of antineoplastic combination therapy, ias an option for treating acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease.
677	676	TA409	2016/17	STA	Aflibercept	Pharmaceutical	Treating visual impairment caused by macular oedema after branch retinal vein occlusion	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
678	677	TA410	2016/17	STA	Talimogene laherparepvec	Pharmaceutical	Treating unresectable metastatic melanoma	Optimised	Optimised recommendation for talimogene laherparepvec an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: ·         treatment with systemically administered immunotherapies is not suitable and ·         the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.
679	678	TA411	2016/17	STA	Necitumumab, in combination with gemcitabine and cisplatin	Pharmaceutical	Untreated advanced or metastatic squamous non-small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
680	679	TA412	2016/17	STA	Radium‑223 dichloride	Pharmaceutical	Treating hormone-relapsed prostate cancer with bone metastases	Optimised	Optimised recommendation for radium‑223 dichloride as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults, only if: they have already had docetaxel or docetaxel is contraindicated or is not suitable for them. The drug is only recommended if the company provides radium‑223 dichloride with the discount agreed in the patient access scheme.
681	680	TA413	2016/17	STA	Elbasvir–grazoprevir	Pharmaceutical	Chronic hepatitis C	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
682	681	TA414	2016/17	STA	Cobimetinib in combination with vemurafenib	Pharmaceutical	Unresectable or metastatic BRAF V600 mutation-positive melanoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
683	682	TA415	2016/17	STA	Certolizumab pegol in combination with methotrexate	Pharmaceutical	Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor	Optimised	Optimised recommendation for certolizumab pegol, in combination with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor‑alpha (TNF‑alpha) inhibitor, only if: disease activity is severe and rituximab is contraindicated or not tolerated and the company provides certolizumab pegol with the agreed patient access scheme.
684	683	TA415	2016/17	STA	Certolizumab pegol monotherapy	Pharmaceutical	Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor	Optimised	Optimised recommendation for certolizumab pegol, as monotherapy, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other DMARDs including at least 1 TNF‑alpha inhibitor, only if: disease activity is severe and rituximab therapy cannot be given because methotrexate is contraindicated or not tolerated and the company provides certolizumab pegol with the agreed patient access scheme.
685	684	TA416	2016/17	STA	Osimertinib	Pharmaceutical	Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer	Recommended (CDF)	Recommended in line with clinical practice for use within the Cancer Drugs fund only if the conditions in the managed access agreement for osimertinib are followed.
686	685	TA417	2016/17	STA	Nivolumab	Pharmaceutical	Previously treated advanced renal cell carcinoma	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
687	686	TA418	2016/17	STA	Dapagliflozin in combinatin with metformin and a sulfonylurea	Pharmaceutical	Treating type 2 diabetes	Recommended	Recommended in line with clinical practice.
688	687	TA419	2016/17	STA	Apremilast	Pharmaceutical	Treating moderate to severe plaque psoriasis	Recommended	Recommended in line with clinical practice and following agreement of patient access scheme.
689	688	TA420	2016/17	STA	Ticagrelor in combination with aspirin	Pharmaceutical	Preventing atherothrombotic events after myocardial infarction	Recommended	Recommended in line with marketing authorisation
690	689	TA421	2016/17	STA	Everolimus in combination with exemestane	Pharmaceutical	Treating advanced breast cancer after endocrine therapy	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
691	690	TA422	2016/17	STA	Crizotinib	Pharmaceutical	Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
692	691	TA423	2016/17	STA	Eribulin	Pharmaceutical	Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	Optimised	Optimised recommendation for eribulin as an option for treating locally advanced or metastatic breast cancer in adults, only when: •it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) •the company provides eribulin with the discount agreed in the patient access scheme.
693	692	TA424	2016/17	STA	Pertuzumab in combination with trastuzumab and chemotherapy	Pharmaceutical	Neoadjuvant treatment of HER2-positive breast cancer	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
694	693	TA425	2016/17	STA	Dasitinib	Pharmaceutical	Treating imatinib-resistant or intolerant chronic myeloid leukaemia	Optimised	Optimised recommendation for dasatinib as an option for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if: • they cannot have imatinib, or their disease is imatinib-resistant and •the companies provide the drugs with the discounts agreed in the relevant patient access schemes.
695	694	TA425	2016/17	STA	Nilotinib	Pharmaceutical	Treating imatinib-resistant or intolerant chronic myeloid leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of patient access scheme.
696	695	TA425	2016/17	STA	High-dose imatinib	Pharmaceutical	Treating imatinib-resistant or intolerant chronic myeloid leukaemia	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
697	696	TA426	2016/17	STA	Dasatinib	Pharmaceutical	Untreated chronic myeloid leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
698	697	TA426	2016/17	STA	Nilotinib	Pharmaceutical	Untreated chronic myeloid leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
699	698	TA426	2016/17	STA	Imatinib	Pharmaceutical	Untreated chronic myeloid leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
700	699	TA427	2016/17	STA	Pomalidomide, in combination with low‑dose dexamethasone	Pharmaceutical	Multiple myeloma previously treated with lenalidomide and bortezomib	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
701	700	TA428	2016/17	STA	Pembrolizumab	Pharmaceutical	PD-L1-positive non-small-cell lung cancer after chemotherapy	Optimised	Optimised recommendation for pempbrolizumab for treating locally advanced or metastatic PD‑L1‑positive non‑small‑cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]‑positive tumour), only if: • pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression, and • the company provides pembrolizumab with the discount agreed in the patient access scheme revised in the context of this appraisal.
702	701	TA429	2016/17	STA	Ibrutinib alone	Pharmaceutical	Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
703	702	TA430	2016/17	STA	Sofosbuvir–velpatasvir	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation for sofosbuvir–velpatasvir for treating chronic hepatitis C based on HCV genotype, liver disease stage, and only if the company provides the drug with the discount agreed in the simple discount agreement. Please see the final guidance section 1 for the detailed recommendations.
704	703	TA431	2016/17	STA	Mepolizumab as an add-on to optimised standard therapy	Pharmaceutical	Severe refractory eosinophilic asthma	Optimised	Optimised recommendation for mepolizumab, as an add-on to optimised standard therapy, for treating severe refractory eosinophilic asthma in adults, only if: •the blood eosinophil count is 300 cells/microlitre or more in the previous 12 months and •the person has agreed to and followed the optimised standard treatment plan and ◦has had 4 or more asthma exacerbations needing systemic corticosteroids in the previous 12 months or ◦has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months and •the company provides the drug with the discount agreed in the patient access scheme.
705	704	TA432	2016/17	STA	Everolimus	Pharmaceutical	Advanced renal cell carcinoma after previous treatment	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
706	705	TA433	2016/17	STA	Apremilast, alone or in combination with disease-modifying antirheumatic drugs (DMARDs)	Pharmaceutical	Active psoriatic arthritis	Optimised	Optimised recommendation for apremilast alone or in combination with disease-modifying antirheumatic drugs (DMARDs), as an option for treating active psoriatic arthritis in adults only if: • they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and • their disease has not responded to adequate trials of at least 2 standard DMARDs, given either alone or in combination and • the company provides apremilast with the discount agreed in the patient access scheme.
707	706	TA434	2016/17	STA	Elotuzumab	Pharmaceutical	Previously treated multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
708	707	TA435	2016/17	STA	Tenofovir alafenamide	Pharmaceutical	Chronic hepatitis B	Terminated Appraisal - non submission	The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
709	708	TA436	2016/17	STA	Bevacizumab	Pharmaceutical	EGFR mutation-positive non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
710	709	TA437	2016/17	STA	Ibrutinib with bendamustine and rituximab	Pharmaceutical	Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
711	710	TA438	2016/17	STA	Alectinib	Pharmaceutical	Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
712	711	TA439	2016/17	MTA	Cetuximab	Pharmaceutical	Previously untreated metastatic colorectal cancer	Recommended	Recommended in line with marketing authorisation.
713	712	TA439	2016/17	MTA	Panitumumab	Pharmaceutical	Previously untreated metastatic colorectal cancer	Recommended	Recommended in line with marketing authorisation.
714	713	TA440	2017/18	STA	Pegylated liposomal irinotecan in combination with 5‑fluorouracil and leucovorin	Pharmaceutical	Pancreatic cancer after gemcitabine	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
715	714	TA441	2017/18	STA	Daclizumab	Pharmaceutical	Relapsing–remitting multiple sclerosis	Optimised	This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. Optimised recommendation for daclizumab for treating multiple sclerosis in adults, only if: the person has active relapsing–remitting multiple sclerosis previously treated with disease-modifying therapy, or rapidly evolving severe relapsing–remitting multiple sclerosis (that is, at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI) and alemtuzumab is contraindicated or otherwise unsuitable and the company provides the drug with the discount agreed in the patient access scheme
716	715	TA442	2017/18	STA	Ixekizumab	Pharmaceutical	Moderate to severe plaque psoriasis	Optimised	Optimised recommendation for ixekizumab for treating plaque psoriasis in adults, only if: •the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 • the disease has not responded to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them, and • the company provides the drug with the discount agreed in the patient access scheme.
717	716	TA443	2017/18	STA	Obeticholic acid	Pharmaceutical	Primary biliary cholangitis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
718	717	TA444	2017/18	STA	Afatinib	Pharmaceutical	Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy	Terminated appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
719	718	TA445	2017/18	MTA	Certolizumab pegol alone, or in combination with methotrexate	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Optimised	Optimised recommendation for certolizumab pegol alone, or in combination with methotrexate, for treating active psoriatic arthritis in adults only if: •it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or •the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks. Certolizumab pegol is only recommended if the company provides it as agreed in the patient access scheme.
720	719	TA445	2017/18	MTA	Secukinumab alone, or in combination with methotrexate	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Optimised	Optimised recommendation for secukinumab alone, or in combination with methotrexate, for treating active psoriatic arthritis in adults only if: •it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or •the person has had a TNF‑alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or •TNF‑alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis). Secukinumab is only recommended if the company provides it as agreed in the patient access scheme.
721	720	TA446	2017/18	STA	Brentuximab vedotin	Pharmaceutical	CD30-positive Hodgkin lymphoma after autologous stem cell transplant	Optimised	Optimised recommendation for brentuximab vedotin as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if: •they have relapsed or refractory disease after autologous stem cell transplant and •the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.
722	721	TA446	2017/18	STA	Brentuximab vedotin	Pharmaceutical	CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option	Optimised (CDF)	Optimised recommendation for brentuximab vedotin for use within the Cancer Drugs Fund, as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if: •they have relapsed or refractory disease after at least 2 previous therapies and •they cannot have autologous stem cell transplant or multi-agent chemotherapy and •the conditions of the managed access agreement are followed.
723	722	TA447	2017/18	STA	Pembrolizumab	Pharmaceutical	Untreated PD-L1-positive metastatic non-small-cell lung cancer	Optimised (CDF)	Optimised recommendation for pembrolizumab for use within the Cancer Drugs Fund as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults only if: •their tumours express PD-L1 with at least a 50% tumour proportion score and have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations •pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression •the conditions in the managed access agreement for pembrolizumab are followed
724	723	TA448	2017/18	STA	Etelcalcetide	Pharmaceutical	Secondary hyperparathyroidism	Optimised	Optimised recommendation for etelcalcetide as an option for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, only if: •treatment with a calcimimetic is indicated but cinacalcet is not suitable and •the company provides etelcalcetide with the discount agreed in the patient access scheme.
725	724	TA449	2017/18	MTA	Everolimus	Pharmaceutical	Unresectable or metastatic neuroendocrine tumours in people with progressive disease	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
726	725	TA449	2017/18	MTA	Sunitinib	Pharmaceutical	Unresectable or metastatic neuroendocrine tumours in people with progressive disease	Recommended	Recommended in line with marketing authorisation.
727	726	TA450	2017/18	STA	Blinatumomab	Pharmaceutical	Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
728	727	TA451	2017/18	STA	Ponatinib	Pharmaceutical	Chronic myeloid leukaemia and acute lymphoblastic leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
729	728	TA452	2017/18	STA	Ibrutinib	Pharmaceutical	Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
730	729	TA453	2017/18	STA	Bortezomib	Pharmaceutical	Multiple myeloma after second or subsequent relapse	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
731	730	TA454	2017/18	STA	Daratumumab	Pharmaceutical	Relapsed or refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
732	731	TA455	2017/18	MTA	Adalimumab	Pharmaceutical	Plaque psoriasis in children and young people	Optimised	Optimised recommendation for adalimumab as an option for treating plaque psoriasis in children and young people aged 4 years or older, only if the disease: •is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and •has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated.
733	732	TA455	2017/18	MTA	Etanercept	Pharmaceutical	Plaque psoriasis in children and young people	Optimised	Optimised recommendation for etanercept as an option for treating plaque psoriasis in children and young people aged 6 years or older, only if the disease: •is severe, as defined by a total PASI of 10 or more and •has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated
734	733	TA455	2017/18	MTA	Ustekinumab	Pharmaceutical	Plaque psoriasis in children and young people	Optimised	Optimised recommendation for ustekinumab as an option for treating plaque psoriasis in children and young people aged 12 years or older, only if the disease: •is severe, as defined by a total PASI of 10 or more •has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated
735	734	TA456	2017/18	STA	Ustekinumab	Pharmaceutical	Moderately to severely active Crohn’s disease after previous treatment	Recommended	Recommended in line with marketing authorisation.
736	735	TA457	2017/18	STA	Carfilzomib in combination with dexamethasone	Pharmaceutical	Previously treated multiple myeloma	Optimised	Optmised recommendation for carfilzomib in combination with dexamethasone as an option for treating multiple myeloma in adults, only if: •they have had only 1 previous therapy, which did not include bortezomib and •the company provides carfilzomib with the discount agreed in the patient access scheme
737	736	TA458	2017/18	STA	Trastuzumab emtansine	Pharmaceutical	HER2-positive advanced breast cancer after trastuzumab and a taxane	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
738	737	TA459	2017/18	STA	Collagenase clostridium histolyticum	Pharmaceutical	Dupuytren's contracture	Optimised	People who meet the inclusion criteria for the ongoing clinical trial (HTA-15/102/04), comparing collagenase clostridium histolyticum (CCH) with limited fasciectomy, are encouraged to participate in the study. For people not taking part in the ongoing clinical trial, optimised recommendation for CCH for treating Dupuytren's contracture with a palpable cord in adults only if all of the following apply: •There is evidence of moderate disease (functional problems and metacarpophalangeal joint contracture of 30° to 60° and proximal interphalangeal joint contracture of less than 30° or first web contracture) plus up to 2 affected joints. •Percutaneous needle fasciotomy (PNF) is not considered appropriate, but limited fasciectomy is considered appropriate by the treating hand surgeon. •The choice of treatment (CCH or limited fasciectomy) is made on an individual basis after discussion between the responsible hand surgeon and the patient about the risks and benefits of the treatments available. •One injection is given per treatment session by a hand surgeon in an outpatient setting.
739	738	TA460	2017/18	MTA	Adalimumab	Pharmaceutical	Non-infectious uveitis	Optimised	Optimised recommendation for dexamethasone intravitreal implant as an option for treating non-infectious uveitis in the posterior segment of the eye in adults, only if there is •active disease (that is, current inflammation in the eye) and •worsening vision with a risk of blindness.
740	739	TA460	2017/18	MTA	Dexamethasone intravitreal implant	Pharmaceutical	Non-infectious uveitis	Optimised	Optimised recommendation for dexamethasone intravitreal implant as an option for treating non-infectious uveitis in the posterior segment of the eye in adults, only if there is •active disease (that is, current inflammation in the eye) and •worsening vision with a risk of blindness.
741	740	TA461	2017/18	STA	Roflumilast as an add-on to bronchodilator therapy	Pharmaceutical	Chronic obstructive pulmonary disease	Optimised	Optimised recommendation for Roflumilast as an add-on to bronchodilator therapy as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if: •the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and •the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid.
742	741	TA462	2017/18	STA	Nivolumab	Pharmaceutical	Relapsed or refractory classical Hodgkin lymphoma	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
743	742	TA463	2017/18	STA	Cabozantinib	Pharmaceutical	Previously treated advanced renal cell carcinoma	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
744	743	TA464	2017/18	MTA	Oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium)	Pharmaceutical	Osteoporosis	Optimised	Optimised recommendation for oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) as options for treating osteoporosis in adults only if: •the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and •the 10‑year probability of osteoporotic fragility fracture is at least 1%.
745	744	TA464	2017/18	MTA	Intravenous bisphosphonates (ibandronic acid and zoledronic acid)	Pharmaceutical	Osteoporosis	Optimised	Optimised recommendation for Intravenous bisphosphonates (ibandronic acid and zoledronic acid) as options for treating osteoporosis in adults only if: •the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and •the 10‑year probability of osteoporotic fragility fracture is at least 10% or •the 10‑year probability of osteoporotic fragility fracture is at least 1% and the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated.
746	745	TA465	2017/18	STA	Olaratumab in combination with doxorubicin	Pharmaceutical	Advanced soft tissue sarcoma	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for advanced soft tissue sarcoma in adults, only if: •they have not had any previous systemic chemotherapy for advanced soft tissue sarcoma •they cannot have curative treatment with surgery or their disease does not respond to radiotherapy •the conditions in the managed access agreement for olaratumab are followed
747	746	TA466	2017/18	STA	Baricitinib with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for baricitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if: •disease is severe (a disease activity score [DAS28] of more than 5.1) and •the company provides baricitinib with the discount agreed in the patient access scheme.
748	747	TA466	2017/18	STA	Baricitinib with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for baricitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if: •disease is severe (a DAS28 of more than 5.1) and •they cannot have rituximab and •the company provides baricitinib with the discount agreed in the patient access scheme
749	748	TA466	2017/18	STA	Baricitinib monotherapy	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for baricitinib as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance when the criteria for combination treatment described in section 1.1 and 1.2 are met.
750	749	TA467	2017/18	STA	Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)	Pharmaceutical	Limbal stem cell deficiency after eye burns	Optimised	Optimised recommendation for holoclar as an option in people with moderate to severe limbal stem cell deficiency after eye burns, only if: •it is only used to treat 1 eye and •people have already had a conjunctival limbal autograft or •there is not enough tissue for a conjunctival limbal autograft or it is contraindicated and •the company provides it with the discount agreed in the patient access scheme.
751	750	TA467	2017/18	STA	Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)	Pharmaceutical	Limbal stem cell deficiency after eye burns for treating both eyes	Only in Research	Only in research recommendation for holoclar in people with moderate to severe limbal stem cell deficiency after eye burns for treating both eyes, only when there is not enough tissue for a conjunctival limbal autograft.
752	751	TA468	2017/18	STA	Methylnaltrexone bromide	Pharmaceutical	Opioid-induced constipation	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
753	752	TA469	2017/18	STA	Idelalisib with ofatumumab	Pharmaceutical	Chronic lymphocytic leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
754	753	TA470	2017/18	STA	Ofatumumab with chemotherapy	Pharmaceutical	Chronic lymphocytic leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
755	754	TA471	2017/18	STA	Eluxadoline	Pharmaceutical	Irritable bowel syndrome with diarrhoea	Recommended	Recommended in line with clinical practice.
756	755	TA472	2017/18	STA	Obinutuzumab with bendamustine	Pharmaceutical	Follicular lymphoma refractory to rituximab	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed access agreement for obinutuzumab are followed.
757	756	TA473	2017/18	STA	Cetuximab in combination with platinum-based chemotherapy	Pharmaceutical	Recurrent or metastatic squamous cell cancer of the head and neck	Optimised	Optimised recommendation for cetuximab in combination with platinum-based chemotherapy as an option for treating recurrent or metastatic squamous cell cancer of the head and neck in adults only: •if the cancer started in the oral cavity and •when the company provides the drug in line with the commercial access agreement with NHS England.
758	757	TA474	2017/18	STA	Sorafenib	Pharmaceutical	Advanced hepatocellular carcinoma	Optimised	Optmised recommendation for sorafenib only for people with Child-Pugh grade A liver impairment, only if the company provides sorafenib within the agreed commercial access arrangement.
759	758	TA475	2017/18	STA	Dimethyl fumarate	Medical device	Moderate to severe plaque psoriasis	Optimised	Optimised recommendation for dimethyl fumarate only if the disease: •is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and •has not responded to other systemic therapies, including, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated.
760	759	TA476	2017/18	STA	Paclitaxel as albumin-bound nanoparticles (nab‑paclitaxel) with gemcitabine	Pharmaceutical	Untreated metastatic pancreatic cancer	Optimised	Optimised recommendation for nab‑paclitaxel with gemcitabine only if: •other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy and •the company provides nab‑paclitaxel with the discount agreed in the patient access scheme.
761	760	TA477	2017/18	MTA	Autologous chondrocyte implantation	Pharmaceutical	Symptomatic articular cartilage defects of the knee	Optimised	Optimised recommendation for autologous chondrocyte implantation (ACI) as an option for treating symptomatic articular cartilage defects of the knee, only if: •the person has not had previous surgery to repair articular cartilage defects •there is minimal osteoarthritic damage to the knee (as assessed by clinicians experienced in investigating knee cartilage damage using a validated measure for knee osteoarthritis) •the defect is over 2 cm2 and •the procedure is done at a tertiary referral centre.
762	761	TA478	2017/18	STA	Brentuximab vedotin	Pharmaceutical	Relapsed or refractory systemic anaplastic large cell lymphoma	Optimised	Optimised recommendation for brentuximab vedotin as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if: •they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and •the company provides brentuximab vedotin according to the commercial access agreement with NHS England.
763	762	TA479	2017/18	STA	Reslizumab, as an add-on therapy	Pharmaceutical	Severe eosinophilic asthma	Optimised	Optimised recommendation for reslizumab, as an add-on therapy, as an option for the treatment of severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug, only if: •the blood eosinophil count has been recorded as 400 cells per microlitre or more •the person has had 3 or more severe asthma exacerbations needing systemic corticosteroids in the past 12 months and •the company provides reslizumab with the discount agreed in the patient access scheme.
764	763	TA480	2017/18	STA	Tofacitinib with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for tofacitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if: • disease is severe (a disease activity score [DAS28] of more than 5.1) and • the company provides tofacitinib with the discount agreed in the patient access scheme.
765	764	TA480	2017/18	STA	Tofacitinib with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for tofacitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot have, other DMARDs, including at least 1 biological DMARD, only if: • disease is severe (a DAS28 of more than 5.1) and • they cannot have rituximab and • the company provides tofacitinib with the discount agreed in the patient access scheme.
766	765	TA480	2017/18	STA	Tofacitinib monotherapy	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for tofacitinib as monotherapy for adults who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in sections 1.1 and 1.2 are met.
767	766	TA481	2017/18	MTA	Basiliximab	Pharmaceutical	Kidney transplant in adults	Recommended	Recommended in line with clinical practice
768	767	TA481	2017/18	MTA	Immediate-release tacrolimus	Pharmaceutical	Kidney transplant in adults	Recommended	Recommended in line with clinical practice.
769	768	TA481	2017/18	MTA	Mycophenolate mofetil	Pharmaceutical	Kidney transplant in adults	Recommended	Recommended in line with marketing authorisation.
770	769	TA481	2017/18	MTA	Rabbit anti-human thymocyte immunoglobulin	Pharmaceutical	Kidney transplant in adults	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
771	770	TA481	2017/18	MTA	Prolonged-release tacrolimus	Pharmaceutical	Kidney transplant in adults	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
772	771	TA481	2017/18	MTA	Mycophenolate sodium	Pharmaceutical	Kidney transplant in adults	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
773	772	TA481	2017/18	MTA	Sirolimus	Pharmaceutical	Kidney transplant in adults	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
774	773	TA481	2017/18	MTA	Everolimus	Pharmaceutical	Kidney transplant in adults	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
775	774	TA481	2017/18	MTA	Belatacept	Pharmaceutical	Kidney transplant in adults	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
776	775	TA482	2017/18	MTA	Basiliximab	Pharmaceutical	Kidney transplant in children and young people	Recommended	Recommended in line with clinical practice
777	776	TA482	2017/18	MTA	Immediate-release tacrolimus	Pharmaceutical	Kidney transplant in children and young people	Recommended	Recommended in line with clinical practice.
778	777	TA482	2017/18	MTA	Mycophenolate mofetil	Pharmaceutical	Kidney transplant in children and young people	Recommended	Recommended in line with marketing authorisation.
779	778	TA482	2017/18	MTA	Rabbit anti-human thymocyte immunoglobulin	Pharmaceutical	Kidney transplant in children and young people	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
780	779	TA482	2017/18	MTA	Prolonged-release tacrolimus	Pharmaceutical	Kidney transplant in children and young people	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
781	780	TA482	2017/18	MTA	Mycophenolate sodium	Pharmaceutical	Kidney transplant in children and young people	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
782	781	TA482	2017/18	MTA	Sirolimus	Pharmaceutical	Kidney transplant in children and young people	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
783	782	TA482	2017/18	MTA	Everolimus	Pharmaceutical	Kidney transplant in children and young people	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
784	783	TA482	2017/18	MTA	Belatacept	Pharmaceutical	Kidney transplant in children and young people	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
785	784	TA483	2017/18	STA	Nivolumab	Pharmaceutical	Previously treated squamous non-small-cell lung cancer	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy, only if: •nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and •the conditions in the managed access agreement are followed.
786	785	TA484	2017/18	STA	Nivolumab	Pharmaceutical	Previously treated non-squamous non-small-cell lung cancer	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy, only if: •their tumours are PD‑L1 positive and •nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and •the conditions in the managed access agreement are followed.
787	786	TA485	2017/18	STA	Sarilumab with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for sarilumab, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if: •disease is severe (a disease activity score [DAS28] of more than 5.1) and •the company provides sarilumab with the discount agreed in the patient access scheme.
788	787	TA485	2017/18	STA	Sarilumab with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for sarilumab, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if: •disease is severe (a DAS28 of more than 5.1) and •they cannot have rituximab and •the company provides sarilumab with the discount agreed in the patient access scheme.
789	788	TA485	2017/18	STA	Sarilumab with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for sarilumab, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if: •disease is severe (a DAS28 of more than 5.1) and •the company provides sarilumab with the discount agreed in the patient access scheme.
790	789	TA485	2017/18	STA	Sarilumab monotherapy	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for sarilumab as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in sections 1.1 and 1.2 are met.
791	790	TA486	2017/18	STA	Aflibercept	Pharmaceutical	Choroidal neovascularisation	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
792	791	TA487	2017/18	STA	Venetoclax	Pharmaceutical	Chronic lymphocytic leukaemia	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating chronic lymphocytic leukaemia, that is, in adults: •with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or •without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo‑immunotherapy and a B‑cell receptor pathway inhibitor and •only if the conditions in the managed access agreement are followed
793	792	TA488	2017/18	STA	Regorafenib	Pharmaceutical	Previously treated unresectable or metastatic gastrointestinal stromal tumours	Optimised	Optimised recommendation for regorafenib as an option for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib, only if: •their Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1 and •the company provides regorafenib with the discount agreed in the patient access scheme.
794	793	TA489	2017/18	STA	Vismodegib	Pharmaceutical	Basal cell carcinoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
795	794	TA490	2017/18	STA	Nivolumab	Pharmaceutical	Squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy, only if: •the disease has progressed within 6 months of having chemotherapy •nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression and •the conditions in the managed access agreement are followed.
796	795	TA491	2017/18	STA	Ibrutinib	Pharmaceutical	Waldenstrom’s macroglobulinaemia	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 prior therapy, only if the conditions in the managed access agreement for ibrutinib are followed.
797	796	TA492	2017/18	STA	Atezolizumab	Pharmaceutical	Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed.
798	797	TA493	2017/18	STA	Cladribine tablets	Pharmaceutical	Relapsing–remitting multiple sclerosis	Optimised	Optimised recommendation for cladribine tablets as an option for treating highly active multiple sclerosis in adults, only if the person has: •rapidly evolving severe relapsing–remitting multiple sclerosis, that is, at least 2 relapses in the previous year and at least 1 T1 gadolinium-enhancing lesion at baseline MRI or •relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as 1 relapse in the previous year and MRI evidence of disease activity.
799	798	TA494	2017/18	STA	Naltrexone–bupropion	Pharmaceutical	Managing overweight and obesity	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
800	799	TA495	2017/18	STA	Palbocicli, with an aromatase inhibitor	Pharmaceutical	Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
801	800	TA496	2017/18	STA	Ribociclib with an aromatase inhibitor	Pharmaceutical	Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
802	801	TA497	2017/18	STA	Golimumab	Pharmaceutical	Non-radiographic axial spondyloarthritis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
803	802	TA498	2017/18	STA	Lenvatinib plus everolimus	Pharmaceutical	Previously treated advanced renal cell carcinoma	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
804	803	TA499	2017/18	STA	Glecaprevir–pibrentasvir	Pharmaceutical	Chronic hepatitis C	Recommended	Recommended in line with marketing authorisation and if the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit.
805	804	TA500	2017/18	STA	Ceritinib	Pharmaceutical	Untreated ALK-positive non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
806	805	TA501	2017/18	MTA	Intrabeam radiotherapy system	Pharmaceutical	Adjuvant treatment of early breast cancer	Only in Research	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Use of the Intrabeam radiotherapy system is recommended only using machines that are already available and in conjunction with NHS England specified clinical governance, data collection and submission arrangements.
807	806	TA502	2017/18	STA	Ibrutinib	Pharmaceutical	Relapsed or refractory mantle cell lymphoma	Optimised	Optimised recommendation for ibrutinib as an option for treating relapsed or refractory mantle cell lymphoma in adults, only if: •they have had only 1 previous line of therapy and •the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.
808	807	TA503	2017/18	STA	Fulvestrant	Pharmaceutical	Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
809	808	TA504	2017/18	STA	Pirfenidone	Pharmaceutical	Idiopathic pulmonary fibrosis	Optimised	Optimised recommendation for pirfenidone for treating idiopathic pulmonary fibrosis in adults only if: •the person has a forced vital capacity (FVC) between 50% and 80% predicted •the company provides pirfenidone with the discount agreed in the patient access scheme and •treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted FVC within any 12‑month period).
810	809	TA505	2017/18	STA	Ixazomib with lenalidomide and dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma	Optimised (CDF)	Optimised recommendation for ixazomib, with lenalidomide and dexamethasone, for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults only if: •they have already had 2 or 3 lines of therapy and •the conditions in the managed access agreement for ixazomib are followed.
811	810	TA506	2017/18	STA	Lesinurad	Pharmaceutical	Chronic hyperuricaemia in people with gout	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
812	811	TA507	2017/18	STA	Sofosbuvir–velpatasvir–voxilaprevir	Pharmaceutical	Chronic hepatitis C	Optimised	Optimised recommendation for sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C based on HCV genotype, liver disease stage, treatment history and only if the company provides the drug with the discount agreedwith the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations.
813	812	TA508	2017/18	STA	Autologous chondrocyte implantation using chondrosphere	Pharmaceutical	Symptomatic articular cartilage defects of the knee	Optimised	Optimised recommendation for autologous chondrocyte implantation (ACI) using chondrosphere as an option for treating symptomatic articular cartilage defects of the femoral condyle and patella of the knee (International Cartilage Repair Society grade III or IV) in adults, only if: •the person has not had previous surgery to repair articular cartilage defects •there is minimal osteoarthritic damage to the knee (as assessed by clinicians experienced in investigating knee cartilage damage using a validated measure for knee osteoarthritis) and •the defect is over 2 cm2.
814	813	TA509	2017/18	STA	Pertuzumab in combination with trastuzumab and docetaxel	Pharmaceutical	HER2-positive breast cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
815	814	TA510	2017/18	STA	Daratumumab monotherapy	Pharmaceutical	Relapsed and refractory multiple myeloma	Optimised (CDF)	Optimised recommendation for daratumumab monotherapy for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults whose previous therapy included a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last therapy, only if: •they have daratumumab after 3 previous therapies and •the conditions in the managed access agreement are followed.
816	815	TA511	2017/18	STA	Brodalumab	Pharmaceutical	Moderate to severe plaque psoriasis	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
817	816	TA512	2017/18	STA	Tivozanib	Pharmaceutical	Advanced renal cell carcinoma	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
818	817	TA513	2017/18	STA	Obinutuzumab	Pharmaceutical	Untreated advanced follicular lymphoma	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
819	818	TA514	2017/18	STA	Regorafenib	Pharmaceutical	Previously treated advanced hepatocellular carcinoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
820	819	TA515	2017/18	STA	Eribulin	Pharmaceutical	Locally advanced or metastatic breast cancer after 1 chemotherapy regimen	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
821	820	TA516	2017/18	STA	Cabozantinib	Pharmaceutical	Medullary thyroid cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
822	821	TA517	2018/19	STA	Avelumab (second-line and beyond treatment)	Pharmaceutical	Metastatic Merkel cell carcinoma	Recommended	Recommended in line with marketing authorisation
823	822	TA517	2018/19	STA	Avelumab (first-line)	Pharmaceutical	Metastatic Merkel cell carcinoma	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in adults, only if: •they have not had chemotherapy for metastatic disease and •the conditions in the managed access agreement for avelumab are followed.
824	823	TA518	2018/19	STA	Tocilizumab when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids)	Pharmaceutical	Giant cell arteritis	Optimised	Optimised recommendation for tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), as an option for treating giant cell arteritis in adults, only if: •they have relapsing or refractory disease •they have not already had tocilizumab •tocilizumab is stopped after 1 year of uninterrupted treatment at most and •the company provides it with the discount agreed in the patient access scheme.
825	824	TA519	2018/19	STA	Pembrolizumab	Pharmaceutical	Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if: •pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and •the conditions in the managed access agreement for pembrolizumab are followed.
826	825	TA520	2018/19	STA	Atezolizumab	Pharmaceutical	Locally advanced or metastatic non-small-cell lung cancer after chemotherapy	Optimised	Optimised recommendation for atezolizumab as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour), only if: •atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and •the company provides atezolizumab with the discount agreed in the patient access scheme.
827	826	TA521	2018/19	STA	Guselkumab	Pharmaceutical	Moderate to severe plaque psoriasis	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
828	827	TA522	2018/19	STA	Pembrolizumab	Pharmaceutical	Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable, only if: •pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and •the conditions of the managed access agreement for pembrolizumab are followed.
829	828	TA523	2018/19	STA	Midostaurin	Pharmaceutical	Untreated acute myeloid leukaemia	Recommended	Recommended in line withmarketing authorisation and following agreement of a patient access scheme.
830	829	TA524	2018/19	STA	Brentuximab vedotin	Pharmaceutical	CD30-positive Hodgkin lymphoma	Optimised	Optimised recommendation for brentuximab vedotin as an option for treating CD30‑positive Hodgkin lymphoma in adults with relapsed or refractory disease, only if: •they have already had autologous stem cell transplant or •they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable and •the company provides brentuximab vedotin according to the patient access scheme
831	830	TA525	2018/19	STA	Atezolizumab	Pharmaceutical	Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
832	831	TA526	2018/19	STA	Arsenic trioxide	Pharmaceutical	Acute promyelocytic leukaemia	Recommended	Recommended in line with marketing authorisation.
833	832	TA527	2018/19	MTA	Interferon beta‑1a	Pharmaceutical	Multiple sclerosis	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
834	833	TA527	2018/19	MTA	Interferon beta‑1b (Extavia)	Pharmaceutical	Multiple sclerosis	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
835	834	TA527	2018/19	MTA	Interferon beta‑1b (Betaferon)	Pharmaceutical	Multiple sclerosis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
836	835	TA527	2018/19	MTA	Glatiramer acetate	Pharmaceutical	Multiple sclerosis	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
837	836	TA528	2018/19	STA	Niraparib	Pharmaceutical	Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	Optimised (CDF)	Optimised recommendation for niraparib for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults, only if: •they have a germline BRCA mutation and have had 2 courses of platinum-based chemotherapy or •they do not have a germline BRCA mutation and have had 2 or more courses of platinum-based chemotherapy and •the conditions in the managed access agreement for niraparib are followed.
838	837	TA529	2018/19	STA	Crizotinib	Pharmaceutical	ROS1-positive advanced non-small-cell lung cancer	Recommended (CDF)	Recommended for use within the Cancer Drugs Fund as an option for treating ROS1‑positive advanced non-small-cell lung cancer (NSCLC) in adults, only if the conditions in the managed access agreement are followed.
839	838	TA530	2018/19	STA	Nivolumab	Pharmaceutical	Locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
840	839	TA531	2018/19	STA	Pembrolizumab	Pharmaceutical	Untreated PD-L1-positive metastatic non-small-cell lung cancer	Recommended	Recommended in line with clinical practice and following agreement of a commercial access agreement.
841	840	TA532	2018/19	STA	Cenegermin	Pharmaceutical	Neurotrophic keratitis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
842	841	TA533	2018/19	STA	Ocrelizumab	Pharmaceutical	Relapsing–remitting multiple sclerosis	Optimised	Optimised recommendation for ocrelizumab as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if: alemtuzumab is contraindicated or otherwise unsuitable and the company provides ocrelizumab according to the commercial arrangement.
843	842	TA534	2018/19	STA	Dupilumab	Pharmaceutical	Severe atopic dermatitis	Optimised	Optimised recommendation for dupilumab as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated the company provides dupilumab according to the commercial arrangement
844	843	TA535	2018/19	MTA	Lenvatinib	Pharmaceutical	Thyroid cancer	Optimised	Optimised recommendation for lenvatinib as an option for treating thyroid cancer in adults whose disease does not respond to radioactive iodine, only if: • they have not had a tyrosine kinase inhibitor before or • they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification) • the company provides lenvatinib according to the patient access scheme
845	844	TA535	2018/19	MTA	Sorafenib	Pharmaceutical	Thyroid cancer	Optimised	Optimised recommendation for sorafenib as an option for treating thyroid cancer in adults whose disease does not respond to radioactive iodine, only if: • they have not had a tyrosine kinase inhibitor before or • they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification) • the compay provides sorafenib according to the commercial access agreement
846	845	TA536	2018/19	STA	Alectinib	Pharmaceutical	Non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
847	846	TA537	2018/19	STA	Ixekizumab	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
848	847	TA537	2018/19	STA	Ixekizumab	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
849	848	TA537	2018/19	STA	Ixekizumab	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
850	849	TA538	2018/19	STA	Dinutuximab	Pharmaceutical	Neuroblastoma	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
851	850	TA539	2018/19	MTA	Lutetium (177Lu) oxodotreotide	Pharmaceutical	Unresectable or metastatic pancreatic neuroendocrine tumours	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
852	851	TA539	2018/19	MTA	Lutetium (177Lu) oxodotreotide	Pharmaceutical	Unresectable or metastatic gastrointestinal neuroendocrine tumours	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
853	852	TA540	2018/19	STA	Pembrolizumab	Pharmaceutical	Relapsed or refractory classical Hodgkin lymphoma	Optimised (CDF)	Optimised recommendation for pembrolizumab for use within the Cancer Drugs Fund as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had brentuximab vedotin and cannot have autologous stem cell transplant, only if: •pembrolizumab is stopped after 2 years of treatment or earlier if the person has a stem cell transplant or the disease progresses and •the conditions in the managed access agreement for pembrolizumab are followed
854	853	TA541	2018/19	STA	Inotuzumab	Pharmaceutical	Relapsed or refractory B-cell acute lymphoblastic leukaemia	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
855	854	TA542	2018/19	STA	Cabozantinib	Pharmaceutical	Untreated advanced renal cell carcinoma	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
856	855	TA543	2018/19	STA	Tofacitinib	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
857	856	TA543	2018/19	STA	Tofacitinib	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
858	857	TA544	2018/19	STA	Dabrafenib with trametinib	Pharmaceutical	Resected BRAF V600 mutation-positive melanoma	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
859	858	TA545	2018/19	STA	Gemtuzumab ozogamicin with daunorubicin and cytarabine	Pharmaceutical	Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above	Optimised	Recommended in line with clinical practice and following agreement of a patient access scheme.
860	859	TA546	2018/19	STA	Padeliporfin	Pharmaceutical	Adults with previously untreated, unilateral, low-risk prostate cancer in adults	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available.
861	860	TA547	2018/19	STA	Tofacitinib	Pharmaceutical	Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
862	861	TA548	2018/19	STA	Decitabine	Pharmaceutical	Untreated acute myeloid leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
863	862	TA549	2018/19	STA	Denosumab	Pharmaceutical	Preventing skeletal-related events in multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
864	863	TA550	2018/19	STA	Vandetanib	Pharmaceutical	Medullary thyroid cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
865	864	TA551	2018/19	STA	Lenvatinib	Pharmaceutical	Untreated advance hepatocellular carcinoma	Optimised	Recommended in line with clinical practice and following agreement of a patient access scheme.
866	865	TA552	2018/19	STA	Liposomal cytarabine–daunorubicin	Pharmaceutical	Untreated acute myeloid leukaemia	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
867	866	TA553	2018/19	STA	Pembrolizumab	Pharmaceutical	Melanoma with high risk of recurrence	Recommended (CDF)	Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of stage III melanoma with lymph node involvement in adults who have had complete resection. It is recommended only if the conditions in the managed access agreement for pembrolizumab are followed.
868	867	TA554	2018/19	STA	Tisagenlecleucel	Pharmaceutical	Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years	Recommended (CDF)	Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B‑cell acute lymphoblastic leukaemia in people aged up to 25 years, only if the conditions in the managed access agreement are followed.
869	868	TA555	2018/19	STA	Regorafenib	Pharmaceutical	Previously treated advanced hepatocellular carcinoma	Optimised	Recommended in line with clinical practice and following agreement of a patient access scheme.
870	869	TA556	2018/19	STA	Darvadstrocel	Pharmaceutical	Complex perianal fistulas in Crohn’s disease	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
871	870	TA557	2018/19	STA	Pembrolizumab	Pharmaceutical	Untreated, metastatic, non-squamous non-small-cell lung cancer	Optimised (CDF)	Pembrolizumab, with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. It is only recommended if: •pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and •the company provides pembrolizumab according to the managed access agreement.
872	871	TA558	2018/19	STA	Nivolumab	Pharmaceutical	Completely resected melanoma with lymph node involvement or metastatic disease	Recommended (CDF)	Nivolumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. It is recommended only if the conditions in the managed access agreement are followed.
873	872	TA559	2018/19	STA	Axicabtagene ciloleucel	Pharmaceutical	Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	Recommended (CDF)	Axicabtagene ciloleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B‑cell lymphoma or primary mediastinal large B‑cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed.
874	873	TA560	2018/19	STA	Bevacizumab	Pharmaceutical	First recurrence of platinum-sensitive advanced ovarian cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
875	874	TA561	2018/19	STA	Venetoclax	Pharmaceutical	Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
876	875	TA562	2018/19	STA	Encorafenib	Pharmaceutical	Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme. There are patient access schemes for encorafenib and binimetinib
877	876	TA563	2018/19	STA	Abemaciclib	Pharmaceutical	Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist	Recommended	Recommended in line with marketing authorisation and only if company provides it according to the commercial agreement
878	877	TA564	2018/19	STA	Dabrafenib	Pharmaceutical	Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
879	878	TA565	2018/19	STA	Benralizumab	Pharmaceutical	Severe eosinophilic asthma	Optimised	Optimised recommendation for benralizumab as an add-on therapy, is recommended as an option for treating severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta-agonists, only if: •the person has agreed to and followed the optimised standard treatment plan and •the blood eosinophil count has been recorded as 300 cells per microlitre or more and the person has had 4 or more exacerbations needing systemic corticosteroids in the previous 12 months, or has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months (that is, the person is eligible for mepolizumab) or •the blood eosinophil count has been recorded as 400 cells per microlitre or more with 3 or more exacerbations needing systemic corticosteroids in the past 12 months (that is, the person is eligible for reslizumab). Benralizumab is recommended only if the company provides it according to the commercial arrangement.
880	879	TA566	2018/19	MTA	Unilateral cochlear implantation	Medical device	Severe to profound deafness in children and adults	Recommended	Partial update of guidance TA166 (recommendation 1.5). Recommendation in line with clinical practice. Unilateral cochlear implantation is recommended as an option for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids; Simultaneous bilateral cochlear implantation is recommended as an option for the following groups of people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids, including children and adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness; Sequential bilateral cochlear implantation is not recommended as an option for people with severe to profound deafness
881	880	TA566	2018/19	MTA	Simultaneous bilateral cochlear implantation	Medical device	Severe to profound deafness in children and adults	Optimised	Partial update of guidance TA166 (recommendation 1.5). Optimised recommendation for use in specific circumstances for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids; or children; or adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness.
882	881	TA566	2018/19	MTA	Sequential bilateral cochlear implantation	Medical device	Sequential bilateral cochlear implantation	Not recommended	Partial update of guidance TA166 (recommendation 1.5). At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
883	882	TA567	2018/19	STA	Tisagenlecleucel	Pharmaceutical	Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies	Recommended (CDF)	Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed.
884	883	TA568	2018/19	STA	Abatacept	Pharmaceutical	Psoriatic arthritis after DMARDs	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
885	884	TA569	2018/19	STA	Pertuzumab	Pharmaceutical	Adjuvant treatment of HER2-positive early stage breast cancer	Optimised	Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if: •they have lymph node-positive disease •the company provides it according to the commercial arrangement.
886	885	TA570	2018/19	STA	Pembrolizumab	Pharmaceutical	Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
887	886	TA571	2018/19	STA	Brigatinib	Pharmaceutical	ALK-positive advanced non-small-cell lung cancer after crizotinib	Recommended	Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
888	887	TA572	2018/19	STA	Ertugliflozin	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
889	888	TA572	2018/19	STA	Ertugliflozin	Pharmaceutical	Type 2 diabetes	Recommended	Recommended in line with clinical practice.
890	889	TA573	2019/20	STA	Daratumumab	Pharmaceutical	Multiple myeloma	Recommended (CDF)	Recommended in the CDF
891	890	TA574	2019/20	STA	Certolizumab pegol	Pharmaceutical	Moderate to severe plaque psoriasis	Optimised	Certolizumab pegol is recommended as an option for treating plaque psoriasis in adults, only if: •the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and •the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and •the lowest maintenance dosage of certolizumab pegol is used (200 mg every 2 weeks) after the loading dosage and •the company provides the drug according to the commercial arrangement.
892	891	TA575	2019/20	STA	Tildrakizuamb	Pharmaceutical	Moderate to severe plaque psoriasis	Recommended	Tildrakizumab is recommended as an option for treating plaque psoriasis in adults, only if: •the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and •the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and •the company provides the drug according to the commercial arrangement.
893	892	TA576	2019/20	STA	Bosutinib	Pharmaceutical	Chronic myeloid leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
894	893	TA577	2019/20	STA	Brentuximab vedotin	Pharmaceutical	CD30-positive cutaneous T-cell lymphoma	Optimised	Optimised recommendation for brentuximab vedotin for treating CD30‑positive cutaneous T‑cell lymphoma after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome
895	894	TA578	2019/20	STA	Durvalumab	Pharmaceutical	Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation	Recommended (CDF)	Durvalumab monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express PD‑L1 on at least 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation only if: •they have had concurrent platinum-based chemoradiation •the conditions in the managed access agreement are followed.
896	895	TA579	2019/20	STA	Abemaciclib	Pharmaceutical	Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Recommended (CDF)	Abemaciclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in people who have had endocrine therapy only if: •exemestane plus everolimus would be the most appropriate alternative and •the conditions in the managed access agreement for abemaciclib with fulvestrant are followed.
897	896	TA580	2019/20	STA	Enzalutamide	Pharmaceutical	Hormone-relapsed non-metastatic prostate cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
898	897	TA581	2019/20	STA	Nivolumab with ipilimumab	Pharmaceutical	Untreated advanced renal cell carcinoma	Recommended (CDF)	Nivolumab with ipilimumab is recommended for use within the Cancer Drugs Fund as an option for adults with untreated advanced renal cell carcinoma that is intermediate- or poor-risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. It is recommended only if the conditions in the managed access agreement for nivolumab with ipilimumab are followed.
899	898	TA582	2019/20	STA	Cabozantinib	Pharmaceutical	Previously treated advanced hepatocellular carcinoma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
900	899	TA583	2019/20	STA	Ertugliflozin	Pharmaceutical	Type 2 diabetes mellitus	Optimised	Optimised recommendation for ertugliflozin with metformin and a dipeptidyl peptidase‑4 (DPP‑4) inhibitor as an option for treating type 2 diabetes in adults when diet and exercise alone do not provide adequate glycaemic control, only if: the disease is uncontrolled with metformin and a DPP‑4 inhibitor, and a sulfonylurea or pioglitazone is not appropriate.
901	900	TA584	2019/20	STA	Atezolizmab with bevacizumab, paclitaxel and carboplatin	Pharmaceutical	First-line treatment of metastatic non-squamous non-small cell lung cancer	Recommended	Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults: •who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% or •when targeted therapy for epidermal growth factor receptor (EGFR)‑positive or anaplastic lymphoma kinase (ALK)‑positive NSCLC has failed. It is only recommended if: •atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and •he company provides atezolizumab and bevacizumab according to the commercial arrangements
902	901	TA585	2019/20	STA	Ocrelizumab	Pharmaceutical	Early primary progressive multiple sclerosis	Recommended	Ocrelizumab is recommended, within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. It is recommended only if the company provides it according to the commercial arrangement.
903	902	TA586	2019/20	STA	Lenalidomide with dexamethasone	Pharmaceutical	Multiple myeloma in adults who have hade at least one prior therapy	Optimised	Optimised recommendation for lenalidomide plus dexamethasone for treating multiple myeloma in adults only if: they have only 1 previous therapy, which included bortezomib
904	903	TA587	2019/20	STA	Lenalidomide with dexamethasone	Pharmaceutical	Previously untreated multiple myeloma who are not eligible for transplant	Optimised	Optimised recommendation for lenalidomide plus dexamethasone for previously untreated multiple myeloma in adults who are not eligible for a stem cell transplant, only if: •thalidomide is contraindicated (including for pre-existing conditions that it may aggravate) or •the person cannot tolerate thalidomide
905	904	TA588	2019/20	STA	Nusinersen	Pharmaceutical	Spinal muscular atrophy	Optimised	Optimised recommendation for nusinersen for treating 5q spinal muscular atrophy (SMA) only if: • people have pre-symptomatic SMA, or SMA types 1, 2 or 3 and • the conditions in the managed access agreement are followed.
906	905	TA589	2019/20	STA	Blinatumomab	Pharmaceutical	Acute lymphoblastic leukaemia in remission with minimal residual disease activity	Optimised	Optimised recommendation for blinatumomab for treating Philadelphia-chromosome-negative CD19‑positive B‑precursor acute lymphoblastic leukaemia in adults with minimal residual disease (MRD) of at least 0.1%, only if: • the disease is in first complete remission and • the company provides blinatumomab according to the commercial arrangement
907	906	TA590	2019/20	STA	Fluocinolone acetonide	Pharmaceutical	Recurrent non-infectious uveitis	Recommended	Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
908	907	TA591	2019/20	STA	Letermovir	Pharmaceutical	Preventing cytomegalovirus disease after a stem cell transplant	Recommended	Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
909	908	TA592	2019/20	STA	Cemiplimab	Pharmaceutical	Metastatic or locally advanced cutaneous squamous cell carcinoma	Recommended (CDF)	Cemiplimab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate. It is recommended only if the conditions in the managed access agreement are followed. Treatment with cemiplimab should be continued until disease progression or for up to 24 months (whichever is sooner).
910	909	TA593	2019/20	STA	Ribociclib with fulvestrant	Pharmaceutical	Hormone receptor-positive, HER2-negative, advanced breast cancer	Optimised (CDF)	Ribociclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if: • exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and • the conditions in the managed access agreement for ribociclib with fulvestrant are followed.
911	910	TA594	2019/20	STA	Brentuximab vedotin	Pharmaceutical	Untreated advanced Hodgkin lymphoma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
912	911	TA595	2019/20	STA	Dacomitinib	Pharmaceutical	Untreated EGFR mutation-positive non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
913	912	TA596	2019/20	STA	Risankizumab	Pharmaceutical	Moderate to severe plaque psoriasis	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
914	913	TA597	2019/20	STA	Dapagliflozin with insulin	Pharmaceutical	Type 1 diabetes	Optimised	Optimised recommendation for dapagliflozin with insulin only if: • they are on insulin doses of more than 0.5 units/kg of body weight/day and • they have completed a structured education programme that is evidence based, quality assured, delivered by trained educators and includes information about diabetic ketoacidosis, such as: ◦how to recognise its risk factors, signs and symptoms ◦how and when to monitor blood ketone levels ◦what actions to take for elevated blood ketones, and • treatment is started and supervised by a consultant physician specialising in endocrinology and diabetes.
915	914	TA598	2019/20	STA	Olaparib	Pharmaceutical	Advanced ovarian, fallopian tube or peritoneal cancer	Recommended (CDF)	Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed.
916	915	TA599	2019/20	STA	Sodium zirconium cyclosilicate	Pharmaceutical	Hyperkalaemia	Optimised	Optimised recommendation Sodium zirconium cyclosilicate is recommended as an option for treating hyperkalaemia in adults only if used: •in emergency care for acute life-threatening hyperkalaemia alongside standard care or •in outpatient care for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they: ◦have a confirmed serum potassium level of at least 6.0 mmol/litre ◦are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia and ◦are not on dialysis. Sodium zirconium cyclosilicate is recommended only if the company provides it according to the commercial arrangement.
917	916	TA600	2019/20	STA	Pembrolizumab with carboplatin and paclitaxel	Pharmaceutical	Untreated metastatic squamous non-small-cell lung cancer	Recommended (CDF)	Pembrolizumab, with carboplatin and paclitaxel, is recommended for use within the Cancer Drugs Fund as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults only if: •pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and •the company provides pembrolizumab according to the managed access agreement
918	917	TA601	2019/20	STA	Bezlotoxumab	Pharmaceutical	Preventing recurrent Clostridium difficile infection	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
919	918	TA602	2019/20	STA	Pomalidomide with bortezomib and dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
920	919	TA603	2019/20	STA	Lenalidomide with bortezomib and dexamethasone	Pharmaceutical	Untreated multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
921	920	TA604	2019/20	STA	Idelalisib	Pharmaceutical	Refractory follicular lymphoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
922	921	TA605	2019/20	STA	Xeomin (botulinum neurotoxin type A)	Pharmaceutical	Chronic sialorrhoea	Recommended	Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
923	922	TA606	2019/20	STA	Lanadelumab	Pharmaceutical	Preventing recurrent attacks of hereditary angioedema	Optimised	Recommended in line with clinical practice and following agreement of a patient access scheme.
924	923	TA607	2019/20	STA	Rivaroxabn	Pharmaceutical	Preventing atherothrombotic events in people with coronary or peripheral artery disease	Recommended	Recommended in line with clinical practice
925	924	TA608	2019/20	STA	Ibrutinib with rituximab	Pharmaceutical	Waldenstrom’s macroglobulinaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
926	925	TA609	2019/20	STA	Ramucirumab	Pharmaceutical	Unresectable hepatocellular carcinoma after sorafenib	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
927	926	TA610	2019/20	STA	Pentosan polysulfate sodium	Pharmaceutical	Badder pain syndrome	Optimised	Optimised recommendation for pentosan polysulfate for treating bladder pain syndrome with glomerulations or Hunner's lesions in adults with urinary urgency and frequency, and moderate to severe pain, only if: • their condition has not responded to an adequate trial of standard oral treatments •it is not offered in combination with bladder instillations •any previous treatment with bladder instillations was not stopped because of lack of response •it is used in secondary care and •the company provides pentosan polysulfate sodium according to the commercial arrangement.
928	927	TA611	2019/20	STA	Rucaparib	Pharmaceutical	Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	Recommended (CDF)	Rucaparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, only if the conditions in the managed access agreement for rucaparib are followed.
929	928	TA612	2019/20	STA	Neratinib	Pharmaceutical	Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	Optimised	Optimised recommendation for neratinib for the extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑positive early stage breast cancer in adults who completed adjuvant trastuzumab-based therapy less than 1 year ago only if: •trastuzumab is the only HER2‑directed adjuvant treatment they have had, and •if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or axilla following the neoadjuvant treatment, and •the company provides neratinib according to the commercial arrangement.
930	929	TA613	2019/20	STA	Fluocinolone acetonide intravitreal implant	Pharmaceutical	Chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
931	930	TA614	2019/20	STA	Cannabidiol with clobazam	Pharmaceutical	Seizures associated with Dravet syndrome	Optimised	Optimised recommendation for cannabidiol with clobazam for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if: •the frequency of convulsive seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment •the company provides cannabidiol according to the commercial arrangement.
932	931	TA615	2019/20	STA	Cannabidiol with clobazam	Pharmaceutical	Seizures associated with Lennox–Gastaut syndrome	Optimised	Cannabidiol with clobazam is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older, only if: •the frequency of drop seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment •the company provides cannabidiol according to the commercial arrangement
933	932	TA616	2019/20	STA	Cladribine	Pharmaceutical	Relapsing–remitting multiple sclerosis	Optimised	Reissue of TA493 with the addition of 'or a significant increase in T2 lesion load compared with a previous MRI' to the recommendations. Optimised recommendation for cladribine for treating highly active multiple sclerosis in adults, only if the person has: •rapidly evolving severe relapsing–remitting multiple sclerosis, that is with at least: ◦2 relapses in the previous year and ◦1 T1 gadolinium-enhancing lesion at baseline MRI or a significant increase in T2‑lesion load compared with a previous MRI, or •relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as 1 relapse in the previous year and MRI evidence of disease activity.
934	933	TA617	2019/20	MTA	Lusutrombopag	Pharmaceutical	Trombocytopenia in people with chronic liver disease needing a planned invasive procedure	Recommended	Recommended in line with the marketing authorisation NB No recommendation could be made for avatrombopag since the company hadn't agreed a list price in the UK
935	934	TA618	2019/20	STA	Atezolizumab with carboplatin and nab-paclitaxel	Pharmaceutical	Untreated advanced non-squamous non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
936	935	TA619	2019/20	STA	Palbociclib with fulvestrant	Pharmaceutical	Hormone receptor-positive, HER2-negative, advanced breast cancer	Recommended (CDF)	Palbociclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if: •exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and •the conditions in the managed access agreement for palbociclib with fulvestrant are followed.
937	936	TA620	2019/20	STA	Olaparib	Pharmaceutical	Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	Optimised	Optimised recommendation for olaparib for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy only if: •they have a BRCA1 or BRCA2 mutation •they have had 3 or more courses of platinum-based chemotherapy and •the company provides olaparib according to the commercial arrangement.
938	937	TA620	2019/20	STA	Olaparib	Pharmaceutical	Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	Optimised (CDF)	Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy only if: •they have a BRCA1 or BRCA2 mutation •they have had 2 courses of platinum-based chemotherapy and •the conditions in the managed access agreement for olaparib are followed.
939	938	TA621	2019/20	STA	Osimertinib	Pharmaceutical	Untreated EGFR mutation-positive non-small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
940	939	TA622	2019/20	STA	Sotagliflozin with insulin	Pharmaceutical	Type 1 diabetes	Recommended	Recommended in line with clinical practice
941	940	TA623	2019/20	STA	Patiromer	Pharmaceutical	Hyperkalaemia	Optimised	Recommended in line with clinical practice
942	941	TA624	2019/20	STA	Peginterferon beta-1a	Pharmaceutical	Relapsing–remitting multiple sclerosis	Recommended	Recommended in line with clinical practice
943	942	TA625	2019/20	STA	Recombinant human parathyroid hormone	Pharmaceutical	Hypoparathyroidism	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
944	943	TA627	2020/21	STA	Lenalidomide with rituximab	Pharmaceutical	Previously treated follicular lymphoma	Recommended	Recommmended in line with marketing autorisation
945	944	TA628	2020/21	STA	Lorlatinib	Pharmaceutical	Previously treated ALK-positive advanced non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation
946	945	TA629	2020/21	STA	Obinutuzumab with bendamustine	Pharmaceutical	Follicular lymphoma after rituximab	Recommended	Recommended in line with marketing autorisation
947	946	TA630	2020/21	STA	Larotrectinib	Pharmaceutical	NTRK fusion-positive solid tumours	Recommended (CDF)	Larotrectinib is recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children if: •the disease is locally advanced or metastatic or surgery could cause severe health problems and •they have no satisfactory treatment options. It is recommended only if the conditions in the managed access agreement for larotrectinib are followed.
948	947	TA626	2020/21	STA	Avatrombopag	Pharmaceutical	Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure	Recommended	Avatrombopag is recommended, within its marketing authorisation, as an option for treating severe thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having a planned invasive procedure. Avatrombopag and lusutrombopag need to be taken more than a week before a procedure, so cannot be used for emergency procedures. The economic modelling does not fully account for the benefits for patients and service delivery when using avatrombopag and lusutrombopag
949	948	TA631	2020/21	STA	Fremanezumab	Pharmaceutical	Prophylaxis of migraine in adults who have at least 4 migraine days per month	Optimised	Optimsed recommendation for preventing migraine in adults, only if: the migraine is chronic, that is, 15 or more headache days a month for more than 3 months with at least 8 of those having features of migraine; at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement. 1.2 Stop fremanezumab if the migraine frequency does not reduce by at least 30% after 12 weeks of treatment.
950	949	TA632	2020/21	STA	Trastuzumab emtansine	Pharmaceutical	adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy	Recommended	Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement
951	950	TA633	2020/21	STA	Ustekinumab	Pharmaceutical	Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'	Optimised	Ustekinumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if: a tumour necrosis factor‑alpha inhibitor has failed (that is the disease has responded inadequately or has lost response to treatment) or a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is not suitable, and the company provides ustekinumab at the same price or lower than that agreed with the Commercials Medicines Unit
952	951	TA634	2020/21	STA	Daratumumab with lenalidomide and dexamethasone	Pharmaceutical	Untreated multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
953	952	TA635	2020/21	STA	Ramucirumab with erlotinib	Pharmaceutical	Untreated EGFR mutation-positive non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
954	953	TA636	2020/21	STA	Eculizumab	Pharmaceutical	Refractory myasthenia gravis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
955	954	TA637	2020/21	STA	Ranibuzimab	Pharmaceutical	Diabetic retinopathy	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
956	955	TA638	2020/21	STA	Atezolizumab with carboplatin and etoposide	Pharmaceutical	Untreated extensive-stage small-cell lung cancer	Optimised	Optimised recommendation for untreated extensive-stage small-cell lung cancer in adults, only if: •they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and • the company provides atezolizumab according to the commercial arrangement.
957	956	TA639	2020/21	STA	Atezolizumab with nab-paclitaxel	Pharmaceutical	Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	Recommended	Recommended in line with marketing autorisation
958	957	TA640	2020/21	STA	Treosulfan with fludarabine	Pharmaceutical	Malignant disease before allogeneic stem cell transplant	Optimised	Optimsed recommendation for conditioning treatment before allogeneic haematopoietic stem cell transplant (allo-HSCT) for people with malignant diseases for whom a reduced intensity regimen, such as low-dose busulfan with fludarabine, would be suitable.
959	958	TA641	2020/21	STA	Brentuximab vedotin in combination	Pharmaceutical	Untreated systemic anaplastic large cell lymphoma	Recommended	Recommended in line with marketing authorisation
960	959	TA642	2020/21	STA	Gilteritinib	Pharmaceutical	Relapsed or refractory acute myeloid leukaemia	Optimised	Optimsed recommendation for treating relapsed or refractory FLT3‑mutation-positive acute myeloid leukaemia (AML) in adults only if the company provides gilteritinib according to the commercial arrangement. Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant.
961	960	TA643	2020/21	STA	Entrectinib	Pharmaceutical	ROS1-positive advanced non-small-cell lung cancer	Recommended	Recommended in line with marketing autorisation
962	961	TA644	2020/21	STA	Entrectinib	Pharmaceutical	NTRK fusion-positive solid tumours	Recommended (CDF)	Entrectinib is recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if: •the disease is locally advanced or metastatic or surgery could cause severe health problems and •they have not had an NTRK inhibitor before and •they have no satisfactory treatment options. It is recommended only if the conditions in the managed access agreement for entrectinib are followed.
963	962	TA645	2020/21	STA	Avelumab with axitinib for untreated advanced renal cell carcinoma	Pharmaceutical	Untreated advanced renal cell carcinoma	Recommended (CDF)	Avelumab with axitinib is recommended for use within the Cancer Drugs Fund as an option for untreated advanced renal cell carcinoma in adults. It is recommended only if the conditions in the managed access agreement for avelumab with axitinib are followed.
964	963	TA646	2020/21	STA	Glasdegib	Pharmaceutical	Untreated acute myeloid leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
965	964	TA647	2020/21	STA	Eculizumab	Pharmaceutical	Relapsing neuromyelitis optica	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
966	965	TA648	2020/21	STA	Dupilumab	Pharmaceutical	Chronic rhinosinusitis with nasal polyps	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
967	966	TA649	2020/21	STA	Polatuzumab vedotin with rituximab and bendamustine	Pharmaceutical	Relapsed or refractory diffuse large B-cell lymphoma	Recommended	Recommended in line with marketing autorisation
968	967	TA650	2020/21	STA	Pembrolizumab with axitinib	Pharmaceutical	Untreated advanced renal cell carcinoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
969	968	TA651	2020/21	STA	Naldemedine	Pharmaceutical	Treating opioid-induced constipation	Recommended	Recommended in line with marketing authorisation
970	969	TA652	2020/21	STA	Alpelisib with fulvestrant	Pharmaceutical	Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
971	970	TA653	2020/21	STA	Osimertinib	Pharmaceutical	EGFR T790M mutation-positive advanced non-small-cell lung cancer	Optimised	Optimised recommendation for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults, only if: • their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and • the company provides osimertinib according to the commercial arrangement.
972	971	TA654	2020/21	STA	Osimertinib	Pharmaceutical	Untreated EGFR mutation-positive non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation
973	972	TA655	2020/21	STA	Nivolumab	Pharmaceutical	Advanced squamous non-small-cell lung cancer after chemotherapy	Optimised	Optimsed recommendation for treating locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if: • it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses and • they have not had a PD‑1 or PD‑L1 inhibitor before. It is recommended only if the company provides nivolumab according to the commercial arrangement.
974	973	TA656	2020/21	STA	Siponimod	Pharmaceutical	Secondary progressive multiple sclerosis	Recommended	Recommended in line with the marketing authorisation and only if company provides it according to the patient access scheme
975	974	TA657	2020/21	STA	Carfilzomib for previously treated multiple myeloma	Pharmaceutical	Previously treated multiple myeloma	Recommended	Reissue of TA457 to allow previous treatment with bortezomib since clincial practiac has changed. Recommendations now read: Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma in adults, only if: •they have had only 1 previous therapy and •the company provides carfilzomib according to the commercial arrangement.
976	975	TA658	2020/21	STA	Isatuximab with pomalidomide and dexamethasone	Pharmaceutical	Relapsed and refractory multiple myeloma	Recommended (CDF)	Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only if: •they have had 3 previous lines of treatment •the conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are followed.
977	976	TA659	2020/21	STA	Galcanezumab	Pharmaceutical	Preventing migraine	Optimised	Optimised recommendation for preventing migraine in adults, only if: •they have 4 or more migraine days a month •at least 3 preventive drug treatments have failed and •the company provides it according to the commercial arrangement.
978	977	TA660	2020/21	STA	Darolutamide with androgen deprivation therapy	Pharmaceutical	Hormone-relapsed non-metastatic prostate cancer	Recommended	Recommended in line with the marketing autorisation and only if company provides it according to the patient access scheme
979	978	TA661	2020/21	STA	Pembrolizumab	Pharmaceutical	Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma	Optimised	Optimised recommendation for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD‑L1 with a combined positive score (CPS) of 1 or more. This is only if: •pembrolizumab is given as a monotherapy •pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and •the company provides pembrolizumab according to the commercial arrangement.
980	979	TA662	2020/21	STA	Durvalumab in combination	Pharmaceutical	Untreated extensive-stage small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
981	980	TA663	2020/21	STA	Venetoclax with obinutuzumab	Pharmaceutical	Untreated chronic lymphocytic leukaemia	Optimised	Optimised recommendation for adults only if: •there is a 17p deletion or TP53 mutation, or •there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR), is unsuitable, and •the companies provide the drugs according to the commercial arrangements.
982	981	TA663	2020/21	STA	Venetoclax with obinutuzumab	Pharmaceutical	Untreated chronic lymphocytic leukaemia	Recommended (CDF)	Venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated CLL in adults, only if: •there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and •the conditions in the managed access agreement for venetoclax plus obinutuzumab are followed.
983	982	TA664	2020/21	STA	Liraglutide	Pharmaceutical	Managing overweight and obesity	Optimised	Optimised recommendation for Liraglutide for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if: •they have a body mass index (BMI) of at least 35 kg/m2 (or at least 32.5 kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and •they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and •they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia and •it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and •the company provides it according to the commercial arrangement.
984	983	TA665	2020/21	STA	Upadacitinib with methotrexate	Pharmaceutical	Severe rheumatoid arthritis	Optimised	Optimised recommendation for upadacitinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if: •disease is severe (a disease activity score [DAS28] of more than 5.1) and •the company provides upadacitinib according to the commercial arrangement.
985	984	TA665	2020/21	STA	Upadacitinib with methotrexate	Pharmaceutical	Severe rheumatoid arthritis	Optimised	Optimised recommendation for upadacitinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if: •disease is severe (a DAS28 of more than 5.1) and •they cannot have rituximab and •the company provides upadacitinib according to the commercial arrangement.
986	985	TA665	2020/21	STA	Upadacitinib with methotrexate	Pharmaceutical	Severe rheumatoid arthritis	Optimised	Optimised recommendation for upadacitinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if: •disease is severe (a DAS28 of more than 5.1) and •the company provides upadacitinib according to the commercial arrangement.
987	986	TA665	2020/21	STA	Upadacitinib monotherapy	Pharmaceutical	Severe rheumatoid arthritis	Optimised	Optimised recommendation for upadacitinib monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in sections 1.1, 1.2 or 1.3 are met.
988	987	TA666	2020/21	STA	Atezolizumab with bevacizumab	Pharmaceutical	Advanced or unresectable hepatocellular carcinoma	Optimised	Optimsed recommendation for Atezolizumab plus bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment, only if: •they have Child‑Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and •the company provides it according to the commercial arrangement.
989	988	TA667	2020/21	STA	Caplacizumab	Pharmaceutical	Acute acquired thrombotic thrombocytopenic purpura	Recommended	Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
990	989	TA668	2020/21	STA	Encorafenib plus cetuximab	Pharmaceutical	Previously treated BRAF V600E mutation-positive metastatic colorectal cancer	Recommended	Recommmended in line with the marketing autorisation and only if company provides it according to the commercial access agreement
991	990	TA669	2020/21	STA	Trifluridine–tipiracil	Pharmaceutical	Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
992	991	TA670	2020/21	STA	Brigatinib	Pharmaceutical	ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor	Recommended	Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
993	992	TA671	2020/21	STA	Mepolizumab	Pharmaceutical	Severe eosinophilic asthma	Optimised	Optimised recommendation for mepolizumab, as an add-on therapy for treating severe refractory eosinophilic asthma, only if: •it is used for adults who have agreed to and followed the optimised standard treatment plan and •the blood eosinophil count has been recorded as 300 cells per microlitre or more and the person has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, or has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months or •the blood eosinophil count has been recorded as 400 cells per microlitre or more and the person has had at least 3 exacerbations needing systemic corticosteroids in the previous 12 months (so they are also eligible for either benralizumab or reslizumab). Mepolizumab is recommended only if the company provides it according to the commercial arrangement.
994	993	TA672	2020/21	STA	Brolucizumab	Pharmaceutical	Wet age-related macular degeneration	Optimised	Optimised recommendation for brolucizumab for treating wet age-related macular degeneration in adults, only if, in the eye to be treated: •the best-corrected visual acuity is between 6/12 and 6/96 •there is no permanent structural damage to the central fovea •the lesion size is less than or equal to 12 disc areas in greatest linear dimension and •there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes). It is recommended only if the company provides brolucizumab according to the commercial arrangement.
995	994	TA673	2020/21	STA	Niraparib	Pharmaceutical	Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	Recommended (CDF)	Niraparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for niraparib are followed.
996	995	TA674	2020/21	STA	Pembrolizumab	Pharmaceutical	Untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
997	996	TA675	2020/21	STA	Vernakalant	Pharmaceutical	Rapid conversion of recent onset atrial fibrillation to sinus rhythm	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
998	997	TA676	2020/21	STA	Filgotinib with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for filgotinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs), only if: •disease is moderate or severe (a disease activity score [DAS28] of 3.2 or more) and •the company provides filgotinib according to the commercial arrangement.
999	998	TA676	2020/21	STA	Filgotinib with methotrexate	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised recommendation for filgotinib, with methotrexate, treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if: •disease is severe (a DAS28 of more than 5.1) and •they cannot have rituximab and •the company provides filgotinib according to the commercial arrangement.
1000	999	TA676	2020/21	STA	Filgotinib with methotrexate	Pharmaceutical	Severe rheumatoid arthritis	Optimised	Optimised recommendation for filgotinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if: •disease is severe (a DAS28 of more than 5.1) and •the company provides filgotinib according to the commercial arrangement.
1001	1000	TA676	2020/21	STA	Filgotinib monotherapy	Pharmaceutical	Moderate to severe rheumatoid arthritis	Optimised	Optimised reccomendation for filgotinib monotherapy when methotrexate is contraindicated or if people cannot tolerate it, when the criteria in sections 1.1, 1.2 or 1.3 are met.
1002	1001	TA677	2020/21	STA	Autologous anti-CD19-transduced CD3+ cells	Pharmaceutical	Relapsed or refractory mantle cell lymphoma	Recommended (CDF)	Treatment with autologous anti-CD19-transduced CD3+ cells is recommended for use within the Cancer Drugs Fund as an option for relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton's tyrosine kinase (BTK) inhibitor. It is only recommended if the conditions in the managed access agreement for autologous anti‑CD19‑transduced CD3+ cells treatment are followed.
1003	1002	TA678	2020/21	STA	Omalizumab	Pharmaceutical	Chronic rhinosinusitis with nasal polyps	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1004	1003	TA679	2020/21	STA	Dapagliflozin	Pharmaceutical	Chronic heart failure with reduced ejection fraction	Optimised	Optimised recommendation for Dapagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with: •angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or •sacubitril valsartan, with beta blockers, and, if tolerated, MRAs.
1005	1004	TA680	2020/21	STA	Lenalidomide	Pharmaceutical	Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma	Optimised	Optimised recommendation for lenalidomide as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults, only if: •the dosage schedule is 10 mg per day on days 1 to 21 of a 28‑day cycle and •the company provides lenalidomide according to the commercial arrangement. NOTE: The use of lenalidomide as a maintenance treatment after an autologous stem cell transplant at a dosage of 10 mg per day on days 1 to 21 of a 28-day cycle is outside the terms of the marketing authorisation for lenalidomide. Consequently, the statutory funding requirement does not apply to this recommendation.
1006	1005	TA681	2020/21	STA	Baricitinib for treating moderate to severe atopic dermatitis	Pharmaceutical	Moderate to severe atopic dermatitis	Optimised	Optimised recommendation for baricitinib for treating moderate to severe atopic dermatitis in adults, only if: •the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are not suitable, and •the company provides it according to the commercial arrangement.
1007	1006	TA682	2020/21	STA	Erenumab	Pharmaceutical	Migraine	Optimised	Optimised recommendation for erenumab for preventing migraine in adults, only if: •they have 4 or more migraine days a month •at least 3 preventive drug treatments have failed •the 140 mg dose of erenumab is used and •the company provides it according to the commercial arrangement.
1008	1007	TA683	2020/21	STA	Pembrolizumab with pemetrexed and platinum chemotherapy	Pharmaceutical	Untreated, metastatic, non-squamous non-small-cell lung cancer	Recommended	Recommmended in line with the marketing autorisation and only if company provides it according to the commerical access agreement
1009	1008	TA684	2020/21	STA	Nivolumab	Pharmaceutical	Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease	Recommended	Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
1010	1009	TA685	2020/21	STA	Anakinra	Pharmaceutical	Still’s disease	Optimised	Optimised recommendation for anakinra ifor treating Still's disease with moderate to high disease activity, or continued disease activity after non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. It is only recommended for: •adult-onset Still's disease that has responded inadequately to 2 or more conventional disease‑modifying antirheumatic drugs (DMARDs) •systemic juvenile idiopathic arthritis in people 8 months and older with a body weight of 10 kg or more that has not responded to at least 1 conventional DMARD.
1011	1010	TA686	2020/21	STA	Blinatumomab	Pharmaceutical	Previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1012	1011	TA687	2020/21	STA	Ribociclib with fulvestrant	Pharmaceutical	Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Recommended	CDF review of TA593
1013	1012	TA688	2020/21	MTA	Selective internal radiation therapy SIR-Spheres	Pharmaceutical	Hepatocellular carcinoma	Optimised	Optimsed recommendation selective internal radiation therapy (SIRT) SIR‑Spheres for treating unresectable advanced hepatocellular carcinoma (HCC) in adults, only if: •used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and •the company provides SIR‑Spheres according to the commercial arrangement.
1014	1013	TA688	2020/21	MTA	Selective internal radiation therapy TheraSphere	Pharmaceutical	Hepatocellular carcinoma	Optimised	Olptimised recommendation for SIRT TheraSphere for treating unresectable advanced HCC in adults, only if: •used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and •the company provides TheraSphere according to the commercial arrangement.
1015	1014	TA688	2020/21	MTA	Selective internal radiation therapy QuiremSpheres	Pharmaceutical	Hepatocellular carcinoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1016	1015	TA689	2021/22	STA	Acalabrutinib	Pharmaceutical	Chronic lymphocytic leukaemia	Optimised	Optimised recommendation for untreated chronic lymphocytic leukaemia (CLL) in adults, only if: • there is a 17p deletion or TP53 mutation, or • there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable, and • the company provides the drug according to the commercial arrangement.
1017	1016	TA689	2021/22	STA	Acalabrutinib	Pharmaceutical	Chronic lymphocytic leukaemia	Optimised	Optimised recommendation: as monotherapy is recommended, within its marketing authorisation, as an option for previously treated CLL in adults. It is recommended only if the company provides the drug according to the commercial arrangement.
1018	1017	TA690	2021/22	STA	Teduglutide	Pharmaceutical	Short bowel syndrome	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1019	1018	TA691	2021/22	STA	Avelumab	Pharmaceutical	Untreated metastatic Merkel cell carcinoma	Recommended	CDF review of recommendation 1.2 of TA517: for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease
1020	1019	TA692	2021/22	STA	Pembrolizumab	Pharmaceutical	Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	Not recommended	CDF review of TA519. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1021	1020	TA693	2021/22	STA	Olaparib plus bevacizumab	Pharmaceutical	Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer	Optimised (CDF)	Optimised CDF recommendation for maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when: •there has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab, and •the cancer is associated with homologous recombination deficiency (HRD). It is recommended only if the conditions in the managed access agreement for olaparib are followed.
1022	1021	TA694	2021/22	STA	Bempedoic acid with ezetimibe	Pharmaceutical	Primary hypercholesterolaemia or mixed dyslipidaemia	Optimised	Optimised recommendation for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if: •statins are contraindicated or not tolerated, •ezetimibe alone does not control low-density lipoprotein cholesterol well enough, and •the company provides bempedoic acid and bempedoic acid with ezetimibe according to the commercial arrangement. Bempedoic acid with ezetimibe can be used as separate tablets or a fixed-dose combination.
1023	1022	TA695	2021/22	STA	Carfilzomib with dexamethasone and lenalidomide	Pharmaceutical	Previously treated multiple myeloma	Optimised	Optimised recommenation for treating multiple myeloma in adults, only if: •they have had only 1 previous therapy, which included bortezomib, and •the company provides carfilzomib according to the commercial arrangement.
1024	1023	TA696	2021/22	STA	Tafamidis for treating transthyretin amyloidosis with cardiomyopathy	Pharmaceutical	Transthyretin amyloidosis with cardiomyopathy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1025	1024	TA697	2021/22	STA	Andexanet alfa	Pharmaceutical	Reversing anticoagulation from apixaban or rivaroxaban	Optimised	Optimiised recommendation for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding, only if: • the bleed is in the gastrointestinal tract, and •the company provides andexanet alfa according to the commercial arrangement.
1026	1025	TA697	2021/22	STA	Andexanet alfa	Pharmaceutical	Reversing anticoagulation from apixaban or rivaroxaban	Only in research	Only in research recommenation for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the skull (intracranial haemorrhage; ICH), in the form of an ongoing randomised trial mandated by the regulator.
1027	1026	TA698	2021/22	STA	Ravulizumab	Pharmaceutical	Paroxysmal nocturnal haemoglobinuria	Recommended	Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
1028	1027	TA699	2021/22	STA	Ofatumumab for treating relapsing multiple sclerosis	Pharmaceutical	Relapsing multiple sclerosis	Recommended	Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
1029	1028	TA700	2021/22	STA	Selinexor with low-dose dexamethasone for treating refractory multiple myeloma	Pharmaceutical	Refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1030	1029	TA701	2021/22	STA	Crisaborole	Pharmaceutical	Mild to moderate atopic dermatitis in people 2 years and older	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1031	1030	TA702	2021/22	STA	Ibrutinib with obinutuzumab	Pharmaceutical	Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1032	1031	TA703	2021/22	STA	Ibrutinib with rituximab	Pharmaceutical	Untreated chronic lymphocytic leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1033	1032	TA704	2021/22	STA	Trastuzumab deruxtecan	Pharmaceutical	HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies	Recommended (CDF)	Trastuzumab deruxtecan is recommended for use within the Cancer Drugs Fund as an option for treating HER2‑positive unresectable or metastatic breast cancer in adults after 2 or more anti‑HER2 therapies. It is recommended only if the conditions in the managed access agreement are followed.
1034	1033	TA705	2021/22	STA	Atezolizumab	Pharmaceutical	Untreated advanced non-small-cell lung cancer	Recommended	Recommmended in line with the marketing authorisation and only if company provides it according to the patient access scheme
1035	1034	TA706	2021/22	STA	Ozanimod	Pharmaceutical	Relapsing–remitting multiple sclerosis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1036	1035	TA707	2021/22	STA	Nivolumab	Pharmaceutical	Previously treated unresectable advanced or recurrent oesophageal cancer	Recommended	Recommmended in line with the marketing auhtorisation and only if company provides it according to the commerical access agreement
1037	1036	TA708	2021/22	STA	Budesonide orodispersible tablet	Pharmaceutical	Inducing remission of eosinophilic oesophagitis	Optimised	Optimised recommendation for inducing remission of eosinophilic oesophagitis in adults. This is an optimised recommendation because although the licence was extended during the course of the appraisal, the company submission covered only induction.
1038	1037	TA709	2021/22	STA	Pembrolizumab	Pharmaceutical	Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	Optimised	Optimised recommendation for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults, only if: •pembrolizumab is stopped after 2 years and no documented disease progression, and •the company provides pembrolizumab according to the commercial arrangement.
1039	1038	TA710	2021/22	STA	Ravulizumab	Pharmaceutical	Atypical haemolytic uraemic syndrome	Recommended	Recommmended in line with the marketing authorisation and only if company provides it according to the patient access scheme
1040	1039	TA711	2021/22	STA	Guselkumab	Pharmaceutical	Active psoriatic arthritis after inadequate response to DMARDs	Optimised	Optimised recommendation for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them, only if they have: • peripheral arthritis with 3 or more tender joints and 3 or more swollen joints •moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10) •had 2 conventional DMARDs and at least 1 biological DMARD. Guselkumab is recommended only if the company provides it according to the commercial arrangement.
1041	1040	TA712	2021/22	STA	Enzalutamide	Pharmaceutical	Hormone-sensitive metastatic prostate cancer	Recommended	Recommended in line with the marketing authorisation and only if company provides it according to the patient access scheme
1042	1041	TA713	2021/22	STA	Nivolumab	Pharmaceutical	Advanced non-squamous non-small-cell lung cancer after chemotherapy	Optimised	CDF review of TA484. locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if: •their tumours are PD-L1 positive, and •it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses, and • they have not had a PD-1 or PD-L1 inhibitor before. It is recommended only if the company provides nivolumab according to the commercial arrangement.
1043	1042	TA714	2021/22	STA	Dasatinib	Pharmaceutical	Philadelphia-chromosome-positive acute lymphoblastic leukaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1044	1043	TA715	2021/22	MTA	Adalimumab with methotrexate	Pharmaceutical	Moderate rheumatoid arthritis after conventional DMARDs have failed	Optimised	Optimised recommendation for adalimumab with methotrexate for treating active rheumatoid arthritis in adults, only if: • intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and •disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and •the company provides adalimumab at the same or lower prices than those agreed with the Commercial Medicines Unit.
1045	1044	TA715	2021/22	MTA	Etanercept with methotrexate	Pharmaceutical	Moderate rheumatoid arthritis after conventional DMARDs have failed	Optimised	Optimised recommendation for etanercept with methotrexate for treating active rheumatoid arthritis in adults, only if: • intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and •disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and •the company provides etanercept at the same or lower prices than those agreed with the Commercial Medicines Unit.
1046	1045	TA715	2021/22	MTA	Infliximab with methotrexate	Pharmaceutical	Moderate rheumatoid arthritis after conventional DMARDs have failed	Optimised	Optimised recommendation for infliximab with methotrexate for treating active rheumatoid arthritis in adults, only if: • intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and •disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and •the company provides infliximab at the same or lower prices than those agreed with the Commercial Medicines Unit.
1047	1046	TA715	2021/22	MTA	Abatacept with methotrexate	Pharmaceutical	Moderate rheumatoid arthritis after conventional DMARDs have failed	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1048	1047	TA715	2021/22	MTA	Adalimumab monotherapy	Pharmaceutical	Moderate rheumatoid arthritis after conventional DMARDs have failed	Optimised	Optimised recommendation for adalimumab monotherapy for treating active rheumatoid arthritis in adults, only if: • intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and •disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and •the company provides adalimumab at the same or lower prices than those agreed with the Commercial Medicines Unit.
1049	1048	TA715	2021/22	MTA	Etanercept monotherapy	Pharmaceutical	Moderate rheumatoid arthritis after conventional DMARDs have failed	Optimised	Optimised recommendation for etanercept monotherpay for treating active rheumatoid arthritis in adults, only if: • intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and •disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and •the company provides etanercept at the same or lower prices than those agreed with the Commercial Medicines Unit.
1050	1049	TA716	2021/22	STA	Nivolumab with ipilimumab	Pharmaceutical	Previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	Recommended	Recommmended in line with the marketing auhtorisation and only if company provides it according to the commerical access agreements
1051	1050	TA717	2021/22	STA	Duvelisib	Pharmaceutical	Relapsed follicular lymphoma after 2 or more systemic therapies	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1052	1051	TA718	2021/22	STA	Ixekizumab	Pharmaceutical	Axial spondyloarthritis	Optimised	Optimised recommendation for reating active ankylosing spondylitis that is not controlled well enough with conventional therapy, or active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs), in adults. It is recommended only if: tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and the company provides ixekizumab according to the commercial arrangement.
1053	1052	TA719	2021/22	STA	Secukinumab	Pharmaceutical	Non-radiographic axial spondyloarthritis	Optimised	Optimsed recommendation for reating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if: tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides secukinumab according to the commercial arrangement.
1054	1053	TA720	2021/22	STA	Chlormethine gel	Pharmaceutical	Mycosis fungoides-type cutaneous T-cell lymphoma	Optimised	Optimised recommendation for treating early stage (stage 1A, 1B, and 2A) mycosis fungoides-type cutaneous T‑cell lymphoma (MF‑CTCL) in adults, only if the company provides chlormethine gel according to the commercial arrangement.
1055	1054	TA721	2021/22	STA	Abiraterone	Pharmaceutical	Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1056	1055	TA722	2021/22	STA	Pemigatinib	Pharmaceutical	Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	Recommended	Recommmended in line with the marketing auhtorisation and only if company provides it according to the patient access scheme
1057	1056	TA723	2021/22	STA	Bimekizumab	Pharmaceutical	Moderate to severe plaque psoriasis	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
1058	1057	TA724	2021/22	STA	Nivolumab with ipilimumab and chemotherapy	Pharmaceutical	Untreated metastatic non-small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1059	1058	TA725	2021/22	STA	Abemaciclib with fulvestrant	Pharmaceutical	Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
1060	1059	TA726	2021/22	STA	Daratumumab with pomalidomide and dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1061	1060	TA727	2021/22	STA	Isatuximab with carfilzomib and dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1062	1061	TA728	2021/22	STA	Midostaurin	Pharmaceutical	Advanced systemic mastocytosis	Recommended	Recommended in line with clinical practice and following agreement of acommerical access agreement.
1063	1062	TA729	2021/22	STA	Sapropterin	Pharmaceutical	Hyperphenylalaninaemia in phenylketonuria	Optimised	Optimised recommendation for treating hyperphenylalaninaemia that responds to sapropterin (response as defined in the summary of product characteristics) in people with phenylketonuria (PKU), only if they are: •under 18 and a dose of 10 mg/kg is used, only using a higher dose if target blood phenylalanine levels cannot be achieved at 10 mg/kg •aged 18 to 21 inclusive, continuing the dose they were having before turning 18 or at a maximum dose of 10 mg/kg • pregnant (from a positive pregnancy test until birth). Sapropterin is recommended only if the company provides it according to the commercial arrangement.
1064	1063	TA730	2021/22	STA	Avapritinib	Pharmaceutical	Unresectable or metastatic gastrointestinal stromal tumours	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1065	1064	TA731	2021/22	STA	Vericiguat	Pharmaceutical	Chronic heart failure with reduced ejection fraction	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1066	1065	TA732	2021/22	STA	Baloxavir marboxil	Pharmaceutical	Acute uncomplicated influenza	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1067	1066	TA733	2021/22	STA	Inclisiran	Pharmaceutical	Primary hypercholesterolaemia or mixed dyslipidaemia	Optimised	Optimised recommendation for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if: •there is a history of any of the following cardiovascular events: ◦acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation) ◦coronary or other arterial revascularisation procedures ◦coronary heart disease ◦ischaemic stroke or ◦peripheral arterial disease, and • low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is: ◦maximum tolerated statins with or without other lipid-lowering therapies or, ◦other lipid-lowering therapies when statins are not tolerated or are contraindicated, and •the company provides inclisiran according to the commercial arrangement.
1068	1067	TA733	2021/22	STA	Inclisiran	Pharmaceutical	Primary hypercholesterolaemia or mixed dyslipidaemia	Only in research	Only in research recommendatio fort reating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults who have no history of cardiovascular events. This research is in the form of a clinical trial currently in development.
1069	1068	TA734	2021/22	STA	Secukinumab	Pharmaceutical	Moderate to severe plaque psoriasis in children and young people	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
1070	1069	TA735	2021/22	STA	Tofacitinib	Pharmaceutical	Juvenile idiopathic arthritis	Optimised	Optimised recommendation for for treating active polyarticular juvenile idiopathic arthritis (JIA; rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis in people 2 years and older. This is if their condition has responded inadequately to previous treatment with disease-modifying antirheumatic drugs (DMARDs), and only if: •a tumour necrosis factor (TNF)‑alpha inhibitor is not suitable or does not control the condition well enough, and •the company provides tofacitinib according to the commercial arrangement.
1071	1070	TA736	2021/22	STA	Nivolumab	Pharmaceutical	Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
1072	1071	TA737	2021/22	STA	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy	Pharmaceutical	Untreated advanced oesophageal and gastro-oesophageal junction cancer	Recommended	Recommended in line with clinical practice and following agreement of a commerical access agreement.
1073	1072	TA738	2021/22	STA	Berotralstat for preventing recurrent attacks of hereditary angioedema	Pharmaceutical	Recurrent attacks of hereditary angioedema	Optimised	Optimised recommenation for preventing recurrent attacks of hereditary angioedema in people 12 years and older, only if: •they have at least 2 attacks per month, and •it is stopped if the number of attacks per month does not reduce by at least 50% after 3 months. It is only recommended if the company provides berotralstat according to the commercial arrangement.
1074	1073	TA739	2021/22	STA	Atezolizumab	Pharmaceutical	Untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
1075	1074	TA740	2021/22	STA	Apalutamide with androgen deprivation therapy	Pharmaceutical	High-risk hormone-relapsed non-metastatic prostate cancer	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
1076	1075	TA741	2021/22	STA	Apalutamide with androgen deprivation therapy	Pharmaceutical	Hormone-sensitive metastatic prostate cancer	Optimised	Optimised recommendation for treating hormone-sensitive metastatic prostate cancer in adults, only if: • docetaxel is not suitable • the company provides apalutamide according to the commercial arrangement
1077	1076	TA742	2021/22	STA	Selpercatinib	Pharmaceutical	Advanced thyroid cancer with RET alterations	Recommended (CDF)	Selpercatinib is recommended for use within the Cancer Drugs Fund, as an option for treating: advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after cabozantinib or vandetanib. It is recommended only if the conditions in the managed access agreement are followed.
1078	1077	TA743	2021/22	STA	Crizanlizumab	Pharmaceutical	Preventing sickle cell crises in sickle cell disease	Optimised	Crizanlizumab is recommended as an option for preventing recurrent sickle cell crises (vaso-occlusive crises) in people aged 16 or over with sickle cell disease only if the conditions in the managed access agreement are followed.
1079	1078	TA744	2021/22	STA	Upadacitinib with methotrexate	Pharmaceutical	Moderate rheumatoid arthritis	Optimised	Optimised recommendation for upadacitinib, with methotrexate, for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease‑modifying antirheumatic drugs (DMARDs), only if: disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and the company provides upadacitinib according to the commercial arrangement. The scope for this technology appraisal also included severe rheumatoid arthritis. This is covered by TA665.
1080	1079	TA744	2021/22	STA	Upadacitinib monotherapy	Pharmaceutical	Moderate rheumatoid arthritis	Optimised	Optimsed recommendation for upadacitinib monotherapy when methotrexate is contraindicated or if people cannot tolerate it, when the criteria in section 1.1 are met. The scope for this technology appraisal also included severe rheumatoid arthritis. This is covered by TA665.
1081	1080	TA745	2021/22	STA	NBTXR-3	Pharmaceutical	Advanced soft tissue sarcoma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1082	1081	TA746	2021/22	STA	Nivolumab	Pharmaceutical	Resected oesophageal or gastro-oesophageal junction cancer	Recommended	Recommended in line with clinical practice and following agreement of a commerical access agreement.
1083	1082	TA747	2021/22	STA	Nintedanib for treating progressive fibrosing interstitial lung diseases	Pharmaceutical	Progressive fibrosing interstitial lung diseases	Recommended	Recommended in line with clinical practice and following agreement of a patient access scheme.
1084	1083	TA748	2021/22	STA	Mexiletine	Pharmaceutical	Myotonia in non-dystrophic myotonic disorders	Recommended	Recommended in line with the marketing authorisation and only if company provides it according to the patient access scheme
1085	1084	TA749	2021/22	STA	Liraglutide	Pharmaceutical	Managing obesity in people aged 12 to 17 years	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1086	1085	TA750	2021/22	STA	Olaparib	Pharmaceutical	Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1087	1086	TA751	2021/22	STA	Dupilumab	Pharmaceutical	Severe asthma with type 2 inflammation	Optimised	Optimised recommendation for dupilumab as add-on maintenance therapy for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over, despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment, only if: • the dosage used is 400 mg initially and then 200 mg subcutaneously every other week • the person has agreed to and follows an optimised standard treatment plan • the person has a blood eosinophil count of 150 cells per microlitre or more and fractional exhaled nitric oxide of 25 parts per billion or more, and has had at least 4 or more exacerbations in the previous 12 months • the person is not eligible for mepolizumab, reslizumab or benralizumab, or has asthma that has not responded adequately to these biological therapies • the company provides dupilumab according to the commercial arrangement.
1088	1087	TA752	2021/22	STA	Belimumab	Pharmaceutical	Active autoantibody-positive systemic lupus erythematosus	Optimised	Optimised recommendation for belimumab as add-on treatment for active autoantibody-positive systemic lupus erythematosus in people with high disease activity despite standard treatment, only if: • high disease activity is defined as at least 1 serological biomarker (positive anti-double-stranded DNA or low complement) and a SELENA‑SLEDAI score of greater than or equal to 10 • treatment is continued beyond 24 weeks only if the SELENA‑SLEDAI score has improved by 4 points or more • the company provides belimumab according to the commercial arrangement. This guidance reviews the additional evidence collected as part of the MAA for TA397 and replaces TA397.
1089	1088	TA753	2021/22	STA	Cenobamate	Pharmaceutical	Focal onset seizures in epilepsy	Optimised	Optimsed recommendation for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines. It is recommended only if: • it is used as an add-on treatment, after at least 1 other add-on treatment has not controlled seizures, and • treatment is started in a tertiary epilepsy service.
1090	1089	TA754	2021/22	STA	Mogamulizumab	Pharmaceutical	Previously treated Sézary syndrome	Recommended	Optimised recommendation for treating Sézary syndrome in adults who have had at least 1 systemic treatment. It is recommended only if the company provides mogamulizumab according to the commercial arrangement.
1091	1090	TA754	2021/22	STA	Mogamulizumab	Pharmaceutical	Previously treated mycosis fungoides	Optimised	Optimised recommendation for treating mycosis fungoides in adults, only if: • their condition is stage 2B or above and they have had at least 2 systemic treatments and • the company provides mogamulizumab according to the commercial arrangement.
1092	1091	TA755	2021/22	STA	Risdiplam	Pharmaceutical	Spinal muscular atrophy	Optimised	Optimised recommendation for risdiplam for treating 5q spinal muscular atrophy (SMA) in people 2 months and older with a clinical diagnosis of SMA types 1, 2 or 3 or with pre-symptomatic SMA and 1 to 4 SMN2 copies. It is recommended only if the conditions of the managed access agreement are followed.
1093	1092	TA756	2021/22	STA	Fedratinib	Pharmaceutical	Disease-related splenomegaly or symptoms in myelofibrosis	Recommended (CDF)	Fedratinib is recommended for use within the Cancer Drugs Fund as an option for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults. It is recommended only if: they have previously had ruxolitinib and the conditions in the managed access agreement for fedratinib are followed.
1094	1093	TA757	2021/22	STA	Cabotegravir with rilpivirine	Pharmaceutical	Treating HIV-1	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1095	1094	TA758	2021/22	STA	Solriamfetol	Pharmaceutical	Excessive daytime sleepiness caused by narcolepsy	Optimised	Optimised recommendation for soiriamfetol for treating excessive daytime sleepiness in adults with narcolepsy with or without cataplexy. This is only if modafinil and either dexamfetamine or methylphenidate have not worked well enough or are not suitable.
1096	1095	TA759	2021/22	STA	Fostamatinib	Pharmaceutical	Refractory chronic immune thrombocytopenia	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1097	1096	TA760	2021/22	STA	Selpercatinib	Pharmaceutical	Previously treated RET fusion-positive advanced non-small-cell lung cancer	Recommended (CDF)	Selpercatinib is recommended for use within the Cancer Drugs Fund as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults who need systemic therapy after immunotherapy, platinum-based chemotherapy or both. It is recommended only if the conditions in the managed access agreement are followed.
1098	1097	TA761	2021/22	STA	Osimertinib	Pharmaceutical	Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	Optimised (CDF)	Osimertinib is recommended for use within the Cancer Drugs Fund as adjuvant treatment after complete tumour resection in adults with stage 1b to 3a non‑small‑cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. It is recommended only if: •osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity and •the company provides osimertinib according to the managed access agreement.
1099	1098	TA762	2021/22	STA	Olaparib	Pharmaceutical	BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1100	1099	TA763	2021/22	STA	Daratumumab in combination	Pharmaceutical	Multiple myeloma when a stem cell transplant is suitable	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1101	1100	TA764	2021/22	STA	Fremanezumab	Pharmaceutical	Preventing migraine	Optimised	Optimised recommendation for fremanezumab for preventing migraine in adults, only if: •they have 4 or more migraine days a month •at least 3 preventive drug treatments have failed and •the company provides it according to the commercial arrangement. Stop fremanezumab after 12 weeks of treatment if: •in episodic migraine (fewer than 15 headache days a month), the frequency does not reduce by at least 50% •in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine), the frequency does not reduce by at least 30%. Updates and replaces TA631
1102	1101	TA765	2021/22	STA	Venetoclax with azacitidine	Pharmaceutical	Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1103	1102	TA766	2021/22	STA	Pembrolizumab	Pharmaceutical	Adjuvant treatment of completely resected stage 3 melanoma	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme. Replaces TA553
1104	1103	TA767	2021/22	STA	Ponesimod	Pharmaceutical	Relapsing–remitting multiple sclerosis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1105	1104	TA768	2021/22	STA	Upadacitinib	Pharmaceutical	Active psoriatic arthritis after inadequate response to DMARDs	Optimised	Optimised recommendation for upadacitinib, alone or with methotrexate, for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and: they have had 2 conventional DMARDs and at least 1 biological DMARD or TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis). Upadacitinib is recommended only if the company provides it according to the commercial arrangement.
1106	1105	TA769	2021/22	STA	Palforzia	Pharmaceutical	Peanut allergy in children and young people	Recommended	Recommended in line with marketing authorisation.
1107	1106	TA770	2021/22	STA	Pembrolizumab with carboplatin and paclitaxel	Pharmaceutical	Untreated metastatic squamous non-small-cell lung cancer	Optimised	Optimised recommendation for Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if their tumours express PD‑L1 with a tumour proportion score of 0% to 49% their tumours express PD‑L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses and the company provides pembrolizumab according to the commercial arrangement. CDF review of TA600
1108	1107	TA771	2021/22	STA	Daratumumab with bortezomib, melphalan and prednisone	Pharmaceutical	Untreated multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1109	1108	TA772	2021/22	STA	Pembrolizumab	Pharmaceutical	Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies	Recommended	Recommendded in line with marketing authorisation and following agreemenet of a commerical access agreement. Extension to the MA in TA540
1110	1109	TA773	2021/22	STA	Empagliflozin	Pharmaceutical	Chronic heart failure with reduced ejection fraction	Optimised	Optimised recommendation for empagliflozin for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with: an angiotensin-converting enzyme (ACE) inhibitor or angiotensin 2 receptor blocker (ARB), with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA), or sacubitril valsartan with a beta blocker and, if tolerated, an MRA.
1111	1110	TA774	2021/22	STA	Lenalidomide	Pharmaceutical	Relapsed or refractory mantle cell lymphoma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1112	1111	TA775	2021/22	STA	Dapagliflozin	Pharmaceutical	Chronic kidney disease	Optimised	Optimised recommendation for dapagliflozin for treating chronic kidney disease (CKD) in adults. It is recommended only if: it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and people have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 to 75 ml/min/1.73 m2 at the start of treatment and: have type 2 diabetes or have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more.
1113	1112	TA776	2021/22	STA	Pitolisant hydrochloride	Pharmaceutical	Excessive daytime sleepiness caused by obstructive sleep apnoea	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1114	1113	TA777	2021/22	STA	Solriamfetol	Pharmaceutical	Excessive daytime sleepiness caused by obstructive sleep apnoea	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1115	1114	TA778	2021/22	STA	Pegcetacoplan	Pharmaceutical	Paroxysmal nocturnal haemoglobinuria	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1116	1115	TA779	2021/22	STA	Dostarlimab	Pharmaceutical	Previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	Recommended (CDF)	Dostarlimab is recommended for use within the Cancer Drugs Fund as an option for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy. It is recommended only if the conditions in the managed access agreement are followed.
1117	1116	TA780	2021/22	STA	Nivolumab with ipilimumab	Pharmaceutical	Untreated advanced renal cell carcinoma	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1118	1117	TA781	2021/22	STA	Sotorasib	Pharmaceutical	Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	Recommended (CDF)	Sotorasib is recommended for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy. It is recommended only if the conditions in the managed access agreement for sotorasib are followed.
1119	1118	TA782	2021/22	STA	Tagraxofusp	Pharmaceutical	Treating blastic plasmacytoid dendritic cell neoplasm	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1120	1119	TA783	2022/23	STA	Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	Pharmaceutical	Relapsed and refractory multiple myeloma	Optimised	CDF review of TA510 Optimised recommenation for daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment, only if: they have daratumumab after 3 treatments and the company provides daratumumab according to the commercial arrangement.
1121	1120	TA784	2022/23	STA	Niraparib	Pharmaceutical	Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	Optimised	CDF review of TA528. Optimised recommendation for niraparib for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults. It is recommended only if: they have a BRCA mutation and have had 2 courses of platinum-based chemotherapy, or they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and the company provides it according to the commercial arrangement.
1122	1121	TA785	2022/23	STA	Nivolumab with cabozantinib	Pharmaceutical	Untreated advanced renal cell carcinoma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1123	1122	TA786	2022/23	STA	Tucatinib with trastuzumab and capecitabine	Pharmaceutical	HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1124	1123	TA787	2022/23	STA	Venetoclax with low dose cytarabine	Pharmaceutical	Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Optimised	Optimised recommendation for venetoclax with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable, only if: they have over 30% bone marrow blasts the company provides venetoclax according to the commercial arrangement.
1125	1124	TA788	2022/23	STA	Avelumab	Pharmaceutical	Maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy	Optimised	Optimised recommendation for avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy in adults, only if: avelumab is stopped at 5 years of uninterrupted treatment or earlier if the disease progresses and the company provides avelumab according to the commercial arrangement.
1126	1125	TA789	2022/23	STA	Tepotinib	Pharmaceutical	Advanced non-small-cell lung cancer with MET gene alterations	Recommended	Recommended in line with the marketing authorisation and following agreement of a patient access scheme.
1127	1126	TA790	2022/23	STA	TYRX Absorbable Antibacterial Envelope	Medical Device	Preventing infection from cardiac implantable electronic devices	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1128	1127	TA791	2022/23	STA	Romosozumab	Pharmaceutical	Treating severe osteoporosis	Optimised	Optimised recommendation for reating severe osteoporosis in people after menopause who are at high risk of fracture, only if: they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture) and the company provides romosozumab according to the commercial arrangement.
1129	1128	TA792	2022/23	STA	Filgotinib	Pharmaceutical	Moderately to severely active ulcerative colitis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1130	1129	TA793	2022/23	STA	Anifrolumab	Pharmaceutical	Active autoantibody-positive systemic lupus erythematosus	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1131	1130	TA794	2022/23	STA	Diroximel fumarate	Pharmaceutical	Relapsing–remitting multiple sclerosis	Optimised	Optimised recommendation for diroximel fumarate for treating active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years) in adults, only if: they do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis and the company provides diroximel fumarate according to the commercial arrangement.
1132	1131	TA795	2022/23	STA	Ibrutinib	Pharmaceutical	Waldenstrom’s macroglobulinaemia	Not recommended	CDF review of TA491. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1133	1132	TA796	2022/23	STA	Venetoclax	Pharmaceutical	Chronic lymphocytic leukaemia	Recommended	CDF review of TA487 Recommended in line with the martketing authorisation and following agreement of a patient access schemem
1134	1133	TA797	2022/23	STA	Enfortumab vedotin	Pharmaceutical	Previously treated locally advanced or metastatic urothelial cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1135	1134	TA798	2022/23	STA	Durvalumab	Pharmaceutical	Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	Optimised	CDF review of TA578 Optimised recommendation for durvalumab for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD‑L1) on 1% or more of cells and whose disease has not progressed after platinum-based chemoradiation, only if: they have had concurrent platinum-based chemoradiation the company provides durvalumab according to the commercial arrangement.
1136	1135	TA799	2022/23	STA	Faricimab	Pharmaceutical	Diabetic macular oedema	Optimised	Optimised recommendation for faricimab for faricimab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if: the eye has a central retinal thickness of 400 micrometres or more at the start of treatment the company provides faricimab according to the commercial arrangement.
1137	1136	TA800	2022/23	STA	Faricimab	Pharmaceutical	Wet age-related macular degeneration	Optimised	Optimised recommendation for aricimab for treating wet age-related macular degeneration in adults, only if: the eye has a best-corrected visual acuity between 6/12 and 6/96 there is no permanent structural damage to the central fovea the lesion size is 12 disc areas or less in greatest linear dimension there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes) the company provides faricimab according to the commercial arrangement.
1138	1137	TA801	2022/23	STA	Pembrolizumab plus chemotherapy	Pharmaceutical	Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer	Optimised	Optimised recommendation for pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) for treating triple‑negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease. It is recommended only if: the tumours express PD‑L1 with a combined positive score (CPS) of 10 or more and an immune cell staining (IC) of less than 1%, and the company provides pembrolizumab according to the commercial arrangement.
1139	1138	TA802	2022/23	STA	Cemiplimab	Pharmaceutical	Advanced cutaneous squamous cell carcinoma	Optimised	CDF review of TA592 Optimised recommendation for cemiplimabn for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not suitable, only if: it is stopped at 24 months, or earlier if their disease progresses, and the company provides cemiplimab according to the commercial arrangement.
1140	1139	TA803	2022/23	STA	Risankizumab	Pharmaceutical	Psoriatic arthritis after inadequate response to DMARDs	Optimised	Optimised recommendation for risankizumab, alone or with methotrexate for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have: peripheral arthritis with 3 or more tender joints and 3 or more swollen joints moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10) had 2 conventional DMARDs and at least 1 biological DMARD. Risankizumab is recommended only if the company provides it according to the commercial arrangement.
1141	1140	TA804	2022/23	STA	Teduglutide	Pharmaceutical	Short bowel syndrome	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1142	1141	TA805	2022/23	STA	Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides	Pharmaceutical	Reducing the risk of cardiovascular events in people with raised triglycerides	Optimised	Optimised recommendation for Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have: established cardiovascular disease (secondary prevention), defined as a history of any of the following: acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation) coronary or other arterial revascularisation procedures coronary heart disease ischaemic stroke peripheral arterial disease, and low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre.
1143	1142	TA806	2022/23	STA	Belimumab	Pharmaceutical	Lupus nephritis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1144	1143	TA807	2022/23	STA	Roxadustat	Pharmaceutical	Symptomatic anaemia in chronic kidney disease	Optimised	Optimised recommendation for roxadustat for treating symptomatic anaemia associated with chronic kidney disease (CKD) in adults only if: they have stage 3 to 5 CKD with no iron deficiency and they are not on dialysis at the start of treatment and the company provides roxadustat according to the commercial arrangement.
1145	1144	TA808	2022/23	STA	Fenfluramine	Pharmaceutical	Treating seizures associated with Dravet syndrome	Optimised	Optimised recommendation for fenfluramine as an add‑on to other antiseizure medicines for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if: seizures have not been controlled after trying 2 or more antiseizure medicines the frequency of convulsive seizures is checked every 6 months, and fenfluramine is stopped if it has not fallen by at least 30% compared with the 6 months before starting treatment the company provides fenfluramine according to the commercial arrangement.
1146	1145	TA809	2022/23	STA	Imlifidase	Pharmaceutical	Desensitisation treatment before kidney transplant in people with chronic kidney disease	Optimised	Optimised recommendation for desensitisation treatment option for adults who: are waiting for a kidney transplant from a deceased donor are highly sensitised to human leukocyte antigens (HLA) have a positive crossmatch with the donor and are unlikely to have a transplant under the available kidney allocation system (including prioritisation programmes for highly sensitised people). It is recommended only if: a maximum of 1 dose is given it is given in a specialist centre with experience of treating high sensitisation to HLA the company provides imlifidase according to the commercial arrangement.
1147	1146	TA810	2022/23	STA	Abemaciclib with endocrine therapy	Pharmaceutical	Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme. NB The MA is confuisng and split across section 4.1 and 5.1.
1148	1147	TA811	2022/23	STA	Duvelisib	Pharmaceutical	Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1149	1148	TA812	2022/23	STA	Pralsetinib	Pharmaceutical	RET fusion-positive advanced non-small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1150	1149	TA813	2022/23	STA	Asciminib	Pharmaceutical	Chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1151	1150	TA814	2022/23	MTA	Abrocitinib	Pharmaceutical	Moderate to severe atopic dermatitis	Optimised	Optimsed recommendation for abrocitinib treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if: the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable the company provides abrocitinib according to the commercial arrangement.
1152	1151	TA814	2022/23	MTA	Upadacitinib	Pharmaceutical	Moderate to severe atopic dermatitis	Optimised	Optimsed recommendation for upadacitinib are recommended as options for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if: the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable the company provides upadacitinib according to the commercial arrangement.
1153	1152	TA814	2022/23	MTA	Tralokinumab	Pharmaceutical	Moderate to severe atopic dermatitis	Optimised	Optimsed recommendation for ralokinumab is recommended as an option for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults, only if: the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable the company provides tralokinumab according to the commercial arrangement.
1154	1153	TA815	2022/23	STA	Guselkumab	Pharmaceutical	Active psoriatic arthritis after inadequate response to DMARDs	Optimised	Rapid review of TA711. Optimised recommendation for guselkumab, alone or with methotrexate, for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have had 2 conventional DMARDs and:have had at least 1 biological DMARD, or tumour necrosis factor (TNF)-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis). Guselkumab is recommended only if the company provides it according to the commercial arrangement. Active psoriatic arthritis is defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints.
1155	1154	TA816	2022/23	STA	Alpelisib with fulvestrant	Pharmaceutical	Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer	Optimised	Replaces TA652 Optimised recommendation for alpelisib plus fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults, only if: their cancer has progressed after a CDK4/6 inhibitor plus an aromatase inhibitor and the company provides alpelisib according to the commercial arrangement).
1156	1155	TA817	2022/23	STA	Nivolumab	Pharmaceutical	Invasive urothelial cancer at high risk of recurrence	Optimised	Optimsed recommendation for nivolumab for the adjuvant treatment of muscle-invasive urothelial cancer that is at high risk of recurrence after radical resection in adults whose tumours express PD-L1 at a level of 1% or more. It is recommended only if: adjuvant treatment with platinum‑based chemotherapy is unsuitable, and the company provides nivolumab according to the commercial arrangement.
1157	1156	TA818	2022/23	STA	Nivolumab with ipilimumab	Pharmaceutical	Untreated unresectable malignant pleural mesothelioma	Optimised	Optimised recommendation for nivolumab plus ipilimumab is recommended as an option for untreated unresectable malignant pleural mesothelioma in adults, only if: they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 the company provides it according to the commercial arrangement.
1158	1157	TA819	2022/23	STA	Sacituzumab govitecan	Pharmaceutical	Unresectable triple-negative advanced breast cancer after 2 or more therapies	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1159	1158	TA820	2022/23	STA	Brolucizumab	Pharmaceutical	Diabetic macular oedema	Optimised	Optimised recommendation for brolucizumab for treating visual impairment due to diabetic macular oedema in adults, only if: the eye has a central retinal thickness of 400 micrometres or more at the start of treatment the company provides brolucizumab according to the commercial arrangement.
1160	1159	TA821	2022/23	STA	Avalglucosidase alfa	Pharmaceutical	Pompe disease	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1161	1160	TA822	2022/23	STA	Melphalan	Pharmaceutical	Haematological diseases before allogeneic haematopoietic stem cell transplant	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1162	1161	TA823	2022/23	STA	Atezolizumab	Pharmaceutical	Adjuvant treatment of resected non-small-cell lung cancer	Recommended (CDF)	Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose: tumours have the programmed cell death ligand‑1 (PD‑L1) biomarker expression on 50% or more of their tumour cells and whose disease has not progressed after platinum-based adjuvant chemotherapy. It is recommended only if the company provides atezolizumab according to the managed access agreement.
1163	1162	TA824	2022/23	STA	Dexamethasone intravitreal implant	Pharmaceutical	Diabetic macular oedema	Optimised	Replaces TA349. Optimised recommendation for dexamethasone intravitreal implant for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, or if they cannot have non-corticosteroid therapy.
1164	1163	TA825	2022/23	STA	Avacopan	Pharmaceutical	Severe active granulomatosis with polyangiitis or microscopic polyangiitis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1165	1164	TA826	2022/23	STA	Vedolizumab	Pharmaceutical	Chronic refractory pouchitis after surgery for ulcerative colitis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1166	1165	TA827	2022/23	STA	Oral azacitidine	Pharmaceutical	Maintenance treatment of acute myeloid leukaemia after induction therapy	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1167	1166	TA828	2022/23	STA	Ozanimod	Pharmaceutical	Moderately to severely active ulcerative colitis	Optimised	Optimised recommendation for eating moderately to severely active ulcerative colitis in adults, only if: conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or biological treatment cannot be tolerated or is not working well enough, and the company provides it according to the commercial arrangement.
1168	1167	TA829	2022/23	STA	Upadacitinib	Pharmaceutical	Active ankylosing spondylitis	Optimised	Optimised recommendation for upadacitinib for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if: tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides upadacitinib according to the commercial arrangement.
1169	1168	TA830	2022/23	STA	Pembrolizumab	Pharmaceutical	Adjuvant treatment of renal cell carcinoma	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1170	1169	TA831	2022/23	STA	Olaparib	Pharmaceutical	Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1171	1170	TA832	2022/23	STA	Relugolix–estradiol–norethisterone acetate	Pharmaceutical	Moderate to severe symptoms of uterine fibroids	Recommended	Recommended in line with the marketing authorisation
1172	1171	TA833	2022/23	STA	Zanubrutinib	Pharmaceutical	Waldenstrom’s macroglobulinaemia	Optimised	Optimised recommendation for zanubrutinib for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 treatment, only if: bendamustine plus rituximab is also suitable and the company provides it according to the commercial arrangement.
1173	1172	TA834	2022/23	STA	SQ HDM SLIT	Pharmaceutical	Allergic rhinitis and allergic asthma caused by house dust mites	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1174	1173	TA835	2022/23	STA	Fostamatinib	Pharmaceutical	Refractory chronic immune thrombocytopenia	Optimised	Rapid review of TA759. Optimised recommendation for treating refractory chronic immune thrombocytopenia (ITP) in adults, only if: they have previously had a thrombopoietin receptor agonist (TPO‑RA), or a TPO‑RA is unsuitable the company provides fostamatinib according to the commercial arrangement.
1175	1174	TA836	2022/23	STA	Palbociclib with fulvestrant	Pharmaceutical	Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Recommended	CDF review of TA619. Recommended in line with clincial practice and following agreement of a patient access scheme.
1176	1175	TA837	2022/23	STA	Pembrolizumab	Pharmaceutical	Adjuvant treatment of resected stage 2B or 2C melanoma	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1177	1176	TA838	2022/23	STA	Slow-release potassium bicarbonate–potassium citrate	Pharmaceutical	Distal renal tubular acidosis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1178	1177	TA839	2022/23	STA	Ruxolitinib	Pharmaceutical	Acute graft versus host disease refractory to corticosteroids	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1179	1178	TA840	2022/23	STA	Ruxolitinib	Pharmaceutical	Chronic graft versus host disease refractory to corticosteroids	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1180	1179	TA841	2022/23	STA	Carfilzomib with daratumumab and dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1181	1180	TA842	2022/23	STA	Tisagenlecleucel	Pharmaceutical	Follicular lymphoma after 2 or more therapies	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1182	1181	TA843	2022/23	STA	Luspatercept	Pharmaceutical	Anaemia caused by beta-thalassaemia	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1183	1182	TA844	2022/23	STA	Luspatercept	Pharmaceutical	Anaemia caused by myelodysplastic syndromes	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1184	1183	TA845	2022/23	STA	Mepolizumab	Pharmaceutical	Eosinophilic granulomatosis with polyangiitis	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1185	1184	TA846	2022/23	STA	Mepolizumab	Pharmaceutical	Severe hypereosinophilic syndrome	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1186	1185	TA847	2022/23	STA	Mepolizumab	Pharmaceutical	Severe chronic rhinosinusitis with nasal polyps	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1187	1186	TA848	2022/23	STA	Cemiplimab	Pharmaceutical	Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1188	1187	TA849	2022/23	STA	Cabozantinib	Pharmaceutical	Previously treated advanced hepatocellular carcinoma	Optimised	Replaces TA582. Optimised recommendation for cabozantinib for treating advanced hepatocellular carcinoma (HCC) in adults who have had sorafenib, only if: they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the company provides it according to the commercial arrangement.
1189	1188	TA850	2022/23	STA	Amivantamab	Pharmaceutical	EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1190	1189	TA851	2022/23	STA	Pembrolizumab	Pharmaceutical	Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a commerical access arrangement
1191	1190	TA852	2022/23	STA	Trifluridine–tipiracil	Pharmaceutical	Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments	Recommended	Rapide review of TA669. Recommended in line with marketing authorisation and following agreement of a patient access scheme
1192	1191	TA853	2022/23	STA	Avatrombopag	Pharmaceutical	Primary chronic immune thrombocytopenia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1193	1192	TA854	2022/23	STA	Esketamine nasal spray	Pharmaceutical	Treatment-resistant depression	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1194	1193	TA855	2022/23	STA	Mobocertinib	Pharmaceutical	EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1195	1194	TA856	2022/23	STA	Upadacitinib	Pharmaceutical	Moderately to severely active ulcerative colitis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1196	1195	TA857	2022/23	STA	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy	Pharmaceutical	Untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1197	1196	TA858	2022/23	MTA	Lenvatinib	Pharmaceutical	Untreated advanced renal cell carcinoma	Optimised	Optimised recommendation for lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma in adults, only if: their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and nivolumab with ipilimumab would otherwise be offered and the companies provide lenvatinib and pembrolizumab according to the commercial arrangements.
1198	1197	TA858	2022/23	MTA	Pembrolizumab	Pharmaceutical	Untreated advanced renal cell carcinoma	Optimised	Optimised recommendation for lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma in adults, only if: their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and nivolumab with ipilimumab would otherwise be offered and the companies provide lenvatinib and pembrolizumab according to the commercial arrangements.
1199	1198	TA859	2022/23	STA	Angiotensin II	Pharmaceutical	Vasosuppressor-resistant hypotension caused by septic or distributive shock	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1200	1199	TA860	2022/23	STA	Maribavir	Pharmaceutical	Refractory cytomegalovirus infection after transplant	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1201	1200	TA861	2022/23	STA	Upadacitinib	Pharmaceutical	Active non-radiographic axial spondyloarthritis	Optimised	Optimised recommendation for upadacitinib for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if: tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides upadacitinib according to the commercial arrangement.
1202	1201	TA862	2022/23	STA	Trastuzumab deruxtecan	Pharmaceutical	HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	Recommended (CDF)	Trastuzumab deruxtecan is recommended with managed access as an option for treating HER2‑positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. It is only recommended if the conditions in the managed access agreement for trastuzumab deruxtecan are followed.
1203	1202	TA863	2022/23	STA	Somatrogon	Pharmaceutical	Growth disturbance in people 3 years and over	Recommended	Recommended in line with marketing authorisation
1204	1203	TA864	2022/23	STA	Nintedanib	Pharmaceutical	Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	Recommended	Part review of TA379 which did not recommend people with a forced vital capacity above 80% predicted . Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis in adults, only if: they have a forced vital capacity of above 80% predicted the company provides it according to the commercial arrangement.
1205	1204	TA865	2022/23	STA	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy	Pharmaceutical	Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	Optimised	Optimised recommendation for nivolumab with fluoropyrimidine-based and platinum-based combination chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% or more. It is recommended only if: - pembrolizumab plus chemotherapy is not suitable - the company provides nivolumab according to the commercial arrangement.
1206	1205	TA866	2022/23	STA	Regorafenib	Pharmaceutical	Previously treated metastatic colorectal cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1207	1206	TA867	2022/23	STA	Mitapivat	Pharmaceutical	Pyruvate kinase deficiency	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1208	1207	TA868	2022/23	STA	Vutrisiran	Pharmaceutical	Hereditary transthyretin-related amyloidosis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1209	1208	TA869	2022/23	STA	Teclistamab	Pharmaceutical	Relapsed or refractory multiple myeloma after 3 or more therapies	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1210	1209	TA870	2022/23	STA	Ixazomib with lenalidomide and dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma	Optimised	Review of TA505. Optimised recommendation for ixazomib, with lenalidomide and dexamethasone, as an option for treating multiple myeloma in adults, only if: they have had 2 or 3 lines of therapy and the company provides ixazomib according to the commercial arrangement.
1211	1210	TA871	2022/23	STA	Eptinezumab	Pharmaceutical	Preventing migraine	Optimised	Optimised recommendation for eptinezumab for preventing migraine in adults, only if: they have 4 or more migraine days a month at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement.
1212	1211	TA872	2022/23	STA	Axicabtagene ciloleucel	Pharmaceutical	Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	Recommended	CDF review of TA559. Recommended in line with marketing authorisation and following agreement of a patient access scheme
1213	1212	TA873	2022/23	STA	Cannabidiol	Pharmaceutical	Treating seizures caused by tuberous sclerosis complex	Optimised	Optimised recommendation for cannabidiol as an add-on treatment option for seizures caused by tuberous sclerosis complex in people aged 2 years and over, only if: their seizures are not controlled well enough by 2 or more antiseizure medications (either used alone or in combination) or these treatments were not tolerated seizure frequency is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment the company provides cannabidiol according to the commercial arrangement.
1214	1213	TA874	2022/23	STA	Polatuzumab vedotin in combination	Pharmaceutical	Untreated diffuse large B-cell lymphoma	Optimised	Optimised recommendation for polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) for untreated diffuse large B-cell lymphoma (DLBCL) in adults, only if they have an International Prognostic Index (IPI) score of 2 to 5 the company provides it according to the commercial arrangement.
1215	1214	TA875	2022/23	STA	Semaglutide	Pharmaceutical	Managing overweight and obesity	Optimised	Optimised recommendation for semaglutide for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and they have at least 1 weight-related comorbidity and: a body mass index (BMI) of at least 35.0 kg/m2, or a BMI of 30.0 kg/m2 to 34.9 kg/m2 and meet the criteria for referral to specialist weight management services in NICE's guideline on obesity: identification, assessment and management. Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.
1216	1215	TA876	2022/23	STA	Nivolumab with chemotherapy	Pharmaceutical	Neoadjuvant treatment of resectable non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1217	1216	TA877	2022/23	STA	Finerenone	Pharmaceutical	Treating chronic kidney disease in type 2 diabetes	Optimised	Optimised recommendation for finerenone as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. It is recommended only if: it is an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of: angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and sodium–glucose cotransporter‑2 (SGLT2) inhibitors and the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more.
1218	1217	TA878	2022/23	MTA	Nirmatrelvir plus ritonavir	Pharmaceutical	Treating COVID-19	Optimised	Optimised recommendation for nirmatrelvir plus ritonavir for treating COVID‑19 in adults, only if they: do not need supplemental oxygen for COVID‑19 and have an increased risk for progression to severe COVID‑19, as defined in section 5.
1219	1218	TA878	2022/23	MTA	Sotrovimab	Pharmaceutical	Treating COVID-19	Optimised	Optimised recommendation for sotrovimab for treating COVID‑19 in adults and young people aged 12 years and over and weighing at least 40 kg, only if: they do not need supplemental oxygen for COVID‑19 and they have an increased risk for progression to severe COVID‑19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care and nirmatrelvir plus ritonavir is contraindicated or unsuitable. Sotrovimab is only recommended if the company provides it according to the commercial arrangement.
1220	1219	TA878	2022/23	MTA	Tocilizumab	Pharmaceutical	Treating COVID-19	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1221	1220	TA878	2022/23	MTA	Casirivimab plus imdevimab	Pharmaceutical	Treating COVID-19	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1222	1221	TA879	2023/24	STA	Trastuzumab deruxtecan	Pharmaceutical	HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1223	1222	TA880	2023/24	STA	Tezepelumab	Pharmaceutical	Severe asthma	Optimised	Optimised recommendation for tezepelumab as an add-on maintenance treatment for severe asthma in people 12 years and over, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has not worked well enough. It is recommended only if people: have had 3 or more exacerbations in the previous year, or are having maintenance oral corticosteroids. Tezepelumab is recommended only if the company provides it according to the commercial arrangement.
1224	1223	TA881	2023/24	STA	Ripretinib	Pharmaceutical	Advanced gastrointestinal stromal tumour after 3 or more treatments	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1225	1224	TA882	2023/24	STA	Voclosporin with mycophenolate mofetil	Pharmaceutical	Lupus nephritis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1226	1225	TA883	2023/24	STA	Tafasitamab with lenalidomide	Pharmaceutical	Relapsed or refractory diffuse large B-cell lymphoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1227	1226	TA884	2023/24	STA	Capmatinib	Pharmaceutical	Advanced non-small-cell lung cancer with MET exon 14 skipping	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1228	1227	TA885	2023/24	STA	Pembrolizumab plus chemotherapy with or without bevacizumab	Pharmaceutical	Persistent, recurrent or metastatic cervical cancer	Recommended (CDF)	Pembrolizumab plus chemotherapy with or without bevacizumab is recommended for use within the Cancer Drugs Fund as an option for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score (CPS) of at least 1. It is recommended only if: pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and the conditions in the managed access agreement for pembrolizumab are followed.
1229	1228	TA886	2023/24	STA	Olaparib	Pharmaceutical	Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1230	1229	TA887	2023/24	STA	Olaparib	Pharmaceutical	Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	Recommended	Rapid review of TA831. Recommended in line with marketing authorisation and following agreement of a patient access scheme
1231	1230	TA888	2023/24	STA	Risankizumab	Pharmaceutical	Previously treated moderately to severely active Crohn's disease	Optimised	Optimised recommendation for risankizumab for treating moderately to severely active Crohn's disease in people 16 years and over, only if: the disease has not responded well enough or lost response to a previous biological treatment, or a previous biological treatment was not tolerated, or tumour necrosis factor (TNF)-alpha inhibitors are not suitable. Risankizumab is only recommended if the company provides it according to the commercial arrangement.
1232	1231	TA889	2023/24	STA	Ciltacabtagene autoleucel	Pharmaceutical	Relapsed or refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1233	1232	TA890	2023/24	STA	Difelikefalin	Pharmaceutical	Pruritus in people having haemodialysis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1234	1233	TA891	2023/24	STA	Ibrutinib with venetoclax	Pharmaceutical	Untreated chronic lymphocytic leukaemia	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1235	1234	TA892	2023/24	STA	Mosunetuzumab	Pharmaceutical	Relapsed or refractory follicular lymphoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1236	1235	TA893	2023/24	STA	Brexucabtagene autoleucel	Pharmaceutical	Relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	Recommended (CDF)	Brexucabtagene autoleucel is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B‑cell acute lymphoblastic leukaemia in people 26 years and over. It is recommended only if the conditions in the managed access agreement for brexucabtagene autoleucel are followed.
1237	1236	TA894	2023/24	STA	Axicabtagene ciloleucel	Pharmaceutical	Relapsed or refractory follicular lymphoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1238	1237	TA895	2023/24	STA	Axicabtagene ciloleucel	Pharmaceutical	Relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	Recommended (CDF)	Axicabtagene ciloleucel is recommended for use within the Cancer Drugs Fund as an option for treating diffuse large B‑cell lymphoma in adults when an autologous stem cell transplant is suitable if it: has relapsed within 12 months after first-line chemoimmunotherapy or is refractory to first-line chemoimmunotherapy. It is recommended only if the conditions in the managed access agreement for axicabtagene ciloleucel are followed.
1239	1238	TA896	2023/24	STA	Bulevirtide	Pharmaceutical	Chronic hepatitis D	Optimised	Optimised recommendation for bulevirtide for treating chronic hepatitis D in adults with compensated liver disease only if: there is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above) and their hepatitis has not responded to peginterferon alfa‑2a (PEG‑IFN) or they cannot have interferon-based therapy. Bulevirtide is only recommended if the company provides it according to the commercial arrangement.
1240	1239	TA897	2023/24	STA	Daratumumab with bortezomib and dexamethasone	Pharmaceutical	Previously treated multiple myeloma	Optimised	Managed access review of TA573. Optimised recommendation for daratumumab with bortezomib and dexamethasone for treating multiple myeloma in adults, only if they have had just 1 previous line of treatment and: it included lenalidomide or lenalidomide is unsuitable as a second-line treatment and the company provides it according to the commercial arrangement.
1241	1240	TA898	2023/24	STA	Dabrafenib plus trametinib	Pharmaceutical	BRAF V600 mutation-positive advanced non-small-cell lung cancer	Optimised	Review of TA564. Optimised recommendation for dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if: it is used as first-line treatment of advanced stage cancer, and the company provides it according to the commercial arrangement.
1242	1241	TA899	2023/24	STA	Esketamine	Pharmaceutical	Major depressive disorder in adults at imminent risk of suicide	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1243	1242	TA900	2023/24	STA	Tixagevimab plus cilgavimab	Pharmaceutical	Preventing COVID-19	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1244	1243	TA901	2023/24	STA	Cemiplimab	Pharmaceutical	Recurrent or metastatic cervical cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1245	1244	TA902	2023/24	STA	Dapagliflozin	Pharmaceutical	Chronic heart failure with preserved or mildly reduced ejection fraction	Recommended	Recommended in line with marketing authorisation
1246	1245	TA903	2023/24	STA	Darolutamide with androgen deprivation therapy and docetaxel	Pharmaceutical	Hormone-sensitive metastatic prostate cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1247	1246	TA904	2023/24	STA	Pembrolizumab with lenvatinib	Pharmaceutical	Previously treated advanced or recurrent endometrial cancer	Recommended	0
1248	1247	TA905	2023/24	STA	Upadacitinib	Pharmaceutical	Previously treated moderately to severely active Crohn’s disease	Optimised	Optimised recommendation for upadacitinib for treating moderately to severely active Crohn's disease in adults, only if: the disease has not responded well enough or lost response to a previous biological treatment or a previous biological treatment was not tolerated or tumour necrosis factor (TNF)-alpha inhibitors are contraindicated. Upadacitinib is only recommended if the company provides it according to the commercial arrangement.
1249	1248	TA906	2023/24	STA	Rimegepant	Pharmaceutical	Preventing migraine	Optimised	Optimised recommendation for rimegepant for preventing episodic migraine in adults who have at least 4 and fewer than 15 migraine attacks per month, only if at least 3 preventative treatments have not worked.
1250	1249	TA907	2023/24	STA	Deucravacitinib for treating moderate to severe plaque psoriasis	Pharmaceutical	Moderate to severe plaque psoriasis	Optimised	Optimised recommendation for deucravacitinib for treating moderate to severe plaque psoriasis in adults, only if: the Psoriasis Area and Severity Index (PASI) score is 10 or more and the Dermatology Life Quality Index (DLQI) score is more than 10 the condition has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated the company provides deucravacitinib according to the commercial arrangement.
1251	1250	TA908	2023/24	STA	Olaparib	Pharmaceutical	Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy	Optimised	Replaces TA620. Optimised recommendation for olaparib for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults whose cancer has responded to platinum-based chemotherapy, only if: they have a BRCA1 or BRCA2 mutation they have had 2 or more courses of platinum-based chemotherapy the company provides olaparib according to the commercial arrangement.
1252	1251	TA909	2023/24	STA	Lorlatinib	Pharmaceutical	Untreated ALK-positive advanced non-small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1253	1252	TA910	2023/24	STA	Semaglutide	Pharmaceutical	Managing overweight and obesity in young people aged 12 to 17 years	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1254	1253	TA911	2023/24	STA	Selpercatinib	Pharmaceutical	Untreated RET fusion-positive advanced non-small-cell lung cancer	Optimised (CDF)	Optimised recommendation for selpercatinib for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if: it is untreated the conditions in the managed access agreement for selpercatinib are followed.
1255	1254	TA912	2023/24	STA	Cipaglucosidase alfa with miglustat	Pharmaceutical	Late-onset Pompe disease	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1256	1255	TA913	2023/24	STA	Mavacamten	Pharmaceutical	Symptomatic obstructive hypertrophic cardiomyopathy	Optimised	Optimised recommendation for mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3. It is recommended only if: it is an add‑on to individually optimised standard care that includes beta‑blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated, and the company provides it according to the commercial arrangement.
1257	1256	TA914	2023/24	STA	Pembrolizumab	Pharmaceutical	Previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency	Optimised	Optimised recommendation for pembrolizumab for treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults with: advanced or recurrent endometrial cancer that has progressed during or after a platinum-based therapy, who cannot have curative surgery or radiotherapy unresectable or metastatic gastric, small intestine or biliary cancer that has progressed during or after 1 therapy colorectal cancer after fluoropyrimidine combination therapy, only if they cannot have nivolumab with ipilimumab. It is only recommended if: pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and the company provides it according to the commercial arrangement.
1258	1257	TA915	2023/24	STA	Pegunigalsidase alfa	Pharmaceutical	Fabry disease	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1259	1258	TA916	2023/24	STA	Bimekizumab	Pharmaceutical	Active psoriatic arthritis	Optimised	Optimised recommendation for bimekizumab alone or with methotrexate for treating active psoriatic arthritis (defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints) in adults whose condition has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have had 2 conventional DMARDs and: at least 1 biological DMARD or tumour necrosis factor (TNF)-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis). Bimekizumab is recommended only if the company provides it according to the commercial arrangement. This appraisal followed the cost comparison process.
1260	1259	TA917	2023/24	STA	Daratumumab with lenalidomide and dexamethasone	Pharmaceutical	Untreated multiple myeloma when a stem cell transplant is unsuitable	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1261	1260	TA918	2023/24	STA	Bimekizumab	Pharmaceutical	Axial spondyloarthritis	Optimised	Optimised recommendation for bimekizumab in adults for treating active ankylosing spondylitis (AS) when conventional therapy has not worked well enough or is not tolerated, or active non‑radiographic axial spondyloarthritis (nr‑axSpA) with objective signs of inflammation (shown by elevated C‑reactive protein or MRI) when non-steroidal anti‑inflammatory drugs (NSAIDs), have not worked well enough or are not tolerated. It is recommended only if: tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and the company provides it according to the commercial arrangement.
1262	1261	TA919	2023/24	STA	Rimegepant	Pharmaceutical	Acute migraine with or without aura	Optimised	Optimised recommendation for rimegepant for the acute treatment of migraine with or without aura in adults, only if for previous migraines: at least 2 triptans were tried and they did not work well enough or triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough.
1263	1262	TA920	2023/24	STA	Tofacitinib	Pharmaceutical	Active ankylosing spondylitis	Optimised	Optimised recommendation for tofacitinib for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if: tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides tofacitinib according to the commercial arrangement. This appraisal followed the cost comparison process.
1264	1263	TA921	2023/24	STA	Ruxolitinib	Pharmaceutical	Polycythaemia vera	Recommended	Replaces TA356. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1265	1264	TA922	2023/24	STA	Daridorexant	Pharmaceutical	Long-term insomnia	Optimised	Optimised recommendation for daridorexant for treating insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, and whose daytime functioning is considerably affected, only if: cognitive behavioural therapy for insomnia (CBTi) has been tried but not worked, or CBTi is not available or is unsuitable.
1266	1265	TA923	2023/24	STA	Tabelecleucel	Pharmaceutical	Treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1267	1266	TA924	2023/24	STA	Tirzepatide	Pharmaceutical	Treating type 2 diabetes	Optimised	Optimised recommendation for Tirzepatide for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if: triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and they have a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or they have a BMI of less than 35 kg/m2, and: insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related complications. Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.
1268	1267	TA925	2023/24	STA	Mirikizumab	Pharmaceutical	Treating moderately to severely active ulcerative colitis	Optimised	Optimised recommendation for mirikizumab for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if: a tumour necrosis factor (TNF)‑alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment) or a TNF-alpha inhibitor cannot be tolerated or is not suitable and the company provides it according to the commercial arrangement. This appraisal followed the cost comparison process.
1269	1268	TA926	2023/24	STA	Baricitinib	Pharmaceutical	Treating severe alopecia areata	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1270	1269	TA927	2023/24	STA	Glofitamab	Pharmaceutical	Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1271	1270	TA928	2023/24	STA	Cabozantinib	Pharmaceutical	Previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1272	1271	TA929	2023/24	STA	Empagliflozin	Pharmaceutical	Treating chronic heart failure with preserved or mildly reduced ejection fraction	Recommended	Recommended in line with marketing authorisation. This appraisal followed the cost comparison process.
1273	1272	TA930	2023/24	STA	Lutetium-177 vipivotide tetraxetan	Pharmaceutical	Treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1274	1273	TA931	2023/24	STA	Zanubrutinib	Pharmaceutical	Treating chronic lymphocytic leukaemia	Optimised	Optimised recommendation for zanubrutinib for treating chronic lymphocytic leukaemia (CLL) in adults. It is only recommended if the CLL is: untreated and there is a 17p deletion or tumour protein 53 (TP53) mutation or there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable, or relapsed or refractory. Zanubrutinib is recommended only if the company provides it according to the commercial arrangement.
1275	1274	TA932	2023/24	STA	Decitabine–cedazuridine	Pharmaceutical	Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1276	1275	TA933	2023/24	STA	Tisagenlecleucel	Pharmaceutical	Treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1277	1276	TA934	2023/24	STA	Foslevodopa–foscarbidopa	Pharmaceutical	Treating advanced Parkinson’s with motor symptoms	Optimised	Optimised recommendation for Foslevodopa–foscarbidopa is recommended as an option for treating advanced levodopa-responsive Parkinson's in adults whose symptoms include severe motor fluctuations and hyperkinesia or dyskinesia, when available medicines are not working well enough, only if: they cannot have apomorphine or deep brain stimulation, or these treatments no longer control symptoms, and the company provides foslevodopa–foscarbidopa according to the commercial arrangement.
1278	1277	TA935	2023/24	STA	Secukinumab	Pharmaceutical	Moderate to severe hidradenitis suppurativa	Optimised	Optimised recommendation for secukinumab for treating active moderate to severe hidradenitis suppurativa (acne inversa) in adults when it has not responded well enough to conventional systemic treatment, only if: adalimumab is not suitable, did not work or has stopped working the company provides secukinumab according to the commercial arrangements.
1279	1278	TA936	2023/24	STA	Idecabtagene vicleucel	Pharmaceutical	Treating relapsed and refractory multiple myeloma after 3 or more treatments	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1280	1279	TA937	2023/24	STA	Targeted-release budesonide	Pharmaceutical	Treating primary IgA nephropathy	Optimised	Optimised recommendation for targeted-release budesonide for treating primary immunoglobulin A nephropathy (IgAN) when there is a risk of rapid disease progression in adults with a urine protein-to-creatinine ratio of 1.5 g/g or more. Targeted-release budesonide is recommended only if: it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated the company provides it according to the commercial arrangement.
1281	1280	TA938	2023/24	STA	Dupilumab	Pharmaceutical	Treating eosinophilic oesophagitis in people 12 years and over	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1282	1281	TA939	2023/24	STA	Pembrolizumab plus chemotherapy with or without bevacizumab	Pharmaceutical	Persistent, recurrent or metastatic cervical cancer	Optimised	Rapid review of TA885. Optimised recommendation for pembrolizumab plus chemotherapy with or without bevacizumab for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score of at least 1. It is recommended only if: pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and the company provides it according to the commercial arrangements.
1283	1282	TA940	2023/24	STA	Ravulizumab	Pharmaceutical	Treating generalised myasthenia gravis	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1284	1283	TA941	2023/24	STA	Ravulizumab	Pharmaceutical	Treating AQP4 antibody-positive neuromyelitis optica spectrum disorder	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1285	1284	TA942	2023/24	STA	Empagliflozin	Pharmaceutical	Treating chronic kidney disease	Optimised	Optimised recommendation for empagliflozin for treating chronic kidney disease (CKD) in adults, only if: - it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and - people have an estimated glomerular filtration rate of: 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or 45 ml/min/1.73 m2 to 90 ml/min/1.73 m2 and either: a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or type 2 diabetes.
1286	1285	TA943	2023/24	MTA	Hybrid closed loop systems	Pharmaceutical	Managing blood glucose levels in type 1 diabetes	Optimised	Optimised recommendation for hybrid closed loop (HCL) systems for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling hypoglycaemia, despite best possible management with at least 1 of the following: continuous subcutaneous insulin infusion (CSII) real-time continuous glucose monitoring intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following NHS England's and NHS Wales' implementation plans.
1287	1286	TA943	2023/24	MTA	Hybrid closed loop systems	Pharmaceutical	Managing blood glucose levels in type 1 diabetes	Optimised	Optimised recommendation for HCL systems for managing blood glucose levels in type 1 diabetes for children and young people. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following NHS England's and NHS Wales' implementation plans.
1288	1287	TA943	2023/24	MTA	Hybrid closed loop systems	Pharmaceutical	Managing blood glucose levels in type 1 diabetes	Optimised	Optimised recommendation for HCL systems for managing blood glucose levels in type 1 diabetes for women, trans men and non-binary people who are pregnant or planning to become pregnant. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following NHS England's and NHS Wales' implementation plans.
1289	1288	TA944	2023/24	STA	Durvalumab with gemcitabine and cisplatin	Pharmaceutical	Unresectable or advanced biliary tract cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1290	1289	TA945	2023/24	STA	Treosulfan with fludarabine	Pharmaceutical	before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1291	1290	TA946	2023/24	STA	Olaparib with bevacizumab	Pharmaceutical	Maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	Recommended	CDF review of TA693. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1292	1291	TA947	2023/24	STA	Loncastuximab tesirine	Pharmaceutical	Relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments	Optimised	Optimised recommendation for loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) after 2 or more systemic treatments in adults, only if: they have previously had polatuzumab vedotin, or if polatuzumab vedotin is contraindicated or not tolerated, and the company provides it according to the commercial arrangement.
1293	1292	TA948	2023/24	STA	Ivosidenib	Pharmaceutical	Advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1294	1293	TA949	2023/24	STA	Belumosudil	Pharmaceutical	Chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1295	1294	TA950	2023/24	STA	Nivolumab–relatlimab	Pharmaceutical	Untreated unresectable or metastatic melanoma in people 12 years and over	Optimised	Optimised recommendation for nivolumab–relatlimab for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over, only if: nivolumab–relatlimab is stopped after 2 years of treatment, or earlier if the cancer progresses, and the company provides it according to the commercial arrangement.
1296	1295	TA951	2023/24	STA	Olaparib with abiraterone	Pharmaceutical	Untreated hormone-relapsed metastatic prostate cancer	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1297	1296	TA952	2023/24	STA	Talazoparib	Pharmaceutical	Treating HER2-negative advanced breast cancer with germline BRCA mutations	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1298	1297	TA953	2023/24	STA	Fluocinolone acetonide intravitreal implant	Pharmaceutical	Chronic diabetic macular oedema	Recommended	Replaces TA613 and TA301. Recommended in line with marketing authorisation and following agreement of a patient access scheme
1299	1298	TA954	2023/24	STA	Epcoritamab	Pharmaceutical	Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	Optimised	Optimised recommendation for epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults after 2 or more systemic treatments, only if: they have had polatuzumab vedotin, or if polatuzumab vedotin is contraindicated or not tolerated, and the company provides epcoritamab according to the commercial arrangement.
1300	1299	TA955	2023/24	STA	Dupilumab	Pharmaceutical	Moderate to severe prurigo nodularis	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1301	1300	TA956	2023/24	STA	Etrasimod	Pharmaceutical	Treating moderately to severely active ulcerative colitis in people aged 16 and over	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1302	1301	TA957	2023/24	STA	Momelotinib	Pharmaceutical	Myelofibrosis-related splenomegaly or symptoms	Optimised	Optimised recommendation for momelotinib as an option for treating myelofibrosis-related splenomegaly or symptoms in adults with moderate to severe anaemia who have not had a JAK inhibitor or have had ruxolitinib, only if: they have intermediate‑2 or high-risk myelofibrosis, and the company provides momelotinib according to the commercial arrangement.
1303	1302	TA958	2023/24	STA	Ritlecitinib	Pharmaceutical	Severe alopecia areata in people 12 years and over	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1304	1303	TA959	2023/24	STA	Daratumumab in combination	Pharmaceutical	Newly diagnosed systemic amyloid light-chain amyloidosis	Optimised	Optimised recommendation for daratumumab plus bortezomib, cyclophosphamide and dexamethasone for treating newly diagnosed systemic amyloid light-chain (AL) amyloidosis in adults. It is recommended only if: daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses, and the company provides daratumumab according to the commercial arrangement.
1305	1304	TA960	2023/24	STA	Satralizumab	Pharmaceutical	Preventing relapses in neuromyelitis optica spectrum disorders	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1306	1305	TA961	2023/24	STA	Sebelipase alfa	Pharmaceutical	Lysosomal acid lipase deficiency that is not Wolman disease	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1307	1306	TA962	2023/24	STA	Olaparib	Pharmaceutical	Maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	Recommended	Replaces TA598. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1308	1307	TA963	2024/25	STA	Dostarlimab with platinum-based chemotherapy	Pharmaceutical	Advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	Recommended (CDF)	Dostarlimab with platinum-based chemotherapy is recommended with managed access as an option for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who are candidates for systemic therapy. It is only recommended if the conditions in the managed access agreement for dostarlimab are followed.
1309	1308	TA964	2024/25	STA	Cabozantinib with nivolumab	Pharmaceutical	Untreated advanced renal cell carcinoma	Optimised	Optimised recommendation for cabozantinib with nivolumab for untreated advanced renal cell carcinoma in adults, only if: their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria, and nivolumab with ipilimumab or lenvatinib with pembrolizumab would otherwise be offered, and the companies provide cabozantinib and nivolumab according to their commercial arrangements.
1310	1309	TA965	2023/24	STA	Human alpha1-proteinase inhibitor	Pharmaceutical	Treating emphysema	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1311	1310	TA966	2024/25	STA	Pembrolizumab with gemcitabine and cisplatin	Pharmaceutical	Untreated advanced biliary tract cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1312	1311	TA967	2024/25	STA	Pembrolizumab	Pharmaceutical	Relapsed or refractory classical Hodgkin lymphoma in people 3 years and over	Optimised	CDF review of TA540 Optimised recommendation for pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over who have had at least 2 previous treatments and cannot have an autologous stem cell transplant (ASCT). It is recommended only if: they have already had brentuximab vedotin and pembrolizumab is stopped after 2 years of treatment or earlier if the person has a stem cell transplant or the disease progresses and the company provides it according to the commercial arrangement.
1313	1312	TA968	2024/25	STA	Melphalan flufenamide with dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1314	1313	TA969	2024/25	STA	Gefapixant	Pharmaceutical	Refractory or unexplained chronic cough	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1315	1314	TA970	2024/25	STA	Selinexor with dexamethasone	Pharmaceutical	Relapsed or refractory multiple myeloma after 4 or more treatments	Recommended	Partial update of TA700. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1316	1315	TA971	2024/25	MTA	Remdesivir	Pharmaceutical	Treating COVID-19	Optimised	Optimised recommendation for remdesivir for treating COVID‑19 in hospitals in: adults, only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) babies, children and young people, only if they: are aged 4 weeks to 17 years and weigh at least 3 kg, and: have pneumonia, and need supplemental oxygen, or weigh at least 40 kg, and have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID‑19). Remdesivir is only recommended if the company provides it according to the commercial arrangement.
1317	1316	TA971	2024/25	MTA	Rixagevimab plus cilgavimab	Pharmaceutical	Treating COVID-19	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1318	1317	TA972	2024/25	STA	Sirolimus	Pharmaceutical	Treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1319	1318	TA973	2024/25	STA	Atogepant	Pharmaceutical	Preventing migraine	Optimised	Optimised recommendation for atogepant for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have failed.
1320	1319	TA974	2024/25	STA	Selinexor with bortezomib and dexamethasone	Pharmaceutical	Previously treated multiple myeloma	Optimised	Partial update of TA700. Optimised recommendation for selinexor plus bortezomib and dexamethasone for treating multiple myeloma in adults, only if: they have only had 1 previous line of treatment, and their condition is refractory to both daratumumab and lenalidomide, or they have only had 2 previous lines of treatment and their condition is refractory to lenalidomide. Selinexor is only recommended if the company provides it according to the commercial arrangement.
1321	1320	TA975	2024/25	STA	Tisagenlecleucel	Pharmaceutical	Relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under	Recommended	CDF review of TA554. Recommended in line with marketing authorisation and following agreement of a patient access scheme
1322	1321	TA976	2024/25	STA	Trastuzumab deruxtecan	Pharmaceutical	Treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1323	1322	TA977	2024/25	STA	Dabrafenib with trametinib	Pharmaceutical	Treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1324	1323	TA978	2024/25	STA	Zanubrutinib with obinutuzumab	Pharmaceutical	Treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1325	1324	TA979	2024/25	STA	Ivosidenib with azacitidine	Pharmaceutical	Untreated acute myeloid leukaemia with an IDH1 R132 mutation	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1326	1325	TA980	2024/25	STA	Nivolumab	Pharmaceutical	Adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1327	1326	TA981	2024/25	STA	Voxelotor	Pharmaceutical	Haemolytic anaemia caused by sickle cell disease	Optimised	Optimised recommendation for voxelotor, with or without hydroxycarbamide, as an option for treating haemolytic anaemia caused by sickle cell disease in people 12 years and over. It is recommended only if: people are ineligible for, or intolerant of hydroxycarbamide, or hydroxycarbamide alone is insufficiently effective. Voxelotor is only recommended if the company provides it according to the commercial arrangement.
1328	1327	TA982	2024/25	STA	Baricitinib	Pharmaceutical	Juvenile idiopathic arthritis in people 2 years and over	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1329	1328	TA983	2024/25	STA	Pembrolizumab with trastuzumab and chemotherapy	Pharmaceutical	Untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1330	1329	TA984	2024/25	STA	Tafamidis	Pharmaceutical	Transthyretin amyloidosis with cardiomyopathy	Recommended	Review of TA696. Recommended in line with marketing authorisation and following agreement of a patient access scheme
1331	1330	TA985	2024/25	STA	Selective internal radiation therapy with QuiremSpheres	Pharmaceutical	Unresectable advanced hepatocellular carcinoma	Optimised	Optimised recommendation for the selective internal radiation therapy (SIRT) QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (HCC) in adults, only if it is: used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and the company provides it according to the commercial arrangement.
1332	1331	TA986	2024/25	STA	Lebrikizumab	Pharmaceutical	Moderate to severe atopic dermatitis in people 12 years and over	Optimised	Optimised recommendation for lebrikizumab for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in people 12 years and over with a body weight of 40 kg or more, only if: the atopic dermatitis has not responded to at least 1 systemic immunosuppressant or these treatments are not suitable, and dupilumab or tralokinumab would otherwise be offered, and the company provides it according to the commercial arrangement.
1333	1332	TA987	2024/25	STA	Lisocabtagene maraleucel	Pharmaceutical	Relapsed or refractory aggressive B-cell non-Hodgkin lymphoma	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1334	1333	TA988	2024/25	MTA	Ivacaftor–tezacaftor–elexacafto	Pharmaceutical	Treating cystic fibrosis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1335	1334	TA988	2024/25	MTA	Tezacaftor–ivacaftor	Pharmaceutical	Treating cystic fibrosis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1336	1335	TA988	2024/25	MTA	Lumacaftor–ivacaftor	Pharmaceutical	Treating cystic fibrosis	Recommended	Recommended in line with marketing authorisation and following agreement of a patient access scheme
1337	1336	TA989	2024/25	STA	Etranacogene dezaparvovec	Pharmaceutical	Moderately severe or severe haemophilia B	Optimised	Etranacogene dezaparvovec is recommended with managed access as an option for treating moderately severe or severe haemophilia B (congenital factor IX [FIX] deficiency) in adults without anti‑FIX antibodies. It is only recommended if the conditions in the managed access agreement for etranacogene dezaparvovec are followed.
1338	1337	TA990	2024/25	STA	Tenecteplase	Pharmaceutical	Treating acute ischaemic stroke	Recommended	Recommended in line with marketing authorisation. This appraisal followed the cost comparison process
1339	1338	TA991	2024/25	STA	Abaloparatide	Pharmaceutical	Treating osteoporosis after menopause	Optimised	Optimised recommendation
1340	1339	TA992	2024/25	STA	Trastuzumab deruxtecan	Pharmaceutical	Treating HER2-low metastatic or unresectable breast cancer after chemotherapy	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1341	1340	TA993	2024/25	STA	Burosumab	Pharmaceutical	Treating X-linked hypophosphataemia in adults	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1342	1341	TA994	2024/25	STA	Enzalutamide	Pharmaceutical	Treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1343	1342	TA995	2024/25	STA	Relugolix	Pharmaceutical	Treating hormone-sensitive prostate cancer	Recommended	Recommended in line with marketing authorisation.
1344	1343	TA996	2024/25	STA	Linzagolix	Pharmaceutical	Treating moderate to severe symptoms of uterine fibroids	Optimised	Optimised recommendation for linzagolix for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age only if: it is intended to be used for longer-term treatment (normally for more than 6 months and not for people who need short-term treatment, for example, before planned surgery) the following dosage is used: with hormonal add-back therapy (ABT): 200 mg once daily without hormonal ABT: 200 mg once daily for 6 months, then 100 mg once daily.
1345	1344	TA997	2024/25	STA	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy	Pharmaceutical	Untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma	Recommended	Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
1346	1345	TA998	2024/25	STA	Risankizumab	Pharmaceutical	Treating moderately to severely active ulcerative colitis	Optimised	Optimised recommendation for risankizumab for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or has lost response to treatment, only if: a tumour necrosis factor (TNF)-alpha inhibitor: has not worked (that is the condition has not responded well enough or has lost response to treatment), or cannot be tolerated or is not suitable, and the company provides it according to the commercial arrangement. This appraisal followed the cost comparison process
1347	1346	TA999	2024/25	STA	Vibegron	Pharmaceutical	Treating symptoms of overactive bladder syndrome	Optimised	Optimised recommendation for Vibegron as an option for treating the symptoms of overactive bladder syndrome in adults. It is only recommended if antimuscarinic medicines are not suitable, do not work well enough or have unacceptable side effects.
1348	1347	TA1000	2024/25	STA	Iptacopan	Pharmaceutical	Treating paroxysmal nocturnal haemoglobinuria	Recommended	Recommended in line with marketing authorisation
1349	1348	TA1001	2024/25	STA	Zanubrutinib	Pharmaceutical	Treating marginal zone lymphoma after anti-CD20-based treatment	Recommended	Recommended in line with marketing authorisation
1350	1349	TA1002	2024/25	STA	Evinacumab	Pharmaceutical	Treating homozygous familial hypercholesterolaemia in people 12 years and over	Recommended	Recommended in line with marketing authorisation
1351	1350	TA1003	2024/25	STA	Exagamglogene autotemcel	Pharmaceutical	Treating transfusion-dependent beta-thalassaemia in people 12 years and over	Recommended	Exagamglogene autotemcel (exa-cel) is recommended with managed access as an option for treating transfusion-dependent beta-thalassaemia in people 12 years and over, when: a haematopoietic stem cell transplant (HSCT) is suitable, and a human leukocyte antigen-matched related haematopoietic stem cell donor is not available. It is only recommended if the conditions in the managed access agreement for exa-cel are followed.
1352	1351	TA1004	2024/25	STA	Faricimab	Pharmaceutical	Treating visual impairment caused by macular oedema after retinal vein occlusion	Recommended	Recommended in line with marketing authorisation
1353	1352	TA1005	2024/25	STA	Futibatinib	Pharmaceutical	Previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	Recommended	Recommended in line with marketing authorisation
1354	1353	TA1006	2024/25	STA	Empagliflozin	Pharmaceutical	Treating type 2 diabetes in people 10 to 17 years	Terminated Appraisal - non submission	The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1355	1354	TA1007	2024/25	STA	Rucaparib	Pharmaceutical	Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	Recommended	Recommended in line with marketing authorisation
1356	1355	TA1008	2024/25	STA	Trifluridine–tipiracil with bevacizumab	Pharmaceutical	Treating metastatic colorectal cancer after 2 systemic treatments	Recommended	Recommended in line with marketing authorisation
1357	1356	TA1009	2024/25	STA	Latanoprost–netarsudil	Pharmaceutical	Previously treated primary open-angle glaucoma or ocular hypertension	Optimised	Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough, only if: • they have then tried a fixed-dose combination treatment and it has not reduced IOP enough, or • a fixed-dose combination treatment containing beta-blockers is unsuitable.
1358	1357	TA1010	2024/25	STA	Danicopan	Pharmaceutical	Treating paroxysmal nocturnal haemoglobinuria	Optimised	Recommended in line with company positioning
1359	1358	TA1011	2024/25	STA	Belzutifan	Pharmaceutical	Treating tumours associated with von Hippel-Lindau disease	Recommended (CDF)	Recommended in line with marketing authorisation
1360	1359	TA1012	2024/25	STA	Avapritinib	Pharmaceutical	Treating advanced systemic mastocytosis	Recommended	Recommended in line with marketing authorisation
1361	1360	TA1013	2024/25	STA	Quizartinib	Pharmaceutical	For induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	Recommended	Recommended in line with marketing authorisation
1362	1361	TA1014	2024/25	STA	Alectinib	Pharmaceutical	Adjuvant treatment of ALK-positive non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation
1363	1362	TA1015	2024/25	STA	Teclistamab	Pharmaceutical	Treating relapsed and refractory multiple myeloma after 3 or more treatments	Optimised	Review of TA869. Optimised recommendation for teclistamab ifor treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment. It is only recommended if the company provides teclistamab according to the commercial arrangement.
1364	1363	TA1016	2024/25	STA	Elafibranor	Pharmaceutical	For previously treated primary biliary cholangitis	Recommended	Recommended in line with marketing authorisation
1365	1364	TA1017	2024/25	STA	Pembrolizumab	Pharmaceutical	Treating resectable non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation
1366	1365	TA1018	2024/25	STA	Fedratinib	Pharmaceutical	Treating disease-related splenomegaly or symptoms in myelofibrosis	Optimised	Review of TA756. Optimised recommendation for fedratinib for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis. It is recommended for adults, only if: they have had ruxolitinib, and momelotinib is unsuitable, and the company provides fedratinib according to the commercial arrangement.
1367	1366	TA1019	2024/25	STA	Crovalimab	Pharmaceutical	Treating paroxysmal nocturnal haemoglobinuria in people 12 years and over	Recommended	Recommended in line with marketing authorisation
1368	1367	TA1020	2024/25	STA	Eplontersen	Pharmaceutical	Treating hereditary transthyretin-related amyloidosis	Recommended	Recommended in line with marketing authorisation
1369	1368	TA1021	2024/25	STA	Crizotinib	Pharmaceutical	Treating ROS1-positive advanced non-small-cell lung cancer	Optimised	Review of TA529. Optimised recommendation for crizotinibfor treating ROS1-positive advanced non-small-cell lung cancer in adults, only if: they have not had ROS1 inhibitors, the company provides it according to the commercial arrangement.
1370	1369	TA1022	2024/25	STA	Bevacizumab gamma	Pharmaceutical	Treating wet age-related macular degeneration	Recommended	Recommended in line with marketing authorisation
1371	1370	TA1023	2024/25	STA	Elranatamab	Pharmaceutical	Treating relapsed and refractory multiple myeloma after 3 or more treatments	Optimised (CDF)	Optimised recommendation for elranatamab for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti‑CD38 antibody) when the multiple myeloma has progressed on the last treatment. It is only recommended if the conditions in the managed access agreement for elranatamab are followed.
1372	1371	TA1024	2024/25	STA	Toripalimab	Pharmaceutical	For untreated advanced oesophageal squamous cell cancer	Terminated Appraisal - non submission	NICE is unable, at this time, to make a recommendation about the use in the NHS of toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer in adults. This is because Shanghai Junshi Bioscience has requested a delay to the evidence submission.
1373	1372	TA1025	2024/25	STA	Ublituximab	Pharmaceutical	Treating relapsing multiple sclerosis	Optimised	Optimised recommendation for ublituximab for treating relapsing forms of multiple sclerosis, defined as active by clinical or imaging features in adults, only if: the multiple sclerosis is relapsing–remitting, and the company provides it according to the commercial arrangement.
1374	1373	TA1026	2024/25	STA	Tirzepatide	Pharmaceutical	For managing overweight and obesity	Optimised	Optimised recommendation for tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index (BMI) of at least 35 kg/m2 and at least 1 weight-related comorbidity.
1375	1374	TA1027	2024/25	STA	Tebentafusp	Pharmaceutical	For treating advanced uveal melanoma	Recommended	Recommended in line with marketing authorisation
1376	1375	TA1028	2024/25	STA	Bimekizumab	Pharmaceutical	For treating moderate to severe hidradenitis suppurativa	Terminated Appraisal - non submission	NICE is unable to make a recommendation about the use in the NHS of bimekizumab (Bimzelx) for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal.
1377	1376	TA1029	2024/25	STA	Andexanet alfa	Pharmaceutical	For reversing anticoagulation in people with intracranial haemorrhage	Terminated Appraisal - non submission	NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not provide an evidence submission.
1378	1377	TA1030	2024/25	STA	Durvalumab	Pharmaceutical	Before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation
1379	1378	TA1031	2024/25	STA	Vamorolone	Pharmaceutical	For treating Duchenne muscular dystrophy in people 4 years and over	Recommended	Recommended in line with marketing authorisation
1380	1379	TA1032	2024/25	STA	Niraparib	Pharmaceutical	For untreated hormone-relapsed metastatic prostate cancer	Terminated Appraisal - non submission	NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
1381	1380	TA1033	2024/25	STA	Ganaxolone	Pharmaceutical	Treating seizures caused by CDKL5 deficiency disorder in people 2 years and over	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1382	1381	TA1034	2024/25	STA	Anhydrous sodium thiosulfate	Pharmaceutical	Preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours	Recommended	Recommended in line with marketing authorisation
1383	1382	TA1035	2024/25	STA	Vadadustat	Pharmaceutical	For treating symptomatic anaemia in adults having dialysis for chronic kidney disease	Recommended	Recommended in line with marketing authorisation
1384	1383	TA1036	2024/25	STA	Elacestrant	Pharmaceutical	Treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment	Optimised	Optimised recommendation. Elacestrant is recommended as an option for treating oestrogen receptor (ER)-positive HER2-negative locally advanced or metastatic breast cancer with an activating ESR1 mutation that has progressed after at least 1 line of endocrine treatment plus a cyclin-dependent kinase (CDK) 4 and 6 inhibitor in: women, trans men and non-binary people who have been through the menopause trans women and men. Elacestrant is recommended only if: the cancer has progressed after at least 12 months of endocrine treatment plus a CDK 4 and 6 inhibitor, and the company provides it according to the commercial arrangement.
1385	1384	TA1037	2024/25	STA	Pembrolizumab	Pharmaceutical	Adjuvant treatment of resected non-small-cell lung cancer	Recommended	Recommended in line with marketing authorisation
1386	1385	TA1038	2024/25	STA	Selpercatinib	Pharmaceutical	For advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over	Optimised	Updates and replaces TA742. Optimised recommendation. Selpercatinib is recommended as an option in people 12 years and over for treating: advanced RET fusion-positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate), only if systemic treatment is needed after sorafenib or lenvatinib advanced RET-mutant medullary thyroid cancer, only if systemic treatment is needed after cabozantinib or vandetanib. Selpercatinib is only recommended if the company provides it according to the commercial arrangement.
1387	1386	TA1039	2024/25	STA	Selpercatinib	Pharmaceutical	For advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over	Recommended	Recommended in line with marketing authorisation
1388	1387	TA1040	2024/25	STA	Olaparib	Pharmaceutical	For treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy	Recommended	Updates and replaces TA762. Recommended in line with marketing authorisation
1389	1388	TA1041	2024/25	STA	Durvalumab	Pharmaceutical	For untreated extensive-stage small-cell lung cancer	Optimised	Review of TA662. Optimised recommendation to align with comparator. Durvalumab with etoposide and either carboplatin or cisplatin is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if: they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the company provides durvalumab according to the commercial arrangement.
1390	1389	TA1042	2024/25	STA	Selpercatinib	Pharmaceutical	For previously treated RET fusion-positive advanced non-small-cell lung cancer	Optimised	Review of TA760. Optimised recommendation. Selpercatinib is recommended as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults, only if: it has been treated before and the company provides selpercatinib according to the commercial arrangement
1391	1390	TA1043	2024/25	STA	Osimertinib	Pharmaceutical	Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	Recommended	Updates and replaces TA761. Recommended in line with marketing authorisation.
1392	1391	TA1044	2024/25	STA	Exagamglogene autotemcel	Pharmaceutical	For treating severe sickle cell disease in people 12 years and over	Optimised	Optimised recommendation through Managed Access. Exagamglogene autotemcel (exa‑cel) is recommended with managed access as an option for treating sickle cell disease (SCD) in people 12 years and over: who have: recurrent vaso-occlusive crises (VOCs) and a βS/βS, βS/β+ or βS/β0 genotype and when haematopoietic stem cell transplant (HSCT) is suitable, but a human leukocyte antigen-matched related haematopoietic stem cell donor is not available. It is only recommended: for people who have had at least 2 VOCs (as defined in section 3.4) per year during the 2 previous years and if the conditions in the managed access agreement for exa‑cel are followed.
1393	1392	TA1045	2024/25	STA	12 SQ-HDM SLIT	Pharmaceutical	For treating allergic rhinitis caused by house dust mites	Optimised	Updates and replaces TA834. Optimised recommendation. 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT) is recommended, within its marketing authorisation, as an option for treating moderate to severe house dust mite allergic rhinitis in people 12 to 65 years that is: diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test or specific immunoglobulin E [IgE]) and persistent despite use of symptom-relieving medicine.
1394	1393	TA1045	2024/25	STA	12 SQ-HDM SLIT	Pharmaceutical	For treating allergic asthma caused by house dust mites	Not recommended	Updates and replaces TA834. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1395	1394	TA1046	2024/25	STA	Zolbetuximab	Pharmaceutical	For untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1396	1395	TA1047	2024/25	STA	Atezolizumab	Pharmaceutical	For untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable	Terminated Appraisal - non submission	NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults. This is because Roche Products did not provide an evidence submission.
1397	1396	TA1048	2024/25	STA	Lisocabtagene maraleucel	Pharmaceutical	For treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable	Optimised	Optimised recommendation. Lisocabtagene maraleucel (liso‑cel) is recommended as an option for treating large B‑cell lymphoma that is refractory to, or has relapsed within 12 months after, first-line chemoimmunotherapy in adults with: diffuse large B‑cell lymphoma, high-grade B‑cell lymphoma, primary mediastinal large B-cell lymphoma, or follicular lymphoma grade 3B. Liso-cel is recommended only if: an autologous stem cell transplant would be considered suitable, and the company provides it according to the commercial arrangement.
1398	1397	TA1049	2024/25	STA	Blinatumomab	Pharmaceutical	For consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia	Optimised	Optimised recommendation. Blinatumomab with chemotherapy can be used as an option to treat Philadelphia-chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adults, if: the leukaemia is minimal residual disease-negative, it is used at the start of consolidation treatment, the company provides it according to the commercial arrangement.
1399	1398	TA1050	2024/25	STA	Fenfluramine	Pharmaceutical	For treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
1400	1399	TA1051	2025/26	STA	Efanesoctocog alfa	Pharmaceutical	For treating and preventing bleeding episodes in haemophilia A in people 2 years and over	Optimised	Optimised recommendation. Efanesoctocog alfa is recommended as an option for treating and preventing bleeding episodes in people 2 years and over with haemophilia A (congenital factor VIII deficiency), only if: they have a factor VIII activity level of less than 1% (severe haemophilia A) the company provides it according to the commercial arrangement.
1401	1400	TA1052	2025/26	STA	Pegylated liposomal irinotecan	Pharmaceutical	For untreated metastatic pancreatic cancer	Terminated Appraisal - non submission	NICE is unable to make a recommendation on pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults. This is because the company did not provide an evidence submission.
1402	1401	TA1053	2025/26	STA	Cladribine	Pharmaceutical	For treating active relapsing forms of multiple sclerosis	Optimised	Optimised recommendation. Cladribine is recommended as an option for treating active relapsing forms of multiple sclerosis in adults, only: if they have active relapsing–remitting multiple sclerosis, and when high-efficacy disease-modifying therapies would be offered.
1403	1402	TA1054	2025/26	STA	Ruxolitinib	Pharmaceutical	For treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over	Recommended	Updates and replaces TA839. Recommended in line with marketing authorisation
1404	1403	TA1055	2025/26	STA	Rucaparib	Pharmaceutical	For maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	Optimised	Optimised recommendation. Rucaparib is recommended as an option for the maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy in adults, only if: it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option because: NHS England's BEV3 and BEV10 commissioning approval criteria for having it are not met, or it is contraindicated or not tolerated, and the company provides rucaparib according to the commercial arrangemen
1405	1404	TA1056	2025/26	STA	Molnupiravir	Pharmaceutical	For treating COVID-19	Optimised	Optimised recommendation. Molnupiravir is recommended as an option for treating mild to moderate COVID‑19 in adults who have a positive SARS‑CoV‑2 test, only if: they have 1 or more risk factors for progression to severe COVID‑19 (as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) and both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.
1406	1405	TA1057	2025/26	STA	Relugolix–estradiol–norethisterone	Pharmaceutical	For treating symptoms of endometriosis	Recommended	Recommended in line with marketing authorisation
1407	1406	#N/A	2025/26	#N/A	#N/A	Pharmaceutical	#N/A	#N/A	#N/A